UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2019
or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number 001-35547
ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of
incorporation or organization)
36-4392754
(I.R.S. Employer
Identification No.)
222 Merchandise Mart Plaza, Suite 2024, Chicago, IL 60654
(Address of principal executive offices and zip code)
(800) 334-8534
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class:
Common Stock, par value $0.01 per share
Trading Symbol
MDRX
Name of Each Exchange on which Registered
The Nasdaq Stock Market LLC
(Nasdaq Global Select Market)
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
twelve months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§
232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth
company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Non-accelerated filer
☒
☐
Accelerated filer
Smaller reporting company
Emerging growth company
☐
☐
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
The aggregate market value of the voting and non-voting common stock held by non-affiliates of the registrant based upon the closing sale price of the common stock on
June 28, 2019, the last business day of the registrant’s most recently completed second fiscal quarter, was $1,893,913,552. Solely for purposes of this disclosure, shares of common stock
held by executive officers and directors of the registrant as of such date have been excluded because such persons may be deemed to be affiliates. This determination of executive officers
and directors as affiliates is not necessarily a conclusive determination for any other purposes.
As of February 27, 2020, there were 162,700,920 shares of the registrant’s common stock issued and outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive proxy statement related to its 2020 annual meeting of stockholders (the “2020 Proxy Statement”) are incorporated by reference into Part III
of this Annual Report on Form 10-K where indicated. The 2020 Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the
fiscal year to which this report relates.
ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
TABLE OF CONTENTS TO
ANNUAL REPORT ON FORM 10-K
FOR THE FISCAL YEAR ENDED DECEMBER 31, 2019
PART I
PART II
Item
1.
Business
1A.
Risk Factors
1B.
Unresolved Staff Comments
Properties
Legal Proceedings
Mine Safety Disclosures
2.
3.
4.
5.
6.
7.
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Selected Financial Data
Management’s Discussion and Analysis of Financial Condition and Results of Operations
7A.
Quantitative and Qualitative Disclosures About Market Risk
8.
9.
Financial Statements and Supplementary Data
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
9A.
Controls and Procedures
PART III
10.
Directors, Executive Officers and Corporate Governance
11.
Executive Compensation
12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
13.
Certain Relationships and Related Transactions and Director Independence
14.
Principal Accountant Fees and Services
15.
Exhibits and Financial Statement Schedules
16.
Form 10-K Summary
PART IV
2
Page
3
13
31
31
31
31
32
34
36
55
56
111
111
112
112
112
112
112
113
118
Each of the terms “we,” “us,” “our” or “company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. (“Allscripts”) and/or
its wholly-owned subsidiaries and controlled affiliates, unless otherwise stated.
The “Business” section, the “Risk Factors” section, the “Management’s Discussion and Analysis of Financial Condition and Results of Operations”
section and other sections of this Annual Report on Form 10-K (this “Form 10-K”) contain forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking statements are based on the current beliefs and expectations of our management with respect
to future events and are subject to significant risks and uncertainties. Such statements can be identified by the use of words such as “future,” “anticipates,”
“believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “will,” “would,” “could,” “continue,” “can,” “may” and similar terms. Actual results
could differ from those set forth in the forward-looking statements, and reported results should not be considered an indication of future performance. Certain
factors that could cause our actual results to differ materially from those described in the forward-looking statements include, but are not limited to, those
discussed in Part I, Item 1A, “Risk Factors” of this Form 10-K, which are incorporated herein by reference. We do not undertake to update any forward-
looking statements to reflect the impact of circumstances or events that may arise after the date of the forward-looking statements for any reason, except as
required by law.
Item 1. Business
PART I
We deliver information technology (“IT”) solutions and services to help healthcare organizations achieve optimal clinical, financial and operational
results. Our solutions and services are sold to:
• Physicians
• Hospitals
• Governments
• Health systems
• Health plans
• Life-sciences companies
• Retail clinics
• Retail pharmacies
• Pharmacy benefit managers
• Insurance companies
• Employer wellness clinics
• Post-acute organizations
• Consumers
• Lab companies
Our portfolio, which we believe offers some of the most comprehensive solutions in our industry today, helps clients advance the quality and
efficiency of healthcare by providing electronic health records (“EHR”), financial management, population health management, precision medicine and
consumer solutions. Built on an open integrated platform, our solutions enable users to streamline workflows, leverage functionality from other software
vendors and exchange data. The Allscripts Developer Program focuses on nurturing partnerships with other developers to help clients optimize the value of
their Allscripts investment.
Recent Business Developments
We acquired the Pinnacle and Diabetes Collaborative Registries from the American College of Cardiology (“ACC”) as part of our broader strategic
partnership with the ACC on July 2, 2019. As part of this partnership, we began operating Pinnacle and Diabetes Collaborative Registries, which extended
our EHR-enabled ambulatory network to create a large-scale chronic disease network.
3
We acquired the assets of a business engaged in the development, implementation, customization, marketing, licensing and sale of a specialty
prescription drug platform including software that collects, saves and transmits information required to fill a prescription on June 10, 2019. The drug platform
and software enables healthcare providers, pharmacists and payors to digitally interact with one another to fill a prescription.
We acquired all of the outstanding minority interests in Pulse8, Inc. on March 1, 2019, which is a healthcare analytics and technology company that
provides business intelligence software solutions for health plans and at-risk providers to enable them to analyze their risk adjustment and quality
management programs. We initially acquired a controlling stake in Pulse8, Inc. on September 8, 2016.
On January 13, 2020, we announced that we extended our engagement with our largest customer, Northwell Health, which is New York’s largest
health system. Our managed service business supports the organization’s infrastructure as well as our solutions and third-party applications. We also provide
comprehensive service desk support and application management services, as we well as project delivery, strategic and leadership-planning activities.
On December 31, 2018, we sold our investment in Netsmart LLC (“Netsmart”) in exchange for $566.6 million in cash, resulting in a pre-tax gain of
$500 million. Prior to the sale, Netsmart comprised a separate reportable segment, which due to its significance to our historical consolidated financial
statements and results of operations, is reported as a discontinued operation for the years ended December 31, 2018 and 2017 as a result of the sale.
Corporate Information
Founded in 1986, Allscripts is incorporated in Delaware with principal executive offices located at 222 Merchandise Mart Plaza, Suite 2024, Chicago,
Illinois 60654. Our principal website is www.allscripts.com. The contents of this website are not incorporated into this filing. Furthermore, our references to
the URLs for this website are intended to be inactive textual references only.
Solutions
Our portfolio addresses a range of healthcare industry needs, with the goal of helping clients drive smarter care across connected communities of
health. Across care settings, our solutions enable clinical, financial and operational efficiencies while helping patients deepen their engagement in their own
care. Our principal solutions consist of the following:
Electronic Health Records
Allscripts offers a suite of EHRs for hospitals and health systems, as well as community and physician practices. Built on an open platform with
advanced clinical decision support, our EHRs provide analysis and insights. Our EHR solutions deliver a single patient record, workflows and consolidated
analytics. Our innovative solutions help deliver improved patient care and outcomes. Our EHR solutions consist of the following:
Sunrise™ is a comprehensive EHR platform for larger hospital facilities with a combination of services lines. Sunrise supports health systems on a
single platform for both inpatient and outpatient care and provides decision guidance, including computerized provider order entry, note and flowsheet
documentation, clinical summary views and other key workflows necessary for driving quality care. Administrative and operational modules are likewise
available. Functionality is also offered on mobile devices. Offerings include:
• Sunrise™ Acute Care
• Sunrise™ Ambulatory Care
• Sunrise™ Community Care
• Sunrise™ Mobile
• Sunrise™ Surgical Care
• Sunrise™ Rehabilitation
• iPro Anesthesia
• Sunrise™ Wound Care powered by TRUE-see™
• Allscripts® Census Logic
• Allscripts® Surgical Logic
• Allscripts Patient Flow™
• Sunrise™ Oncology
• Allscripts® Clinical Performance Management
• Sunrise™ Financial Manager
• Sunrise™ Health Information Management
Paragon® is an integrated clinical, financial and administrative EHR solution tailored for community hospitals and health systems. Once part of the
Enterprise Information Solutions business (the “EIS Business”) acquired from McKesson Corporation, the solution supports the full scope of care delivery
and business processes, from patient access management and accounting through clinical assessment, documentation and treatment.
Allscripts TouchWorks® EHR is an EHR solution for larger single and multispecialty practices and is built on an open platform that brings data
sources together. This open platform feature, along with the ability to customize workflows, enables clinical staff to effectively coordinate and deliver both
primary and specialized care. Functionality is also offered on mobile devices.
4
Allscripts Professional EHR™ is an EHR solution for small- to mid-size physician practices. Allscripts Professional EHR works in accountable care
organizations (“ACOs”), patient-centered medical homes and Federally Qualified Health Centers, and enables practices to adhere to government initiatives
like Meaningful Use and the Medicare Access and CHIP Reauthorization Act or Merit based Incentive Payment System (“MIPS”). The solution’s mobile
offering, Allscripts Professional EHRTM Mobile, provides on-the-go access to Allscripts Professional EHRTM, driving greater efficiency and improved patient
care.
Practice Fusion is a cloud-based EHR and is an intuitive and easy-to-use solution for clinicians in small and independent practices. The solution
helps drive operational efficiencies with smart charting that adapts to each practice’s specific needs and enables patients to receive medications more quickly.
Practice Fusion also reduces administrative burdens by helping staff simplify front-office tasks and improve billing efficiency.
Payer and Life Sciences
Veradigm™ is the Allscripts payer and life science business unit which is an integrated data systems and services business that combines data-driven
clinical insights with actionable tools that reside in clinical workflow. Veradigm provide solutions to their client base. These solutions help key healthcare
stakeholders improve the quality, efficiency and value of healthcare delivery - including biopharma, health plans, healthcare providers, health technology
partners, and most importantly, the patients they serve.
Consumer Solutions
FollowMyHealth® is a comprehensive patient engagement platform with options for telehealth and remote patient monitoring. This patient
engagement platform, enhanced by the addition of powerful Health Grid functionality, also serves as the foundation for emerging consumer health initiatives,
including automated secure messaging.
Financial Management
Allscripts financial solutions support revenue cycle, claims management, budgeting and analytic functions for healthcare organizations. These tools
can help change clinician behavior to improve patient flow, increase quality, advance outcomes, optimize referral networks, decrease leakage and reduce
costs. Plus, our solutions allow our clients to extract the data needed to support new reimbursement models. Offerings include:
• Sunrise™ Financial Manager
• Sunrise™ Abstracting
• Allscripts Revenue Cycle Management Services
• Allscripts EPSi
• Allscripts Payerpath®
• STAR
Population Health Management
Allscripts CareInMotion™ is a community-connected population health management platform that delivers care coordination, patient engagement,
connectivity, data aggregation and analytics.
• Allscripts care coordination solutions include Allscripts® Care Director, CarePort Care
Management, dbMotion™ Care Coordination Agent, Allscripts® Referral Management
and chronic care management services.
• Our connectivity and data aggregation solutions include the dbMotion™
Solution, dbMotion™ Community powered by OnePartner and Allscripts Fusion™.
• Allscripts Population Health Analytics™ enables healthcare organizations to measure
performance and outcomes, analyze utilization, manage risk, reduce cost and
improve quality across the continuum of care.
Precision Medicine
Through precision medicine, healthcare is evolving from a one-size-fits-all model to a personalized approach aimed at customizing diagnostic,
therapeutic and preventive interventions. 2bPrecise™ seeks to bring the intelligence and insights of precision medicine to the workflow of the clinician—
while making this knowledge available for research, including the study of how a person’s genetic makeup affects the response to medications.
5
Services
In addition to our solutions, Allscripts offers customizable professional and managed service offerings. From hosting, consulting, optimization and
managed IT services to revenue cycle services for practices, Allscripts partners with clients to meet their goals. We provide the following services and more:
• Allscripts® Architecture Advisory Service
• Allscripts® Proactive Application Monitoring Service
• Allscripts® Clinical Quality Program
• Allscripts® FollowMyHealth Engagement and Optimization
• Allscripts® Premier Support
• Allscripts® Revenue Cycle Consulting Services
Our Strategy
Our strategy is built upon our vision of enabling smarter care at virtually every point of the healthcare continuum. Given the breadth of our portfolio
and global client base, we are well positioned to connect providers to patients and payers across all healthcare settings. Smarter care is a strategic imperative
for healthcare organizations globally and requires a balance between managing cost while maintaining the highest quality of care. Our solutions are
positioned to facilitate the transformation in healthcare delivery by connecting communities, driving interoperability, providing data analytics, delivering
consumer engagement features and assisting clients manage the evolution toward value-based care. These key strategic areas all help healthcare providers
better manage populations of patients, especially those with costly chronic conditions, such as diabetes, asthma and heart disease, to help bring down the cost
of care and improve patient outcomes.
•
•
Connecting communities – Our care coordination solutions improve safety and quality as a patient transitions from one care setting to
another. To do so, care coordination solutions help build assessments, monitor results, track outcomes and make modifications in a patient’s
care plan. Healthcare is a group effort and having full visibility into a patient’s care plan is critical. Access to comprehensive patient
information is key, and our community solutions help create an organized, longitudinal patient record spanning all points of care.
Interoperability – We provide clients a wide array of interoperability tools to support their need and desire to connect to numerous
stakeholders in the industry, including other healthcare providers, labs, imaging facilities, public health entities and patients, as well as
other third-party technology providers. Allscripts Open platform is proven, scalable and user-friendly, and connects both clinical and
financial data across every setting. We also offer APIs based on the Fast Healthcare Interoperability Resources. With this platform, clients
can connect to any certified application or device, which saves time and money and gives clients full access to a variety of innovative
solutions.
6
•
•
•
Data analytics – Allscripts understands that healthcare organizations need to analyze dependencies, trends and patterns so that they can
develop business and clinical intelligence. Our analytics offerings help organizations better manage their patient populations by using clean
data for better decisions at the point of care. Insights and analytics serve as the foundation for informed analysis and effective planning.
Consumer engagement – Our patient engagement software helps healthcare organizations achieve better outcomes, reduce emergency
room visits and decrease hospitalizations. Our solutions also integrate with health IT offerings across an organization, regardless of a
provider’s chosen vendor. With a patient engagement platform, individuals and their families have the opportunity to become active
members of their care team, which improves results.
Payer and life sciences – Through Veradigm™, we are positioned to help clients manage the evolution toward value-based care, facilitate
patient medication access and affordability and provide new, efficient operating models for generating the real-world evidence necessary to
accelerate the development of new therapies and to enhance the value of existing ones.
Healthcare IT Industry
The healthcare IT industry in which we operate is highly regulated, and the services we provide are subject to a complex set of healthcare laws and
regulations, including among others, the Medicare Access and CHIP Reauthorization Act (“MACRA”), the Health Information Technology for Economic and
Clinical Health Act (“HITECH”), the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), regulations issued by the Centers for Medicare
and Medicaid Services (“CMS”) and the Department of Health and Human Services (“HHS”), a number of fraud and abuse laws, including the federal Anti-
Kickback Statute and the False Claims Act and the Patient Protection and Affordable Care Act (as amended, the “PPACA”). In addition, the healthcare IT
industry is subject to changing political, legislative, regulatory and other industry standards, which create both significant opportunities as well as certain
challenges. These include:
•
•
Provider Reimbursement: In recent years, there have been significant changes to provider payment models by the United States federal
government, moving more towards a value-based care model similar to those being adopted by commercial payers and state governments. This
leads to increasing pressure on healthcare organizations to reduce costs and increase quality, replacing fee-for-service models in part by
expanding advanced payment models. Such changes to provider payments models could further encourage the adoption of healthcare IT as a
means of improving quality of patient care through increased efficiency, care coordination, and improving access to complete medical
documentation.
o
The passage of MACRA in 2015 codified the creation of new payment models, such as ACOs, that will significantly expand the
number of ambulatory healthcare professionals delivering care under payment programs that are driven by quality measures currently
under development. Many of our clients are also involved with the Comprehensive Primary Care Plus program, which is working
toward similar goals by emphasizing the role of the primary care provider. Other important drivers of healthcare IT adoption in the
primary care space are the Patient Centered Medical Home program, a voluntary program in which many of our clients participate
and that has a strong emphasis on quality measurement and patient engagement, as well as the newly announced Primary Care First
program. Even where some of these programs are being adjusted in part by HHS under the Trump Administration, significant levels
of reimbursements will still require providers to capture, communicate, measure and share outcomes through technology solutions
such as ours, given that those requirements are bound in federal statute.
HITECH: In 2009, the United States federal government enacted HITECH, which authorized the EHR Incentive program (the “meaningful use”
program). This law provided significant incentive funding by the Medicare and Medicaid programs to physicians and hospitals that can prove
they have adopted and are appropriately using technology such as our EHR solutions. CMS establishes and oversees the criteria that healthcare
providers must meet to receive HITECH stimulus funding for those still participating, while the Office of the National Coordinator for Health
Information Technology (“ONC”) establishes and oversees the functionality that EHR products must meet in order for our customers to qualify
for funding under HITECH and other programs pointing to the use of certified EHR technology (CEHRT) as a requirement. Currently, ONC
recognizes an Authorized Testing and Certification Body (ATCB) eligible to test for and designate that EHRs are certified for quality reporting,
such as that required by government programs like meaningful use.
7
•
•
•
•
Privacy and Health Data: Allscripts is subject to numerous privacy and security laws and regulations, including HIPAA and the FTC Act.
HIPAA and its implementing regulations contain substantial restrictions and requirements with respect to the use and disclosure of individuals’
protected health information. HIPAA applies to “Covered Entities,” such as certain healthcare providers, health plans, and health care
clearinghouses, as well as business associates that performed functions on behalf of or provided services to Covered Entities. We consider
ourselves a Covered Entity due to our acting as a “healthcare clearinghouse” through our provision of Allscripts Payerpath due to its filing of
electronic healthcare claims on behalf of healthcare providers that are subject to HIPAA and HITECH. In addition, as a result of our dealings
with certain clients and others in the healthcare industry, which may be considered Covered Entities under or otherwise subject to the
requirements of HIPAA, we are, in some circumstances, considered a business associate under HIPAA. As a business associate, we are subject to
the HIPAA requirements relating to the privacy and security of protected health information. Among other things, HIPAA requires business
associates to (i) maintain physical, technical and administrative safeguards to prevent protected health information from misuse, (ii) report
security incidents and other inappropriate uses or disclosures of the information, including to individuals and governmental authorities, and (iii)
assist Covered Entities from which we obtain health information with certain of their duties under HIPAA. We have policies and safeguards in
place intended to protect health information as required by HIPAA and have processes in place to assist us in complying with applicable laws
and regulations regarding the protection of this data and responding to any security incidents. The Office of Civil Rights is currently considering
updates and changes to HIPAA-related regulations, and Allscripts will adjust our processes and procedures as necessary, should any new rules be
promulgated. Section 5 of the Federal Trade Commission (“FTC”) Act prohibits unfair methods of competition and unfair or deceptive acts or
practices in or affecting commerce. The FTC Act, and the rules promulgated thereunder, may be applicable to health information that is held in a
capacity that does not implicate HIPAA. Therefore, for certain activities and applications, we comply with the FTC Act.
ANSI-5010/ICD-10: Under HIPAA, HHS implemented a new version of the standards for HIPAA-covered electronic transactions, including
claims, remittance advices, and requests and responses for eligibility, which is called ANSI-5010. Additionally, HIPAA required entities to
upgrade to the tenth revision of the International Statistical Classification of Diseases and Related Health Problems from the World Health
Organization, also known as ICD-10, for use in reporting medical diagnoses and inpatient procedures in 2015. These changes in coding
standards required our clients to upgrade to more advanced versions of our solutions.
Federal Anti-Kickback Statute: The federal Anti-Kickback Statute prohibits any person or entity from offering, paying, soliciting or receiving
anything of value, directly or indirectly, for the referral of patients covered by Medicare, Medicaid and other federal healthcare programs or the
leasing, purchasing, ordering or arranging for or recommending the lease, purchase or order of any item, good, facility or services covered by
these programs. Courts have interpreted the law to provide that a financial arrangement may violate this law if any one of the purposes of an
arrangement is to encourage patient referrals or other federal healthcare program business, regardless of whether there are other legitimate
purposes for the arrangement. There are several limited exclusions known as safe harbors that may protect some arrangements from enforcement
penalties. Penalties for federal Anti-Kickback Statute violations can be severe, and include imprisonment, criminal fines, civil money penalties
with triple damages (when the False Claims Act is implicated) and exclusion from participation in federal healthcare programs. The PPACA
broadened the reach of the fraud and abuse laws by, among other things, amending the intent requirement of the federal Anti-Kickback Statute
and the applicable criminal healthcare fraud statutes. Pursuant to the statutory amendment, a person or entity no longer needs to have actual
knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, PPACA provides that the government
may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or
fraudulent claim for purposes of the civil False Claims Act or the civil monetary penalties statute. Many states have adopted laws similar to the
federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare items or services reimbursed by any source, not only
the Medicare and Medicaid programs. HHS has proposed changes to the most recent Anti-Kickback and Stark law regulations, and the final
rules may extend even further allowances for exclusions associated with the purchase of health information technology. The new regulation is
expected to be finalized in 2020.
False Claims Act: The federal False Claims Act prohibits anyone from, among other things, knowingly presenting, or causing to be presented,
for payment to federal programs (including Medicare and Medicaid) claims for items or services that are false or fraudulent. Although we would
not submit claims directly to payors, Allscripts could be held liable under the False Claims Act if we are deemed to “cause” the submission of
false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers through our revenue cycle/claims
management services, or if our EHR products are found to have caused providers to have inaccurately attested to Meaningful Use or MIPS
criteria.
8
•
PPACA: PPACA, which was signed into law in 2010, has impacted us and our clients. While at this time repeal of the law is unlikely, given the
divided Congress following the 2018 midterm election, the Administration may continue to take steps through regulation and executive order to
break down components of the PPACA previously implemented, and legal challenges continue to advance through the justice system. Many
components of the law, including those which have had a positive effect on our business by requiring the expanded use of health IT products, are
expected to remain in effect, however. Certain provisions of PPACA, such as those mandating reductions in reimbursement for certain types of
providers or decreasing the number of covered lives in the United States or the depth of insurance coverage available to patients, may have a
negative effect by reducing the resources available to our current and prospective clients to purchase our products. Further, some ambiguity
remains for the industry as a whole regarding the future of programs initially authorized by the PPACA, which may continue to slow purchasing
decisions as healthcare organizations wait for clarity.
We believe that these and other changes in laws and regulations, along with increasing pressure from private payers to move providers to quality-
based payment programs and market opportunities to maximize the data that is increasingly being created and captured through the care process, will continue
to drive adoption of healthcare IT products and services such as ours. The Administration continues to apply pressure through a variety of levers to increase
interoperability in the industry across a variety of stakeholders, including implementing regulations that increasingly require robust, sophisticated health
technology. For example, although many large physician groups have already purchased EHR technology, we expect those groups may choose to replace their
older EHR technology to comply with future Quality Payment Program requirements and to add new features and functionality. Further, opportunities for
healthcare provider organizations to expand their care coordination efforts in order to successfully comply with new payment programs or to add software
specific to the precision medicine expansion, as outlined in the 21st Century Cures Act passed in December 2016, could lead to additional demand for our
solutions. We also seek replacement markets for health information exchanges and patient portals, despite their recent deployment.
Business Organization
We derive our revenues primarily from sales of our proprietary software (either as a direct license sale or under a subscription delivery model), which
also serves as the basis for our recurring service contracts for software support and maintenance and certain transaction-related services. In addition, we
provide various other client services, including installation, and managed services such as outsourcing, private cloud hosting and revenue cycle management.
During 2019, we realigned our reporting structure as a result of the divestiture of our investment in Netsmart on December 31, 2018, the evolution of
the healthcare IT industry and our increased focus on the payer and life sciences market. Refer to Note 18, “Business Segments,” to our consolidated financial
statements included in Part II, Item 8, “Financial Statements and Supplementary Data” of this Form 10-K for detailed discussion about these changes. We
have eight operating segments aggregated into two reportable segments as follows:
•
•
The Provider reportable segment includes the Hospitals and Health Systems, Ambulatory, CarePort, FollowMyHealth®, EPSiTM, EIS-Classics
and 2bPrecise strategic business units, each of which represents a separate operating segment. This reportable segment derives its revenue from
the sale of integrated clinical software applications, financial management and patient engagement solutions, which primarily include EHR-
related software, connectivity and coordinated care solutions, financial and practice management software, related installation, support and
maintenance, outsourcing, private cloud hosting, revenue cycle management, training and electronic claims administration services.
The Veradigm reportable segment provides data-driven clinical insights with actionable tools for clinical workflow, research, analytics and
media. Its solutions, targeted at key healthcare stakeholders, help improve the quality, efficiency and value of healthcare delivery.
The results of operations related to two of the product offerings acquired with the EIS Business (Horizon Clinicals and Series2000 Revenue Cycle)
are presented throughout our financial statements as discontinued operations and are included in the Provider reportable segment, except for acquisition-
related deferred revenue adjustments, which are included in “Unallocated Amounts”. Refer to Note 17, “Discontinued Operations” to our consolidated
financial statements included in Part II, Item 8, “Financial Statements and Supplementary Data” of this Form 10-K.
Clients
Our clients in the Provider segment include physician practices, hospitals and coordinated community care organizations, which include some of the
most prestigious medical groups and hospitals in the United States and internationally and often serve as reference sources for prospective clients that are
interested in purchasing our solutions. Our clients in the Veradigm segment include health plans and payors, life science companies and physician practices.
No single client accounted for more than 10% of our revenue in the years ended December 31, 2019, 2018 and 2017.
9
Research and Development
Rapid innovation characterizes the healthcare IT industry. We believe our ability to compete successfully depends heavily on our ability to ensure a
continual and timely flow of competitive products, services and technologies to the markets in which we operate.
Because of this, we continue to invest heavily into our research and development efforts. These efforts are primarily focused on developing new
solutions as well as new features and enhancements to our existing solutions, which we believe will ensure that our solutions comply with continually
evolving regulatory requirements and create additional opportunities to connect our systems to the healthcare community.
Competition
The markets for our solutions and services are highly competitive and are characterized by rapidly evolving technology and solution standards and
user needs, as well as frequent introduction of new solutions and services. Some of our competitors may be more established, benefit from greater name
recognition, and have substantially greater financial, technical, and marketing resources than we do.
We compete primarily with numerous types of organizations, including developers of revenue cycle and practice management software and services,
large system integrators, IT service providers, ambulatory and acute care EHR solutions, population health management and value-based care technologies,
analytics systems, care management solutions and post-acute solutions. We generally compete on the basis of several factors, including breadth and depth of
services (including our open architecture and the level of solution integration across care settings), integrated platform, regulatory compliance, reputation,
reliability, accuracy, security, client service, total cost of ownership, innovation and industry acceptance, expertise and experience. We believe we compete
favorably on these metrics and are one of the leading companies offering a suite of healthcare IT solutions.
Moreover, we expect that competition will continue to increase as a result of consolidation in both the IT and healthcare industries. If one or more of
our competitors or potential competitors were to merge or partner with another of our competitors, the change in the competitive landscape could adversely
affect our ability to compete effectively.
Our principal existing competitors in these markets include, but are not limited to (in alphabetical order) AdvancedMD, athenahealth Inc., Availity,
Cerner Corporation, Change Healthcare, CPSI (Computer Programs and Systems Inc.), CureMD Healthcare, eClinicalWorks, Enli Health Intelligence, Epic
Systems Corporation, Evolent Health, Greenway Medical Technologies, Harris Healthcare, Healthagen, Health Catalyst, IBM Watson Health, Inovalon,
IQVIA, Kareo, The Lash Group, Inc., MEDHOST, Inc., Meditech (Medical Information Technology, Inc.), NaviHealth, Nextgen, nThrive, Optum, Philips
Healthcare, Premier Inc., Science 37, Strata, T-System, The TriZetto Group, Inc. (a division of Cognizant Technology Solutions, Inc.), Waystar and Wellsoft
Corporation.
Backlog
We had a contract backlog of $4.4 billion and $3.9 billion as of December 31, 2019 and 2018, respectively, an increase of 13%. Contract backlog
represents the value of bookings and support and maintenance contracts that have not yet been recognized as revenue. Bookings reflect the value of executed
contracts for software, hardware, other client services, private-cloud hosting, outsourcing and subscription-based services. Total contract backlog can
fluctuate between periods based on the level of revenue and bookings as well as the timing and mix of renewal activity and periodic revalidations. We
estimate that approximately 35% of our aggregate contract backlog as of December 31, 2019 will be recognized as revenue during 2020.
Intellectual Property
We rely on a combination of trademark, copyright, trade secret and patent laws in the United States and other jurisdictions, as well as confidentiality
procedures and contractual provisions to protect our proprietary technology and our brand. We also enter into confidentiality and proprietary rights
agreements with our employees, consultants and other third parties and control access to software, documentation and other proprietary information.
Many of our products include intellectual property obtained from third parties. For example:
• Many of our products are built on technology provided by Microsoft Corporation, such as the Microsoft SQL Server information platform, the
Microsoft .NET Framework and the Microsoft Azure cloud platform.
• We license content from companies such as OptumInsight, 3M Health Information Systems, Wolters Kluwer Health, Elsevier, IMO and Clinical
Architecture, which we incorporate or use in certain solutions.
10
It may be necessary in the future to seek or renew licenses relating to various aspects of our products and services. While we have generally been able
to obtain licenses on commercially reasonable terms in the past, there is no guarantee that we can obtain such licenses in the future on reasonable terms or at
all. Because of continuous healthcare IT innovation, current extensive patent coverage and the rapid rate of issuance of new patents, it is possible that certain
components of our solutions may unknowingly infringe upon an existing patent or other intellectual property rights of others. Occasionally, we have been
notified that we may be infringing certain patent or other intellectual property rights of third parties. While the outcome of any litigation or dispute is
uncertain, we do not believe that the resolution any of these infringement notices will have a material adverse impact on our business.
Geographic Information
Historically, the majority of our clients and revenue have been associated with North America, where we have clients in the United States and
Canada. While we remain focused on the North American market, which we expect will continue to drive our revenue in the future, we believe that there are
opportunities for us globally as other countries face similar challenges of controlling healthcare costs while improving the quality and efficiency of healthcare
delivery. As a result, we have increased our efforts to selectively expand the sales of many of our solutions outside of North America, primarily in the United
Kingdom, the Middle East, Asia and Australia.
Employees
As of December 31, 2019, we had approximately 9,600 employees worldwide. None of our employees are covered by a collective bargaining
agreement or are represented by a labor union.
Information about our Executive Officers
The following sets forth certain information regarding our executive officers as of March 2, 2020, based on information furnished by each of them:
Name
Paul Black
Brian Farley
Lisa Khorey
Dennis Olis
Richard Poulton
Age
61
50
53
57
54
Position
Chief Executive Officer
Executive Vice President, General Counsel and Chief Administrative Officer
Executive Vice President, Chief Client Delivery Officer
Chief Financial Officer
President
Paul Black has served as our Chief Executive Officer since December 2012 and is also a member of our Board of Directors (our “Board”). Mr. Black
also served as our President from December 2012 to September 2015. Prior to joining, Mr. Black served as Operating Executive of Genstar Capital, LLC, a
private equity firm, and Senior Advisor at New Mountain Finance Corporation, an investment management company. From 1994 to 2007, Mr. Black served in
various executive positions (including Chief Operating Officer from 2005 to 2007) at Cerner Corporation, a healthcare IT company. Mr. Black has also served
as a director of Truman Medical Centers since 2001.
Brian Farley has served as our Executive Vice President, General Counsel and Chief Administrative Officer since August 2017 and prior to that
served as our Senior Vice President, General Counsel and Corporate Secretary since May 2013. From 2005 to 2013, Mr. Farley served in various positions at
Motorola Inc. and Motorola Mobility LLC, providers of mobile communication devices and video and data delivery solutions. His most recent role at
Motorola Mobility LLC was Corporate Vice President and General Counsel of Motorola’s Home business.
Lisa Khorey has served as our Executive Vice President, Chief Client Delivery Officer since November 2016. Prior to joining Allscripts, Ms. Khorey
was the executive director of Ernst & Young’s National Provider Practice, specializing in analytics. Previously, Ms. Khorey held a variety of technical and
executive leadership roles at University of Pittsburgh Medical Center.
Dennis Olis has served as our Chief Financial Officer since January 2018 and prior to that served as our interim Chief Financial Officer since May
2017. From November 2016 to May 2017, Mr. Olis served as Senior Vice President, Strategic Initiatives and, from November 2012 to November 2016, Mr.
Olis served as Senior Vice President, Operations. Prior to joining, Mr. Olis was employed by Motorola, Inc. and Motorola Mobility LLC, a provider of mobile
communication devices and video and data delivery solutions, for over 28 years. His most recent role at Motorola was Corporate Vice President, Mobile
Device Operations. From 2007 until 2009, he was Corporate Vice President of Finance, Research & Development, Portfolio Management, and Planning at
Motorola.
Richard Poulton has served as our President since October 2015. From October 2012 to March 2016, Mr. Poulton served as our Chief Financial
Officer. From October 2012 to September 2015, Mr. Poulton also served as our Executive Vice President. From 2006 to 2012, Mr. Poulton served in various
positions at AAR Corp., a provider of products and services to commercial aviation and the government and defense industries. His most recent role at AAR
Corp. was Chief Financial Officer and Treasurer. Mr. Poulton also spent more than ten years at UAL Corporation in a variety of financial and business
development roles, including Senior Vice President of Business Development as well as President and Chief Financial Officer of its client-focused Loyalty
Services subsidiary.
11
Available Information
Copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to reports filed
pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are filed with the U.S. Securities and
Exchange Commission (the “SEC”). We are subject to the informational requirements of the Exchange Act and we file or furnish reports, proxy statements
and other information with the SEC. Such reports and information are available free of charge at our website at investor.allscripts.com as soon as reasonably
practicable following our filing of any of these reports with the SEC. The SEC maintains an Internet site that contains reports, proxy and information
statements, and other information regarding issuers that file electronically with the SEC (http://www.sec.gov).
12
Item 1A. Risk Factors
Our business, financial condition, operating results and stock price can be materially and adversely affected by a number of factors, whether
currently known or unknown, including, but not limited to, those described below. Any one or more of such factors, some of which are outside of our control,
could directly or indirectly cause our actual financial condition and operating results to vary materially from our past or anticipated future financial
condition or operating results.
Because of the following factors, as well as other factors affecting our financial condition and operating results, past financial performance should
not be considered a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods.
These risk factors may be important to understanding any statement made by us in this Form 10-K or elsewhere. The following information should be
read in conjunction with Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the consolidated
financial statements and related notes in Part II, Item 8, “Financial Statements and Supplementary Data” of this Form 10-K.
Risks Related to Our Industry
Markets for our products and services are highly competitive and subject to rapid technological change, and we may be unable to compete
effectively in these markets.
The markets for our products and services are intensely competitive and are characterized by rapidly evolving technology, solution standards and user
needs and the frequent introduction of new products and services. There can be no assurance that we capture additional opportunities in the replacement
market. Some of our competitors may be more established, benefit from greater name recognition and have substantially greater financial, technical and
marketing resources than us. Moreover, we expect that competition will continue to increase as a result of potential incentives provided by government
programs and as a result of consolidation in both the IT and healthcare industries. If one or more of our competitors or potential competitors were to merge or
partner with another of our competitors, the change in the competitive landscape could adversely affect our ability to compete effectively.
We compete on the basis of several factors, including:
•
•
•
•
•
•
•
•
•
breadth and depth of services, including our open architecture and the level of product integration across care settings;
integrated platform;
regulatory compliance;
reputation;
reliability, accuracy and security;
client service;
total cost of ownership;
innovation; and
industry acceptance, expertise and experience.
There can be no assurance that we will be able to compete successfully against current and future competitors or that the competitive pressures that
we face will not materially and adversely impact our business, financial condition and operating results.
Consolidation in the healthcare industry could adversely impact our business, financial condition and operating results.
Many healthcare provider organizations are consolidating to create integrated healthcare delivery systems with greater market power. As provider
networks and managed care organizations consolidate, thus decreasing the number of market participants, competition to provide products and services like
ours will become more intense, and the importance of establishing and maintaining relationships with key industry participants will increase. These industry
participants may try to use their market power to negotiate price reductions for our products and services. Further, consolidation of management and billing
services through integrated delivery systems may decrease demand for our products. Such consolidation may also lead integrated delivery systems to require
newly acquired physician practices to replace their current Allscripts EHR product with that already in use in the larger enterprise. Any of these factors could
materially and adversely impact our business, financial condition and operating results.
13
We are subject to a number of existing laws, regulations and industry initiatives, and we are susceptible to a changing regulatory environment.
As a participant in the healthcare industry, our operations and relationships, and those of our clients, are regulated by a number of foreign, federal,
state and local governmental entities. The impact of this regulation on us is direct, to the extent we are ourselves subject to these laws and regulations, and is
also indirect, both in terms of the level of government reimbursement available to our clients and in that, in a number of situations, even if we are not directly
regulated by specific healthcare laws and regulations, our products must be capable of being used by our clients in a manner that complies with those laws
and regulations. The ability of our clients to comply with laws and regulations while using our solutions could affect the marketability of our products or our
compliance with our client contracts, or even expose us to direct liability under the theory that we had assisted our clients in a violation of healthcare laws or
regulations. Because our business relationships with physicians, hospitals and other provider clients are unique and the healthcare IT industry as a whole is
relatively young, the application of many state and federal regulations to our business operations and to our clients is uncertain. In the United States, there are
federal and state privacy and security laws; fraud and abuse laws, including anti-kickback laws and limitations on physician referrals; numerous quality
measurement programs being adopted by our clients; and laws related to distribution and marketing, including off-label promotion of prescription drugs,
which may be directly or indirectly applicable to our operations and relationships or the business practices of our clients. It is possible that a review of our
business practices or those of our clients by courts or regulatory authorities could result in a determination that could adversely affect us. See the risk factor
entitled “The failure by Practice Fusion to comply with the terms of its settlement agreements with the U.S. Department of Justice (the “DOJ”) could have a
material and adverse impact on our business, results of operations and financial condition, and, even if Practice Fusion complies with those settlement
agreements, the costs and burdens of compliance could be significant, and we may face additional investigations and proceedings from other governmental
entities or third parties related to the same or similar conduct underlying the agreements with the DOJ.” Furthermore, as we expand our business globally, we
become subject to comparable laws and regulations in each non-United States jurisdiction in which we operate, which creates additional risks. See the risk
factor entitled “Our business is subject to the risks of global operations” below for more information.
In addition, the healthcare regulatory environment may change in a way that restricts our existing operations or our growth. The healthcare industry
generally and the EHR industry specifically are expected to continue to undergo significant legal and regulatory changes for the foreseeable future, which
could have an adverse effect on our business, financial condition and operating results. We cannot predict the effect of possible future enforcement, legislation
and regulation.
Specific risks include, but are not limited to, risks relating to:
Healthcare Fraud. Federal and state governments continue to enhance regulation of and increase their scrutiny over practices involving healthcare
fraud perpetrated by healthcare providers and professionals whose services are reimbursed by Medicare, Medicaid and other government healthcare
programs. The healthcare industry is subject to laws and regulations on fraud and abuse which, among other things, prohibit the direct or indirect payment or
receipt of any remuneration for patient referrals, or for the purchase or order, or arranging for or recommending referrals or purchases, of any item or service
paid for in whole or in part by these federal or state healthcare programs. Federal enforcement personnel have substantial funding, powers and remedies to
pursue suspected or perceived fraud and abuse. Moreover, both federal and state laws forbid bribery and similar behavior. Any determination by a regulatory,
prosecutorial or judicial authority that any of our activities involving our clients, vendors or channel partners violate any of these laws could subject us to civil
or criminal penalties, require us to change or terminate some portions of our business, require us to refund a portion of our license or service fees and
disqualify us from providing services to clients doing business with government programs, all of which could have a material adverse effect on our business,
financial condition and operating results. Even an unsuccessful challenge by regulatory or prosecutorial authorities of our activities could result in adverse
publicity, require a costly response from us and have a material adverse effect on our business, financial condition and operating results.
Patient Information. As part of the operation of our business, we, and our subcontractors may have access to, or our clients may provide to us,
individually identifiable health information related to the treatment, payment and operations of providers’ practices. In the United States, government and
industry legislation and rulemaking, especially HIPAA, HITECH and standards and requirements published by industry groups such as the Joint Commission
require the use of standard transactions, standard identifiers, security and other standards and requirements for the transmission of certain electronic health
information. National standards and procedures under HIPAA include the “Standards for Electronic Transactions and Code Sets” (the “Transaction
Standards”); the “Security Standards” (the “Security Standards”); and the “Standards for Privacy of Individually Identifiable Health Information” (the
“Privacy Standards”). The Transaction Standards require the use of specified data coding, formatting and content in all specified “HealthCare Transactions”
conducted electronically. The Security Standards require the adoption of specified types of security measures for certain electronic health information, which
is called Protected Health Information (“PHI”). The Privacy Standards grant a number of rights to individuals as to their PHI and restrict the use and
disclosure of PHI by “Covered Entities,” defined as “health plans,” “healthcare providers,” and “healthcare clearinghouses.” Entities that perform services to
or on behalf of Covered Entities where PHI is or is likely to be accessed are called Business Associates.
14
We believe we are a Covered Entity because we act as a “healthcare clearinghouse” through our provision of Allscripts Payerpath which has the
ability to file electronic healthcare claims on behalf of healthcare providers that are subject to HIPAA and HITECH. We also believe that in certain business
relationships we are a Business Associate. The 2013 modifications to the HIPAA Privacy, Security, Breach Notification, and Enforcement Rules impose
additional obligations and burdens on Covered Entities, Business Associates and their subcontractors relating to the privacy and security of PHI. Much of the
Privacy Standards and all of the Security Standards now apply directly to Business Associates and their subcontractors. These rules have increased the cost of
compliance and could subject us to additional enforcement actions, which could further increase our costs and adversely affect the way in which we do
business.
In addition, certain provisions of the Privacy Standards and Security Standards apply to Business Associates when they create, access or receive PHI
in order to perform a function or activity on behalf of a Covered Entity. Covered Entities and Business Associates must enter a written “Business Associate
Agreement”, containing specified written satisfactory assurances, consistent with the Privacy and Security Standards and HITECH and its implementing
regulations, that the third party will safeguard PHI that it creates or accesses and will fulfill other material obligations. Most of our clients are Covered
Entities, and we and our subcontractors function in many of our relationships as a Business Associate of those clients. Under the HIPAA Omnibus Rule,
Business Associates may be held directly liable for violations of HIPAA. Therefore, we could face liability under our Business Associate Agreements and
HIPAA and HITECH if we do not comply with our Business Associate obligations and applicable provisions of the Privacy and Security Standards and
HITECH and its implementing regulations. The penalties for a violation of HIPAA or HITECH are significant and could have an adverse impact upon our
business, financial condition and operating results, if such penalties ever were imposed.
Subject to the discussion set forth above, we believe that the principal effects of HIPAA are, first, to require that our systems be capable of being
operated by us and our clients in a manner that is compliant with the Transaction, Security and Privacy Standards, second, to require us to enter into and
comply with Business Associate Agreements with our Covered Entity clients, and third, to comply with HIPAA when it directly applies to us. For most
Covered Entities, the deadlines for compliance with the Privacy Standards and the Transaction Standards occurred in 2003, and for the Security Standards in
2005, and for the HIPAA Omnibus Rule in 2013.
Additionally, Covered Entities that are providers are required to adopt a unique standard National Provider Identifier (“NPI”), for use in filing and
processing healthcare claims and other transactions. Most Covered Entities were required to use NPIs in standard transactions by 2007. We have policies and
procedures that we believe comply with federal and state confidentiality requirements for the handling of PHI that we receive and with our obligations under
Business Associate Agreements. In particular, we believe that our systems and products are operated by us and capable of being used by our clients in
compliance with the Transaction, Security and Privacy Standards and are capable of being used by or for our clients in compliance with the NPI requirements.
If, however, we or our subcontractors do not follow those procedures and policies, or they are not sufficient to prevent the unauthorized disclosure of PHI, we
could be subject to civil and/or criminal liability, fines and lawsuits, termination of our client contracts or our operations could be shut down. Moreover,
because all HIPAA Standards and HITECH implementing regulations and guidance are subject to change or interpretation, we cannot predict the full future
impact of HIPAA, HITECH or their implementing regulations on our business and operations. In the event that HIPAA, HITECH or their implementing
regulations change or are interpreted in a way that requires any material change to the way in which we do business, our business, financial condition and
operating results could be adversely affected. Additionally, certain state privacy laws are not preempted by HIPAA and HITECH and may impose
independent obligations upon our clients or us. Additional legislation governing the acquisition, storage and transmission or other dissemination of health
record information and other personal information, including social security numbers and other identifiers, continues to be proposed and come into force at
the state level. There can be no assurance that changes to state or federal laws will not materially restrict the ability of providers to submit information from
patient records using our products and services.
Electronic Prescribing. The use of our software by physicians to perform a variety of functions, including electronic prescribing, which refers to the
electronic routing of prescriptions to pharmacies and the ensuing dispensation, is governed by state and federal law, including fraud and abuse laws. States
have differing prescription format requirements, which we have programmed into our software. There is significant variation in the laws and regulations
governing prescription activity, as federal law and the laws of many states permit the electronic transmission of certain controlled prescription orders, while
the laws of several states neither specifically permit nor specifically prohibit the practice. Restrictions exist at the federal level on the use of electronic
prescribing for controlled substances and certain other drugs, including a regulation enacted by the Drug Enforcement Association in mid-2010. However,
some states (most notably New York) have passed complementary laws governing the use of electronic prescribing tools in the use of prescribing opioids and
other controlled substances, and we expect this to continue to be addressed with regulations in other states. In addition, the HHS published its final “E-
Prescribing and the Prescription Drug Program” regulations in 2005 (effective January 1, 2006), and final regulations governing the standards for electronic
prescribing under Medicare Part D in 2008 (effective June 6, 2008) (the “ePrescribing Regulations”). These regulations are required by the Medicare
Prescription Drug, Improvement, and Modernization Act of 2003 (“MMA”) and consist of detailed standards and requirements, in addition to the HIPAA
Standard discussed above, for prescription and other information transmitted electronically in connection with a drug benefit covered by the MMA’s
Prescription Drug Benefit. Further, in 2016, Congress passed the Comprehensive Addiction and Recovery Act, which contained components related to
Prescription Drug Monitoring Programs and other elements that relate to use of our technologies.
15
Incentive programs to drive certain usage patterns of our solutions by eligible professionals began to increase in number starting in 2008 with the
Medicare Improvements for Patients and Providers Act (“MIPPA”), which authorized payments to individual prescribers who were successful electronic
prescribers, and the quality reporting incentive program that is now known as the Physician Quality Reporting System (“PQRS”). Both programs remained in
effect for 2015, with both applying payment adjustments to non-participating providers. Beginning in 2009, HITECH’s EHR Incentive Program (also known
as Meaningful Use) became the most prominent incentive program, reducing the impact the MIPPA and PQRS programs had in spurring greater adoption of
healthcare IT. In 2016, CMS issued preliminary regulations for the Quality Payment Program (“QPP”), which implemented the Medicare Access and CHIP
Reauthorization Act (“MACRA”) for ambulatory clinicians further reducing the impact of MIPPA. Effective on January 1, 2017, the Merit based Incentive
Payment System (“MIPS”), established by MACRA, came into effect. Its goal was to transform the healthcare industry from a fee for service payment to a
value-based payment. MIPS combined three existing quality and value reporting programs (PQRS, VBM and Meaningful Use) into a single points-based
program. MIPSs and Meaningful Use Stage 3 operated simultaneously in 2017 and 2018 but in 2019 only certain Medicaid reporters were eligible for the
Meaningful Use Stage 3 incentives. Eligible clinicians, who report under MIPS, earned a performance-based payment adjustment for their Medicare
payments starting in 2019.
In general, regulations in this area impose certain requirements which can be burdensome and evolve regularly, meaning that any potential benefits
may be reversed by a newly-promulgated regulation that adversely affects our business model. Aspects of our clinical products are affected by such regulation
because of our need to include features or functions in our products to achieve certification, as well as the need of our clients to comply, as discussed above,
and we expect this will continue for the foreseeable future.
We may also be subject, as discussed above, to future legislation and regulations concerning the development and marketing of healthcare software
systems or requirements related to product functionality. These could increase the cost and time necessary to market new services and could affect us in other
respects not presently foreseeable.
Electronic Health Records. A number of important federal and state laws govern the use and content of EHRs, including fraud and abuse laws that
may affect the design of such technology. As a company that provides EHRs to a variety of providers of healthcare, our systems and services must be
designed in a manner that facilitates our clients’ compliance with these laws. We cannot predict the content or effect of possible changes to these laws or new
federal and state laws that might govern these systems and services. Furthermore, several of our products are certified by an Office of the National
Coordinator for Health Information Technology-approved certifying body as meeting the standards for functionality, interoperability and security under
HITECH. Our failure to maintain this certification or otherwise meet industry standards could adversely impact our business.
Under HITECH, eligible healthcare professionals and hospitals have been able to qualify for an additional Medicare and Medicaid payment for the
Meaningful Use of certified EHR technology that meets specified objectives under the EHR Incentive program. Many of our products have been certified as
compliant EHRs or modules, in accordance with the applicable certification criteria set forth by the Secretary of HHS, including the 2015 EHR Certification
Edition criteria (the “2015 Edition”). Such certification does not represent an endorsement of our products or modules by HHS or a guaranty of the receipt of
incentive payments by our clients. If our clients do not receive or lose expected incentive payments, this could harm their willingness to purchase future
products or upgrades, and therefore could have an adverse effect on our future revenues.
On October 6, 2015, CMS published its final rule on Stage 3 of the Meaningful Use Requirements for the Electronic Health Record Incentive
Program. Stage 3 objectives were focused on improving the interoperability of EHR systems in different practices and are intended to bring about
advancements in care delivery by requiring more advanced EHR functionality and standards for structuring data, increasing thresholds compared to Stage 1
and 2 measures, and requiring more coordinated care and patient engagement. New, complex regulatory requirements related to Stage 3 Meaningful Use
certification and voluntary regulations were released within the 2015 Edition criteria. All providers were required to meet the Stage 3 objectives in 2018 for
the entire calendar year in order to attest to Meaningful Use. Effective on January 1, 2017, the MIPS, established by MACRA, came into effect. Its goal was
to transform the healthcare industry from a fee for service payment to a value-based payment. MIPS combined three existing quality and value reporting
programs (PQRS, VBM and Meaningful Use) into a single points-based program. MIPSs and Meaningful Use Stage 3 operated simultaneously in 2017 and
2018 but in 2019 only certain Medicaid reporters were eligible for the Meaningful Use Stage 3 incentives. Eligible clinicians, who report under MIPS, earned
a performance-based payment adjustment for their Medicare payments starting in 2019.
The MACRA and resulting regulations are also anticipated to lead our clients to request advanced quality measurement and analytic functionality
within our products in order to be able to participate in the new payment models, including MIPs and Advanced Alternative Payment that have already been
launched, and any future models that will be launched. Similar programs have also been created and are being expanded by commercial payers and non-
governmental organizations, such as the National Committee for Quality Assurance, which oversee the Patient Centered Medical Home initiatives. The
related product requirements are continually evolving and are not coordinated by these parties amongst themselves, which could cause us to expend additional
resources to assist our clients.
16
Claims Transmission. Our system electronically transmits medical claims by physicians to patients’ payers for approval and reimbursement. In
addition, we offer revenue cycle management services that include the manual and electronic processing and submission of medical claims by physicians to
patients’ payers for approval and reimbursement. Federal law provides that it is both a civil and a criminal violation for any person to submit, or cause to be
submitted, a claim to any payer, including, without limitation, Medicare, Medicaid and all private health plans and managed care plans, seeking payment for
any services or products that overbills or bills for items that have not been provided to the patient. We have in place policies and procedures that we believe
assure that all claims that are transmitted by our system and through our services are accurate and complete, provided that the information given to us by our
clients is also accurate and complete. If, however, we or our subcontractors do not follow those procedures and policies, or they are not sufficient to prevent
inaccurate claims from being submitted, we could be subject to liability.
As discussed above, the HIPAA Transaction and Security Standards also affect our claims transmission services, since those services must be
structured and provided in a way that supports our clients’ HIPAA compliance obligations. Furthermore, to the extent that there is some type of information
security breach, it could have a material adverse effect on our business.
Medical Devices. Certain computer software products are regulated as medical devices under the Federal Food, Drug and Cosmetic Act. The 21st
Century Cures Act, passed in December 2016, clarified the definition of a medical device to exclude health information technology such as Electronic Health
Records; however, the legislation did leave the opportunity for that designation to be revisited if determined to be necessary by changing industry and
technological dynamics. Accordingly, the Food and Drug Administration (the “FDA”) may become increasingly active in regulating computer software
intended for use in healthcare settings. Depending on the product, we could be required to notify the FDA and demonstrate substantial equivalence to other
products on the market before marketing such products or obtain FDA approval by demonstrating safety and effectiveness before marketing a product.
Depending on the intended use of a device, the FDA could require us to obtain extensive data from clinical studies to demonstrate safety or effectiveness or
substantial equivalence. If the FDA requires this data, we could be required to obtain approval of an investigational device exemption before undertaking
clinical trials. Clinical trials can take extended periods of time to complete. We cannot provide assurances that the FDA would approve or clear a device after
the completion of such trials. In addition, these products would be subject to the Federal Food, Drug and Cosmetic Act’s general controls. The FDA can
impose extensive requirements governing pre- and post-market conditions such as approval, labeling and manufacturing, as well as governing product design
controls and quality assurance processes. Failure to comply with FDA requirements can result in criminal and civil fines and penalties, product seizure,
injunction and civil monetary policies—each of which could have an adverse effect on our business.
Health Reform. The activity related to the repeal, repair and/or replacement of the Patient Protection and Affordable Care Act (“PPACA”), including
any changes resulting from continued judicial and congressional challenges to certain aspects of the law, and the 2015 repeal of the Sustainable Growth Rate
and replacement with the MACRA may have an impact on our business. The Affordable Care Act, passed in 2010, contained various provisions which have
impacted us and our clients, and any replacement or adjustment of that law may change requirements related to our products or how our clients use them, as
well as reimbursement available to our clients. The QPP, which implements the MACRA, is oriented around the collection and analysis of quality
measurement data from our clients and expansion of programs such as ACOs. These may have a positive impact by requiring the expanded use of EHRs and
analytics tools to participate in certain federal programs, for example, while others, such as those mandating reductions in reimbursement for certain types of
providers, may have a negative impact by reducing the resources available to purchase our products. Increases in fraud and abuse enforcement and penalties
may also adversely affect participants in the healthcare sector, including us.
Increased government involvement in healthcare could materially and adversely impact our business.
United States healthcare system reform at both the federal and state level could increase government involvement in healthcare, reconfigure
reimbursement rates and otherwise change the business environment of our clients and the other entities with which we have a business relationship. We
cannot predict whether or when future healthcare reform initiatives at the federal or state level or other initiatives affecting our business will be proposed,
enacted or implemented or what impact those initiatives may have on our business, financial condition or operating results. Our clients and the other entities
with which we have a business relationship could react to these initiatives and the uncertainty surrounding these proposals by curtailing or deferring
investments, including those for our products and services.
17
The government had signaled, under the previous presidential Administration, increased enforcement activity targeting healthcare fraud and abuse,
which could adversely impact our business, either directly or indirectly. This decision could be reversed by the current Administration, but is likely to remain
in effect. To the extent that our clients, most of whom are providers, may be affected by this increased enforcement environment, our business could
correspondingly be affected. Additionally, government regulation could alter the clinical workflow of physicians, hospitals and other healthcare participants,
thereby limiting the utility of our products and services to existing and potential clients and curtailing broad acceptance of our products and services. Further
examples of government involvement could include requiring the standardization of technology relating to EHRs, providing clients with incentives to adopt
EHR solutions or developing a low-cost government-sponsored EHR solution. Additionally, certain safe harbors to the federal anti-kickback statute and
corresponding exceptions to the federal Ethics in Patient Referrals Act, known as the Stark Law, may continue to alter the competitive landscape. These safe
harbors and exceptions are intended to accelerate the adoption of electronic prescription systems and EHR systems, and therefore provide new and attractive
opportunities for us to work with hospitals and other donors who wish to provide our solutions to physicians. At the same time, such safe harbors and
exceptions may result in increased competition from providers of acute EHR solutions, whose hospital clients may seek to donate their existing acute EHR
solutions to physicians for use in ambulatory settings.
If the healthcare information technology market fails to continue to develop as quickly as expected, our business, financial condition and operating
results could be materially and adversely affected.
The electronic healthcare information market is rapidly evolving. A number of market entrants have introduced or developed products and services
that are competitive with one or more components of the solutions we offer. We expect that additional companies will continue to enter this market, especially
in response to recent legislative actions. In new and rapidly evolving industries, there is significant uncertainty and risk as to the demand for, and market
acceptance of, recently introduced products and services. Because the markets for our products and services are new and evolving, we are not able to predict
the size and growth rate of the markets with any certainty. If markets fail to develop, develop more slowly than expected or become saturated with
competitors, our business, financial condition and operating results could be materially and adversely impacted.
We may not see the benefits of government programs initiated to accelerate the adoption and utilization of healthcare IT.
While government programs have been initiated to improve the efficiency and quality of the healthcare sector, including expenditures to stimulate
business and accelerate the adoption and utilization of healthcare technology, we may not receive any more of those funds. For example, the passage of
HITECH authorized approximately $30 billion in expenditures, including discretionary funding, to further the adoption of EHRs. However, with most of
those funds expended and taking into consideration the currently conservative fiscal environment within the United States Congress, there can be no certainty
that any additional planned financial incentives, if made, will be made in regard to our services, nor can there be any assurance that HITECH and/or the
MACRA will not be repealed or amended in a manner that would be unfavorable to our business. We also cannot predict the speed at which physicians will
adopt EHR systems in response to such government incentives, whether physicians will select our products and services, or whether physicians will
implement an EHR system at all, whether in response to government funding or at all. If the expected outcomes with respect to government programs do not
materialize, or if physicians do not respond to such programs as expected, then this could materially and adversely impact our revenue growth, financial
condition and operating results.
Changes in interoperability and other regulatory standards applicable to our software could require us to incur substantial additional development
costs.
Our clients and the industry leaders enacting regulatory requirements are concerned with, and often require, that our software solutions be
interoperable with other third-party health IT suppliers. Market forces or governmental authorities have created and could continue to create software
interoperability standards that could apply to our solutions, and if our applicable products or services are not consistent with those standards, we could be
forced to incur substantial additional development costs. We will likely incur increased development costs in delivering solutions to upgrade our software and
healthcare devices to be in compliance with these varying and evolving standards, and delays may result in connection therewith. If our applicable products or
services are not consistent with these evolving standards, our market position and sales could be adversely affected and we may have to invest significantly in
changes to our software solutions, which could materially and adversely impact our financial condition and operating results.
18
Risks Related to Our Company
The realignment of our sales, services and support organizations could adversely affect client relationships and affect our future growth.
We periodically make adjustments to our sales, services and support organizations in response to market opportunities, management changes, product
introductions and other internal and external considerations. These changes could result in a temporary lack of focus and reduced productivity. In addition,
these adjustments could result in our clients experiencing a change in our employees with whom they interact. Any of these changes could adversely impact
individual client relationships, client retention, and sales of products and services to existing clients. It is also possible that these changes could adversely
affect our ability to sell our products and services to new clients. Any such events could materially and adversely impact our business, financial condition and
operating results.
Our clients may not accept our products and services or may delay decisions whether to purchase our products and services.
Our business model depends on our ability to sell our products and services. Acceptance of our products and services may require our clients to adopt
different behavior patterns and new methods of conducting business and exchanging information. We cannot provide assurance that our clients will integrate
our products and services into their workflow or that participants in the healthcare market will accept our products and services as a replacement for
traditional methods of conducting healthcare transactions. Achieving market acceptance for our products and services will require substantial sales and
marketing efforts and the expenditure of significant financial and other resources to create awareness and demand by participants in the healthcare industry. If
we fail to achieve broad acceptance of our products and services by physicians, hospitals and other healthcare industry participants, or if we fail to position
our services as a preferred method for information management and healthcare delivery, our business, financial condition and operating results could be
materially and adversely impacted.
It is difficult to predict the sales cycle and implementation schedule for our products and services.
The duration of the sales cycle and implementation schedule for our products and services depends on a number of factors, including the nature and
size of the potential client and the extent of the commitment being made by the potential client, all of which may be difficult to predict. Our sales and
marketing efforts with respect to hospitals and large health organizations generally involve a lengthy sales cycle due to these organizations’ complex decision-
making processes. Additionally, in light of increased government involvement in healthcare and related changes in the operating environment for healthcare
organizations, our current and potential clients may react by reducing or deferring investments, including their purchases of our solutions or services. If
clients take longer than we expect to decide whether to purchase our solutions, our selling expenses could increase and our revenues could decrease, which
could materially and adversely impact our business, financial condition and operating results. If clients take longer than we expect to implement our solutions,
our recognition of related revenue would be delayed, which could also materially and adversely impact our business, financial condition and operating results.
The implementation of large and complex contracts requires us to devote a sufficient amount of personnel, systems, equipment, technology and other
resources as are necessary to ensure a timely and successful implementation. In addition, due to the amount of resources dedicated to implement large and
complex contracts, our ability to successfully bid for and implement other new customer contracts may be adversely affected. If we fail to implement large
and complex contracts successfully and in a timely manner, or if as a result of resource constraints, we fail to properly implement other new customer
contracts, we may face significant challenges that will adversely affect our business, financial condition and operating results.
Our future success depends upon our ability to grow, and if we are unable to manage our growth effectively, we may incur unexpected expenses and
be unable to meet our clients’ requirements.
We will need to expand our operations if we successfully achieve market acceptance for our products and services. We cannot be certain that our
systems, procedures, controls and existing space will be adequate to support expansion of our operations. Our future operating results will depend on the
ability of our officers and employees to manage changing business conditions and to effectively maintain and improve our technical, administrative, financial
control and reporting systems. We may not be able to expand and upgrade our systems and infrastructure to accommodate these increases. Difficulties in
managing any future growth, including as a result of integrating any prior or future acquisition with our existing businesses, could cause us to incur
unexpected expenses, render us unable to meet our clients’ requirements, and consequently could materially and adversely impact our business, financial
condition and operating results.
We are working to expand our operations in markets outside of the United States. There can be no assurance that these efforts will be successful. We
have limited experience in marketing, selling, implementing and supporting our products and services abroad. Expansion of our global sales and operations
may require us to divert the efforts of our technical and management personnel and could result in significant expense to us, which could materially and
adversely impact our operating results.
19
We may be unable to successfully introduce new products or services or fail to keep pace with advances in technology.
The successful implementation of our business model depends on our ability to adapt to evolving technologies and increasingly aggressive industry
standards and introduce new products and services accordingly. We cannot provide assurance that we will be able to introduce new products on schedule, or at all,
or that such products will achieve market acceptance. Moreover, competitors may develop competitive products that could adversely affect our operating results.
Any failure by us to introduce planned products or other new products or to introduce these products on schedule could have an adverse effect on our revenue
growth and operating results.
If we cannot adapt to changing technologies, our products and services may become obsolete and our business could suffer. Because the markets in
which we operate are characterized by rapid technological change, we may be unable to anticipate changes in our current and potential clients’ or users’
requirements that could make our existing technology obsolete. Our success will depend, in part, on our ability to continue to enhance our existing products
and services, develop new technology that addresses the increasingly sophisticated and varied needs of our prospective clients and users, license leading
technologies and respond to technological advances and emerging industry standards and practices, all on a timely and cost-effective basis. The development
of our proprietary technology entails significant technical and business risks. We may not be successful in using new technologies effectively or adapting our
proprietary technology to evolving client or user requirements or emerging industry standards. Any of the foregoing could materially and adversely impact
our business, financial condition and operating results.
Our business depends in part on our ability to establish and maintain additional strategic relationships.
To be successful, we must continue to maintain our existing strategic relationships and establish additional strategic relationships with leaders in a
number of the markets in which we operate. This is critical to our success because we believe that these relationships contribute towards our ability to:
•
•
•
•
extend the reach of our products and services to a larger number of physicians and hospitals and to other participants in the healthcare industry;
develop and deploy new products and services;
further enhance our brand; and
generate additional revenue and cash flows.
Entering into strategic relationships is complicated because strategic partners may decide to compete with us in some or all of the markets in which
we operate. In addition, we may not be able to maintain or establish relationships with key participants in the healthcare industry if we conduct business with
their competitors.
We depend, in part, on our strategic partners’ ability to generate increased acceptance and use of our products and services. If we lose any of these
strategic relationships or fail to establish additional relationships, or if our strategic relationships fail to benefit us as expected, this could materially and
adversely impact our business, financial condition and operating results.
We have acquired and expect to acquire new companies, investments or technologies, which are subject to significant risks.
We have recently made investments in, or acquisitions of, businesses, joint ventures, new services and technologies, and other intellectual property
rights, including our acquisitions of the EIS Business, the provider and patient engagement solutions business of NantHealth, Practice Fusion and Health
Grid. We expect that we will continue to make such investments and acquisitions in the future.
Our investments and acquisitions involve numerous risks, including:
•
•
•
•
•
•
•
•
•
•
the potential failure to achieve the expected benefits of the investment or acquisition, including the inability to generate sufficient revenue to
offset acquisition or investment costs, or the inability to achieve expected synergies or cost savings;
unanticipated expenses related to acquired businesses or technologies;
the diversion of financial, managerial and other resources from existing operations;
the risks of entering into new markets in which we have little or no experience or where competitors may have stronger positions;
unanticipated regulatory and other compliance risks related to acquired companies or technologies;
potential write-offs or amortization of acquired assets or investments;
the potential loss of key employees, clients or partners of an acquired business;
delays in client purchases due to uncertainty related to any acquisition;
potential unknown liabilities associated with an investment or acquisition; and
the tax effects of any such acquisitions.
20
In addition, prior to their acquisition by us, the EIS Business received a request for documents and information from the U.S. Attorney’s Office
pursuant to a civil investigative demand (a “CID”). The CID relates to the certification of the respective business’s software under the U.S. Office of the
National Coordinator for Health Information Technology’s electronic health record certification program and related business practices. In August 2018, an
additional CID seeking similar information related to a separate EIS Business solution. If either CID leads to a claim or legal proceeding against us or our
businesses that results in the imposition of damages, non-monetary relief, significant compliance, litigation or settlement costs or any other losses, in each
case for which we are not indemnified by the seller of the acquired business, or are otherwise unable to recover against the seller, such damages, relief, costs
or losses could materially and adversely impact our business, financial condition and operating results.
Additionally, prior to their acquisition by us, Practice Fusion received a request for documents and information from the U.S. Attorney’s Office for
the District of Vermont pursuant to a CID. Subsequent to their acquisition by us, Practice Fusion received additional requests for documents and information
pursuant to additional CIDs and HIPAA subpoenas. These requests related to the certification of Practice Fusion’s software under the U.S. Department of
Health and Human Services’ Electronic Health Record Incentive Program, compliance with the Anti-Kickback Statute, and related business practices. On
January 27, 2020, Practice Fusion entered into a series of agreements to resolve these investigations. See risk factor entitled “The failure by Practice Fusion to
comply with the terms of its settlement agreements with the U.S. Department of Justice (the “DOJ”) could have a material and adverse impact on our
business, results of operations and financial condition, and, even if Practice Fusion complies with those settlement agreements, the costs and burdens of
compliance could be significant, and we may face additional investigations and proceedings from other governmental entities or third parties related to the
same or similar conduct underlying the agreements with the DOJ.”
Furthermore, the success of our acquisitions will depend, in part, on our ability to integrate our existing businesses with those of the acquired
businesses, including the integration of employees, products and technologies. These integrations are inherently complex, costly and time-consuming
processes and involve numerous risks, including, but not limited to, unanticipated expenses and the diversion of financial, managerial and other resources
from both our existing operations and those of the acquired businesses. The integration of foreign acquisitions presents additional challenges associated with
integrating operations across different cultures and languages, as well as currency and regulatory risks associated with specific countries.
If we fail to properly evaluate and execute acquisitions or investments, or if we fail to successfully integrate acquired businesses, we may not be able
to achieve projected results or support the amount of consideration paid for such acquired businesses or investments, which could materially and adversely
impact our business, financial condition and operating results.
Finally, if we finance acquisitions or investments by issuing equity or convertible or other debt securities or loans, our existing stockholders may be
diluted, or we could face constraints related to the terms of and repayment obligations related to the incurrence of indebtedness. This could materially and
adversely impact our stock price.
Our products or services could fail to perform properly due to errors or similar problems.
Complex technology, such as ours, often contains defects or errors, some of which may remain undetected for a period of time. It is possible that such
errors may be found after the introduction of new products or services or enhancements to existing products or services. We continually introduce new solutions
and enhancements to our solutions and, despite testing by us, it is possible that errors may occur in our software or offerings. If we detect any errors before we
introduce a solution, we may have to delay deployment for an extended period of time while we address the problem. If we do not discover errors that affect our
new or current solutions or enhancements until after they are deployed, we would need to provide enhancements to correct such errors. Errors in our products or
services could result in:
•
•
•
•
•
•
•
•
•
product-related liabilities, fraud and abuse or patient safety issues;
unexpected expenses and liability and diversion of resources to remedy errors;
harm to our reputation;
lost sales;
delays in commercial releases;
delays in or loss of market acceptance of our solutions;
license termination or renegotiations;
privacy and/or security vulnerabilities; and
misreporting by clients of eCOMs and other measures.
21
Furthermore, our clients may use our products or services together with products or services from other companies or those that they have developed
internally. As a result, when problems occur, it may be difficult to identify the source of the problem. Even when our products or services do not cause these
problems, the existence of these errors may cause us to incur significant costs, divert the attention of our technical personnel from our other solution
development efforts, impact our reputation and cause significant issues with our client relationships.
We may be unable to protect, and we may incur significant costs in enforcing, our intellectual property rights.
Our patents, trademarks, trade secrets, copyrights, and other intellectual property rights are important assets to us. Various events outside of our
control pose a threat to our intellectual property rights, as well as to our products, services, and technologies. For instance, any of our current or future
intellectual property rights may be challenged by others or invalidated through administrative process or litigation. Any of our pending or future patent
applications, whether or not being currently challenged, may not be issued with the scope of the claims we seek, if at all.
We have taken efforts to protect our proprietary rights, including a combination of license agreements, confidentiality policies and procedures,
confidentiality provisions in employment agreements, confidentiality agreements with third parties, and technical security measures, as well as our reliance on
copyright, patent, trademark, trade secret and unfair competition laws. These efforts may not be sufficient or effective. For example, the secrecy of our trade
secrets or other confidential information could be compromised by our employees or by third parties, which could cause us to lose the competitive advantage
resulting from those trade secrets or confidential information. Unauthorized third parties may try to copy or reverse engineer portions of our products or
otherwise infringe upon, misappropriate or use our intellectual property. We may not be able to discover or determine the extent of any unauthorized use of
our proprietary rights. We may also conclude that, in some instances, the benefits of protecting our intellectual property rights may be outweighed by the
expense.
In addition, our platforms incorporate “open source” software components that are licensed to us under various public domain licenses. Open source
license terms are often ambiguous, and there is little or no legal precedent governing the interpretation of many of the terms of certain of these licenses.
Therefore, the potential impact of such terms on our business is somewhat unknown. Further, some enterprises may be reluctant or unwilling to use cloud-
based services, because they have concerns regarding the risks associated with the security and reliability, among other things, of the technology delivery
model associated with these services. If enterprises do not perceive the benefits of our services, then the market for these services may not expand as much or
develop as quickly as we expect, either of which would adversely affect our business, financial condition, or operating results.
Legal standards relating to the validity, enforceability and scope of protection of intellectual property rights are uncertain and still evolving. The laws
of some foreign countries may not be as protective of intellectual property rights as those in the United States, and effective intellectual property protection
may not be available in every country in which our products and services are distributed.
Any impairment of our intellectual property rights, or our failure to protect our intellectual property rights adequately, could give our competitors’
access to our technology and could materially and adversely impact our business and operating results. Any increase in the unauthorized use of our
intellectual property could also divert the efforts of our technical and management personnel and result in significant additional expense to us, which could
materially and adversely impact our operating results. Finally, we may be required to spend significant resources to monitor and protect our intellectual
property rights, including with respect to legal proceedings, which could result in substantial costs and diversion of resources and could materially and
adversely impact our business, financial condition and operating results.
We could be impacted by unfavorable results of legal proceedings and claims, such as being found to have infringed on a third party’s intellectual
property rights.
We are subject to various legal proceedings and claims that have not yet been fully resolved, including the CIDs and other requests related to the EIS
Business and those discussed under Note 21, “Contingencies,” to our consolidated financial statements included in Part II, Item 8, “Financial Statements and
Supplementary Data” of this Form 10-K, and additional claims may arise in the future. For example, companies in our industry, including many of our
competitors, have been subject to litigation based on allegations of patent infringement or other violations of intellectual property rights. In particular, patent
holding companies often engage in litigation seeking to monetize patents that they have purchased or otherwise obtained. As the number of competitors,
patents and patent holding companies in our industry increases, the functionality of our products and services expands, and as we enter into new geographies
and markets, the number of intellectual property rights-related actions against us has increased and is likely to continue to increase. We are vigorously
defending against these actions in a number of jurisdictions.
22
If we are found to infringe one or more patents or other intellectual property rights, regardless of whether we can develop non-infringing technology,
we may be required to pay substantial damages or royalties to a third party, and we may be subject to a temporary or permanent injunction prohibiting us from
marketing or selling certain products or services. Furthermore, certain of our agreements require us to indemnify our clients and third-party service providers
for third party intellectual property infringement claims, which would increase the costs to us of an adverse ruling on such claims and could adversely impact
our relationships with our clients and third party service providers. In certain cases, we may consider the desirability of entering into licensing agreements,
although no assurance can be given that such licenses can be obtained on acceptable terms or that litigation will not occur. These license agreements may also
significantly increase our operating expenses.
Regardless of the merit of particular claims, legal proceedings may be expensive, time-consuming, disruptive to our operations and distracting to our
management. If one or more legal matters were resolved against or settled by us in a reporting period for amounts in excess of management’s expectations,
our consolidated financial statements for that reporting period could be materially and adversely impacted. Such an outcome could result in significant
compensatory, punitive or other monetary damages; disgorgement of revenue or profits; remedial corporate measures; or other injunctive or equitable relief
against us, any of which could materially and adversely impact our business, financial condition and operating results.
We maintain insurance coverage that may apply in the event we are involved in a legal proceeding or claim. This coverage may not continue to be
available on acceptable terms, may not be available in sufficient amounts to cover one or more claims against us, and may include larger self-insured
retentions or exclusions for certain products or services. In addition, the insurer might disclaim coverage as to any future claim. This could increase the
magnitude of the impact of one or more legal proceedings or claims being resolved against or settled by us.
Our exposure to risks associated with various claims, including the use of intellectual property, may be increased as a result of acquisitions of other
companies. For example, we may have a lower level of visibility into the development process with respect to intellectual property, or the care taken to
safeguard against infringement risks, with respect to the acquired company or its technology. In addition, third parties may make infringement or related
claims after we have acquired companies that had not been asserted prior to the acquisition.
Our success depends on the continued service and availability of key personnel.
Much of our future performance depends on the continued availability and service of our key personnel, including our Chief Executive Officer and
our President, the other members of our senior management team, and our other highly qualified personnel, as well as being able to hire additional highly
qualified personnel who have a deep understanding of our industry. Competition in our industry for such personnel, especially with respect to sales and
technical personnel, is intense. We are required to expend significant resources on identifying, hiring, developing, motivating and retaining such personnel
throughout our organization. Many of the companies with whom we compete for such personnel have greater resources than us and may be able to offer more
attractive terms of employment. Our investment in training and developing our employees makes them more attractive to our clients and competitors, who
may then seek to recruit them. Furthermore, our compensation arrangements, such as our equity award programs, may not always be successful in attracting
new employees and retaining and motivating our existing employees. Our failure to attract new highly qualified personnel, or our failure to retain and
motivate our existing key personnel, could materially and adversely impact our business, financial condition and operating results.
Our independent content and service providers may fail to perform adequately or comply with laws, regulations or contractual covenants.
We depend on independent content and service providers for communications and information services and for some of the benefits we provide
through our software applications and services, including the maintenance of managed care pharmacy guidelines, drug interaction reviews, the routing of
transaction data to third-party payers and the hosting of our applications. Our ability to rely on these services could be impaired as a result of the failure of
such providers to comply with applicable laws, regulations and contractual covenants or as a result of events affecting such providers, such as power loss,
telecommunication failures, software or hardware errors, computer viruses and similar disruptive problems, fire, flood and natural disasters. Any such failure
or event could adversely affect our relationships with our clients and damage our reputation. This could materially and adversely impact our business,
financial condition and operating results.
We may have no means of replacing content or services on a timely basis or at all if they are inadequate or in the event of a service interruption or
failure. We also rely on independent content providers for the majority of the clinical, educational and other healthcare information that we provide. In
addition, we depend on our content providers to deliver high quality content from reliable sources and to continually upgrade their content in response to
demand and evolving healthcare industry trends. If these parties fail to develop and maintain high quality, attractive content, the value of our brand and our
business, financial condition and operating results could be materially and adversely impacted.
23
We may be liable for use of content we provide.
We provide content for use by healthcare providers in treating patients. Third-party content suppliers provide certain of this content. If this content is
incorrect or incomplete, adverse consequences, including death, may occur and give rise to product liability and other claims against us. In addition, certain of
our solutions provide applications that relate to patient clinical information, and a court or government agency may take the position that our delivery of
health information directly, including through licensed practitioners, or delivery of information by a third party site that a consumer accesses through our
websites, exposes us to personal injury liability, or other liability for wrongful delivery or handling of healthcare services or erroneous health information.
While we maintain insurance coverage in an amount that we believe is sufficient for our business, we cannot provide assurance that this coverage will prove
to be adequate or will continue to be available on acceptable terms, if at all. A claim that is brought against us that is uninsured or under-insured could
materially and adversely impact our business, financial condition and operating results. Even unsuccessful claims could result in substantial costs and
diversion of management and other resources.
If our security is breached, we could be subject to liability, and clients could be deterred from using our products and services.
Our business relies on the secure electronic transmission, storage and hosting of sensitive information, including PHI, financial information and other
sensitive information relating to our clients, company and workforce. As a result, we face risk of a deliberate or unintentional incident involving unauthorized
access to our computer systems or data that could result in the misappropriation or loss of assets or the disclosure of sensitive information, the corruption of
data, or other disruption of our business operations. In 2018, we were subject to a ransomware attack that impacted two of our data centers, resulting in
outages that left certain of our solutions offline for our clients. Any future denial-of-service, ransomware or other Internet-based attacks may range from mere
vandalism of our electronic systems to systematic theft of sensitive information and intellectual property. We believe that companies in our industry may
continue to be targeted by such events with increasing frequency due to the increasing value of healthcare-related data.
We have devoted and continue to devote significant resources to protecting and maintaining the confidentiality of this information, including
designing and implementing security and privacy programs and controls, training our workforce and implementing new technology. We have no guarantee
that these programs and controls will be adequate to prevent all possible security threats. Any compromise of our electronic systems, including the
unauthorized access, use or disclosure of sensitive information or a significant disruption of our computing assets and networks, could adversely affect our
reputation or our ability to fulfill contractual obligations, could require us to devote significant financial and other resources to mitigate such problems, and
could increase our future cyber security costs, including through organizational changes, deploying additional personnel and protection technologies, further
training of employees, and engaging third party experts and consultants. Moreover, unauthorized access, use or disclosure of such sensitive information could
result in civil or criminal liability or regulatory action, including potential fines and penalties. In addition, any real or perceived compromise of our security or
disclosure of sensitive information may deter clients from using or purchasing our products and services in the future, which could materially and adversely
impact our financial condition and operating results.
We use third-party contractors to store, transmit and host sensitive information for our clients. While we have contractual or other mechanisms in
place with these third-party contractors that require them to have appropriate security programs and controls in place and, frequently, to indemnify us for
security-related breaches, any compromise or failure of these contractors’ privacy and security practices could adversely affect our reputation, require us to
devote financial and other resources to mitigate these breaches, or subject us to litigation from our clients.
Companies, including Allscripts, and governmental agencies have experienced high profile incidents involving data security breaches by entities that
transmit and store sensitive information. Lawsuits resulting from these and other similar security breaches have sought very significant monetary damages.
While we maintain insurance coverage that, subject to policy terms and conditions and subject to a significant self-insured retention, is designed to address
certain aspects of security-related risks, such insurance coverage may be insufficient to cover all losses or all types of claims that may arise in our business,
and we cannot provide assurance that this coverage will prove to be adequate or will continue to be available on acceptable terms.
Changes to the healthcare regulatory landscape could force us to reduce our prices.
We may be subject to pricing pressures with respect to our future sales arising from various sources, including practices of managed care
organizations, group purchasing arrangements made through government programs such as the Regional Extension Centers, and government action affecting
reimbursement levels related to physicians, hospitals, home health professionals or any combination thereof under Medicare, Medicaid and other government
health programs. Our clients and the other entities with which we have a business relationship are affected by changes in statutes, regulations and limitations
in governmental spending for Medicare, Medicaid and other programs. Recent government actions and future legislative and administrative changes could
limit government spending for the Medicare and Medicaid programs, limit payments to hospitals and other providers, increase emphasis on competition,
impose price controls, initiate new and expanded value-based reimbursement programs and create other programs that potentially could have an adverse
effect on our clients and the other entities with which we have a business relationship. If our pricing experiences significant downward pressure, our business
will be less profitable and our financial condition and operating results could be materially and adversely affected.
24
Our failure to license and integrate third-party technologies could harm our business.
We depend upon licenses for some of the technology used in our solutions from third-party vendors and intend to continue licensing technologies
from third parties. These technologies may not continue to be available to us on commercially reasonable terms or at all. Most of these licenses can be
renewed only by mutual consent and may be terminated if we breach the terms of the license and fail to cure the breach within a specified period of time. Our
inability to obtain, maintain or comply with any of these licenses could delay development until equivalent technology can be identified, licensed and
integrated, which would harm our business, financial condition and operating results.
Most of our third-party licenses are non-exclusive, and our competitors may obtain the right to use any of the technology covered by these licenses
and use the technology to compete directly with us. Our use of third-party technologies exposes us to increased risks, including, but not limited to, risks
associated with the integration of new technology into our solutions, the diversion of our resources from development of our own proprietary technology and
our inability to generate revenue from licensed technology sufficient to offset associated acquisition and maintenance costs. In addition, if our vendors choose
to discontinue support of the licensed technology in the future or are unsuccessful in their continued research and development efforts, we may not be able to
modify or adapt our own solutions.
We could fail to maintain and expand our business with our existing clients or effectively transition our clients to newer products.
Our business model depends on our success with maintaining our existing clients and selling new and incremental products and services to our
existing clients. In addition, our success with certain clients requires our achieving interoperability between our new products and our legacy products to
provide a single solution that connects healthcare providers across care settings. Certain of our clinical solutions clients initially purchase one or a limited
number of our products and services. These clients may choose not to expand their use of, or purchase, additional modules. Also, as we deploy new
applications and features for our existing solutions or introduce new solutions and services, our current clients could choose not to purchase these new
offerings. If we fail to generate additional business from our current clients, our revenue could grow at a slower rate or even decrease.
In addition, the transition of our existing clients to current versions of our products presents certain risks, including the risk of data loss or corruption
or delays in completion. If such events occur, our client relationships and reputation could be damaged. Any of the foregoing could materially and adversely
impact our business, financial condition and operating results.
Our business is subject to the risks of global operations.
We operate in several countries outside of the United States, including significant operations in Canada, India, Israel, the UK and Australia, and we
are further expanding our global sales efforts. This subjects our business to risks and challenges associated with operating globally, which include:
•
•
•
•
•
•
•
•
•
•
•
changes in local political, economic, social and labor conditions;
natural disasters, acts of war, terrorism, pandemics or security breaches;
different employee/employer relationships, existence of workers’ councils and labor unions, and other challenges caused by distance, language
and cultural differences;
restrictions on foreign ownership and investments, and stringent foreign exchange controls that may prevent us from repatriating, or make it
cost-prohibitive for us to repatriate, cash earned in countries outside of the United States;
import and export requirements, tariffs, trade disputes and barriers;
longer payment cycles in some countries, increased credit risk and higher levels of payment fraud;
uncertainty regarding liability for our products and services, including uncertainty as a result of local laws and lack of legal precedent;
different or lesser protection of our intellectual property;
different legal and regulatory requirements that may apply to our products and/or how we operate;
the discontinuation of the London Interbank Offered Rate (LIBOR”) after 2021 and the replacement with an alternative reference rate may
adversely impact interest rates; and
localization of our products and services, including translation into foreign languages and associated expenses.
All of the foregoing risks could prevent or restrict us from offering products or services to a particular market, could increase our operating costs, and
could otherwise materially and adversely impact our business, financial condition and operating results.
25
In addition, our compliance with complex foreign and United States laws and regulations that apply to our global operations increases our cost of
doing business. These numerous and sometimes conflicting laws and regulations include, but are not limited to, internal control and disclosure rules, data
privacy requirements, anti-corruption laws (such as the United States Foreign Corrupt Practices Act) and other local laws prohibiting corrupt payments to
government officials, and antitrust and competition regulations. Violations of these laws and regulations could result in, among other things, fines and
penalties, criminal sanctions, prohibitions on the conduct of our business and on our ability to offer our products and services in one or more countries, and
could also affect our global expansion efforts, our business and our operating results. Although we have implemented policies and procedures designed to
ensure compliance with these laws and regulations, there can be no assurance that our employees, contractors, agents or distributors, or third parties with
whom we do business, will not violate our policies. Furthermore, potential changes in data privacy and protection requirements may increase our future legal
and regulatory compliance burden.
Finally, since we conduct business in currencies other than the United States dollar, but report our financial results in United States dollars, we face
exposure to fluctuations in currency exchange rates. Significant fluctuations in exchange rates between the United States dollar and foreign currencies may
make our products and services more expensive for our global clients, or otherwise materially and adversely impact our operating results. We may
occasionally hedge our global currency exposure; however, hedging programs are inherently risky and could expose us to additional risks.
We could be subject to changes in our tax rates, the adoption of new United States or international tax legislation or exposure to additional tax
liabilities.
We are subject to taxation in the United States and numerous foreign jurisdictions. Current economic and political conditions make tax rates in any
jurisdiction, including those in the United States, subject to significant change. Our future effective tax rates could also be affected by changes in the mix of
our earnings in countries with differing statutory tax rates, changes in the valuation of our deferred tax assets and liabilities, or changes in tax laws or their
interpretation, including changes in tax laws affecting our products and services and the healthcare industry more generally. We are also subject to the
examination of our tax returns and other documentation by the Internal Revenue Service and other tax authorities. We regularly assess the likelihood of an
adverse outcome resulting from these examinations to determine the adequacy of our provision for taxes. There can be no assurance as to the outcome of
these examinations or that our assessments of the likelihood of an adverse outcome will be correct. If our effective tax rates were to increase, particularly in
the United States, or if the ultimate determination of our taxes owed is for an amount in excess of amounts previously accrued, then this could materially and
adversely impact our financial condition and operating results.
Our business and reputation may be impacted by IT system failures or other disruptions.
We may be subject to IT systems failures and network disruptions. These may be caused by natural disasters, accidents, power disruptions,
telecommunications failures, acts of terrorism or war, computer viruses, physical or electronic break-ins, or other events or disruptions. System redundancy
may be ineffective or inadequate, and our disaster recovery planning may not be sufficient for all eventualities. Such failures or disruptions could prevent
access to or the delivery of certain of our products or services, compromise our data or our clients’ data or result in delayed or cancelled orders, as well as
potentially expose us to third party claims. System failures and disruptions could also impede our transactions processing services and financial reporting.
War, terrorism, geopolitical uncertainties, public health issues and other business disruptions have caused and could cause damage to the global
economy, and thus have a material and adverse impact on our business, financial condition and operating results. Our business operations are subject to
interruption by natural disasters, fire, power shortages, terrorist attacks and other hostile acts, labor disputes, public health issues and other issues beyond our
control. Such events could decrease our demand for our products or services or make it difficult or impossible for us to develop and deliver our products or
services to our clients. A significant portion of our research and development activities, our corporate headquarters, our IT systems and certain of our other
critical business operations are concentrated in a few geographic areas. In the event of a business disruption in one or more of those areas, we could incur
significant losses, require substantial recovery time and experience significant expenditures in order to resume operations, which could materially and
adversely impact our business, financial condition and operating results.
Our failure to maintain proper and effective internal controls over financial reporting could impair our ability to produce accurate and timely
financial statements.
We maintain internal financial and accounting controls and procedures that are designed to provide reasonable assurance regarding the reliability of
our financial reporting and the preparation of our financial statements in accordance with accounting principles generally accepted in the United States
(“GAAP”). Ensuring that we have adequate internal financial and accounting controls and procedures in place, such that we can provide accurate financial
statements on a timely basis, is a costly and time-consuming process that requires significant management attention. Additionally, if our independent
registered public accounting firm, which is subject to oversight by the Public Company Accounting Oversight Board, is not satisfied with our internal controls
over financial reporting, or if the firm interprets the relevant rules, regulations or requirements related to the maintenance of internal controls over financial
reporting differently than we do, then it may issue an adverse opinion.
As we continue to expand our business, the challenges involved in implementing adequate internal controls over financial reporting will increase.
26
Any failure to maintain adequate controls, any inability to produce accurate financial statements on a timely basis, or any adverse opinion issued by
our independent registered public accounting firm related to our internal controls over financial reporting, could increase our operating costs and materially
and adversely impact our operating results. In addition, investors’ perceptions that our internal controls over financial reporting are inadequate, or that we are
unable to produce accurate financial statements on a timely basis, may harm our stock price and make it more difficult for us to effectively market and sell our
services to clients, which could materially and adversely impact our business, financial condition, and operating results. This could also subject us to
sanctions or investigations by Nasdaq, the SEC or other applicable regulatory authorities, which could require the commitment of additional financial and
management resources.
We could suffer losses due to asset impairment charges.
We are required under GAAP to test our goodwill and indefinite-lived intangible assets for impairment on an annual basis, as well as on an interim
basis if indicators for potential impairment, such as a decline in our stock price, exist. Indicators that are considered include, but are not limited to, significant
changes in performance relative to expected operating results, negative economic trends, or a significant decline in our stock price. In addition, we
periodically review our finite-lived intangible assets for impairment when events or changes in circumstances indicate the carrying value may not be
recoverable. Factors that may be considered a change in circumstances indicating that the carrying value of our intangible assets may not be recoverable
include slower growth rates or the divestiture of a business or asset below its carrying value. We may be required to record a charge to earnings in our
consolidated financial statements during the period in which any impairment of our goodwill or intangible assets is determined. This could materially and
adversely impact on our operating results.
There are inherent uncertainties in management’s estimates, judgments and assumptions used in assessing recoverability of goodwill and intangible
assets. Any changes in key assumptions, including failure to meet business plans, a further deterioration in the market or other unanticipated events and
circumstances, may affect the accuracy or validity of such estimates and could potentially result in an impairment charge.
The failure by Practice Fusion to comply with the terms of its settlement agreements with the U.S. Department of Justice (the “DOJ”) could have a
material and adverse impact on our business, results of operations and financial condition, and, even if Practice Fusion complies with those
settlement agreements, the costs and burdens of compliance could be significant, and we may face additional investigations and proceedings from
other governmental entities or third parties related to the same or similar conduct underlying the agreements with the DOJ.
On January 27, 2020, we announced that our subsidiary Practice Fusion entered into a series of agreements to resolve an investigation conducted by
the DOJ and the U.S. Attorney for the District of Vermont. See the risk factor entitled “We have acquired and expect to acquire new companies, investments
or technologies, which are subject to significant risks.” Practice Fusion has entered a three-year deferred prosecution agreement with the U.S. Attorney for the
District of Vermont (“Deferred Prosecution Agreement”) and a civil settlement agreement with the DOJ (“Civil Settlement Agreement”), and has entered into
separate civil settlement agreements with the Medicaid programs for each U.S. state, the District of Columbia and Puerto Rico (“State Settlement
Agreements” and, together with the Deferred Prosecution Agreement and the Civil Settlement Agreement, the “Settlement Agreements”).
Under the Deferred Prosecution Agreement, Practice Fusion consented to the filing of a two count criminal information: one felony count of violating
the Anti-Kickback Statute and one felony count of conspiracy to violate the Anti-Kickback Statute. The Deferred Prosecution Agreement requires Practice
Fusion to pay a criminal fine of $25.3 million and a forfeiture payment of $959,700 and for the Company and Practice Fusion to regularly review and certify
compliance with the Deferred Prosecution Agreement. Practice Fusion has also agreed to implement Additional Civil Compliance Terms, which include the
appointment of an Oversight Organization, and the implementation of compliance measures set forth in a Compliance Addendum, each as described further in
the Deferred Prosecution Agreement. The Oversight Organization Mandate requires Practice Fusion to retain an Oversight Organization selected by the U.S.
Attorney’s Office for the District of Vermont for three years. The Oversight Organization is required to take steps to provide reasonable assurance that
Practice Fusion establishes and maintains compliance systems, controls and processes reasonably designed, implemented and operated to ensure Practice
Fusion’s compliance with the terms of the Deferred Prosecution Agreement, including the Compliance Addendum, as well as reducing the risk of any
recurrence of misconduct as described in the information and statement of facts. The Compliance Addendum requires Practice Fusion to, within 90 days of
the execution of the Deferred Prosecution Agreement, implement and maintain a Sponsored Clinical Decision Support (“CDS”) Compliance Program that
sets procedures and systems to review all current or future Sponsored CDSs on the Practice Fusion electronic health records system. Practice Fusion is subject
to the Compliance Addendum for a three-year period from the effective date of the Deferred Prosecution Agreement.
27
Practice Fusion also entered into the Civil Settlement Agreement to resolve allegations by the DOJ that false claims were submitted to governmental
healthcare programs. The Civil Settlement Agreement requires Practice Fusion to pay a civil settlement of $118.6 million, which includes $5.2 million
designated for the state Medicaid program expenditures. The payment term is over a period of nine months from the effective date of the Civil Settlement
Agreement. In addition, Practice Fusion entered into the State Settlement Agreements to resolve Medicaid claims under state law analogues to the federal
False Claims Act. The financial terms of the State Settlement Agreements are substantially similar to those set forth in the Civil Settlement Agreement.
See Note 21, “Contingencies,” to our consolidated financial statements included in Part II, Item 8, “Financial Statements and Supplementary Data” of
this Form 10-K for additional information.
Compliance with the terms of the Settlement Agreements could impose significant costs and burdens on us. If we fail to comply with any such
Settlement Agreement, the DOJ may impose substantial monetary penalties, exclude Practice Fusion from Medicare, Medicaid and other federal healthcare
programs, and/or criminally prosecute Practice Fusion, which could have a material adverse effect on our business, financial condition and results of
operations.
Other government investigations or legal or regulatory proceedings, including investigations or proceedings brought by private litigants or
shareholders, federal agencies, private insurers and states’ attorneys general, may follow as a consequence of our entry into the Settlement Agreement or the
existing government investigation of our EIS Business, which could result in criminal liability, the imposition of damages or non-monetary relief, significant
compliance, litigation or settlement costs, other losses, or a diversion of management’s attention from other business concerns and have a material adverse
effect on our business, results of operations and financial condition. We may also be subject to negative publicity related to these matters that could harm our
reputation, reduce demand for our solutions and services, result in employee attrition and negatively impact our stock price.
Risks Related to Our Common Stock and Indebtedness
Our Board of Directors is authorized to issue preferred stock, and our certificate of incorporation, bylaws and debt instruments contain anti-
takeover provisions.
Our Board of Directors (our “Board”) has the authority to issue up to 1,000,000 shares of preferred stock and to determine the preferences, rights and
privileges of those shares without any further vote or action by our stockholders. In the event that we issue shares of preferred stock in the future that have
preference over our common stock with respect to payment of dividends or upon our liquidation, dissolution or winding-up, or if we issue shares of preferred
stock that are convertible into our common stock at greater than a one-to-one ratio, the voting and other rights of the holders of our common stock or our
stock price could be materially and adversely impacted. The ability of our Board to issue shares of preferred stock without any action on the part of our
stockholders could discourage, delay or prevent a change in control of our company or changes in our management that certain of our stockholders may deem
advantageous, which could lower our stock price.
Our certificate of incorporation and bylaws also contain provisions that could discourage, delay, or prevent a change in control of our company or
changes in our management that certain of our stockholders may deem advantageous, which could lower our stock price. These provisions, among other
things, prohibit our stockholders from acting by written consent or calling a special meeting of stockholders, and provide that our Board is expressly
authorized to make, alter or repeal our bylaws. Additionally:
•
•
•
the indentures (the “Indentures”) governing our 1.25% Cash Convertible Senior Notes due 2020 (the “1.25% Notes”) and our 0.875%
Convertible Senior Notes due 2027 (the “0.875% Notes” and, together with the 1.25% Notes, the “Convertible Notes”) may prohibit us from
engaging in a change of control of our company unless, among other things, the surviving entity assumes our obligations under the Convertible
Notes;
if a change of control of our company occurs, the Indenture may permit holders of the Convertible Notes to require us to repurchase all or a
portion of the Convertible Notes, and may also require us to pay a make-whole premium (in cash, in the case of the 1.25% Notes; and in either
cash, shares of our common stock or a combination of cash or shares of our common stock, in the case of the 0.875% Notes) by increasing the
conversion rate for a note holder who elects to convert; and
immediately prior to a change of control of our company, the Second Amended Credit Agreement (as defined under Note 9, “Debt,” to our
consolidated financial statements included in Part II, Item 8, “Financial Statements and Supplementary Data” of this Form 10-K) may require us
to repay all indebtedness outstanding thereunder.
These provisions in our certificate of incorporation, bylaws, and debt instruments could discourage, delay or prevent a change of control of our
company or changes in our management that certain of our stockholders may deem advantageous, and therefore could limit our stock price.
28
Finally, our certificate of incorporation includes an election to be governed by Section 203 of the Delaware General Corporation Law, which prohibits
us from engaging in any business combination with an interested stockholder for a period of three years from the date the person became an interested
stockholder, unless certain conditions are met. This provision could discourage, delay or prevent a change of control of our company by making it more
difficult for stockholders or potential acquirers to effect such a change of control without negotiation, and may apply even if some of our stockholders
consider the acquisition beneficial to them. This provision could also adversely affect our stock price.
Our stock price is subject to volatility.
The market for our common stock has experienced and may experience significant price and volume fluctuations in response to a number of factors,
many of which are beyond our control. Additionally, the stock market in general, and the market prices for companies in our industry in particular, have
experienced extreme volatility that has often been unrelated or disproportionate to the operating performance of those companies. These broad market and
industry fluctuations may materially and adversely impact our stock price, regardless of our actual operating performance. Furthermore, volatility in our stock
price could force us to increase our cash compensation to employees or grant larger stock awards than we have historically, which could materially and
adversely impact our financial condition and operating results.
Some companies that have experienced volatility in the trading price of their stock have been the subject of securities class action litigation. If we are
the subject of such litigation, it could result in substantial costs to us and divert our management’s attention and resources, which could materially and
adversely impact our financial condition and operating results.
Our quarterly operating results may vary.
Our quarterly operating results have varied in the past, and we expect that our quarterly operating results will continue to vary in future periods
depending on a number of factors, some of which we have no control over, including clients’ budgetary constraints and internal acceptance procedures, the
sales, service and implementation cycles for our software products, potential downturns in the healthcare market and in economic conditions generally, and
other factors described in this “Risk Factors” section.
We base our expense levels in part on our expectations concerning future revenue, and these expense levels are relatively fixed in the short-term. If we
have lower revenue than expected, we may not be able to reduce our spending in the short-term in response. Any shortfall in revenue could materially and
adversely impact our operating results. In addition, our product sales cycle for larger sales is lengthy and unpredictable, making it difficult to estimate our
future bookings for any given period. If we do not achieve projected booking targets for a given period, securities analysts may change their recommendations
on our stock price. For these and other reasons, we may not meet the earnings estimates of securities analysts or investors, and our stock price could be
materially and adversely impacted.
Our indebtedness could adversely affect our financial condition and prevent us from fulfilling our obligations.
Our level of indebtedness could have important consequences. For example, it could make it more difficult for us to satisfy our obligations, increase
our vulnerability to general adverse economic and industry conditions, require us to dedicate a substantial portion of our cash flow from operations to
payments on our indebtedness, and otherwise place us at a competitive disadvantage compared to our competitors who have less indebtedness. We may also
be able to incur substantial additional indebtedness in the future. If new indebtedness is added to our current indebtedness levels, the related risks that we face
could intensify.
The Second Amended Credit Agreement and the Indentures each contain, and any future indebtedness would likely contain, a number of restrictive
covenants that impose significant operating and financial restrictions on us, including restrictions on our ability to take actions that may be in our best
interests. Additionally, the Second Amended Credit Agreement requires us to satisfy and maintain specified financial ratios. Our ability to meet those
financial ratios can be affected by events beyond our control, and we may not be able to continue to meet those ratios. A breach of any of these covenants
could result in an event of default under the Second Amended Credit Agreement or the Indenture.
Under the Indentures, holders of the Convertible Notes have the right to require us to repurchase their Convertible Notes upon the occurrence of a
“fundamental change” (as defined in the Indentures) at a fundamental change repurchase price equal to 100% of the principal amount of the notes to be
repurchased, plus accrued and unpaid interest, if any. However, we may not have enough available cash or be able to obtain financing at the time we are
required to make such repurchases of the Convertible Notes. Our failure to repurchase the Convertible Notes at a time when the repurchase is required would
constitute a default under the Indentures, which may result in acceleration of our outstanding indebtedness. In addition, if, upon the occurrence of a
“fundamental change” (as defined in the Indentures), holders of at least $35 million aggregate principal amount of the Convertible Notes require us to
repurchase their respective Convertible Notes, this will result in a default under the Second Amended Credit Agreement, which may result in, among other
things, the requirement to immediately repay all outstanding amounts owed thereunder.
29
Upon the occurrence of an event of default under the Second Amended Credit Agreement or the Indentures, our lenders could terminate all
commitments to extend further credit, and some or all of our outstanding indebtedness may become immediately due and payable. We may not have or be
able to obtain sufficient funds to make these accelerated payments. Additionally, we have pledged substantially all of our tangible and intangible property as
collateral under the Second Amended Credit Agreement, and the lenders under the Second Amended Credit Agreement could proceed against such collateral
if we were unable to timely repay these amounts.
The conditional conversion feature of the Convertible Notes, if triggered, may adversely affect our financial condition and operating results.
In the event the conditional conversion feature of the Convertible Notes is triggered, holders of the Convertible Notes will be entitled to convert the
Convertible Notes at any time during specified periods at their option. See Note 9, “Debt,” to our consolidated financial statements included in Part II, Item 8,
“Financial Statements and Supplementary Data” of this Form 10-K. If one or more holders elect to convert their Convertible Notes, unless we elect (in the
case of the 0.875% Notes only) to satisfy our conversion obligation by delivering solely shares of our common stock, we would be required to settle a portion
or all of our conversion obligations through the payment of cash, which could adversely affect our liquidity. In addition, even if holders do not elect to convert
their Convertible Notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the Convertible
Notes as a current rather than long-term liability, which would result in a material reduction of our net working capital.
The accounting method for convertible debt securities that may be settled in cash, such as the Convertible Notes, could have a material effect on our
reported financial results.
In May 2008, the Financial Accounting Standards Board (“FASB”) issued FASB Staff Position No. APB 14-1, Accounting for Convertible Debt
Instruments That May Be Settled in Cash Upon Conversion (Including Partial Cash Settlement), which has subsequently been codified as Accounting
Standards Codification 470-20, Debt with Conversion and Other Options (“ASC 470-20”). Under ASC 470-20, an entity must separately account for the
liability and equity components of the convertible debt instruments (such as the Convertible Notes) that may be settled entirely or partially in cash upon
conversion in a manner that reflects the issuer’s economic interest cost. The effect of ASC 470-20 on the accounting for the Convertible Notes is that the
equity component is required to be included in the additional paid-in capital section of stockholders’ equity on our consolidated balance sheet, and the value
of the equity component would be treated as original issue discount for purposes of accounting for the debt component of the Convertible Notes. As a result,
we will be required to record a greater amount of non-cash interest expense in current periods presented as a result of the amortization of the discounted
carrying value of the Convertible Notes to their face amount over the term of the Convertible Notes. We will report lower net income in our financial results
because ASC 470-20 will require interest to include both the current period’s amortization of the debt discount and the instrument’s coupon interest, which
could adversely affect our reported or future financial results, the trading price of our common stock and the trading price of the Convertible Notes.
In addition, under certain circumstances, convertible debt instruments (such as the Convertible Notes) that may be settled entirely or partly in cash are
currently accounted for utilizing the treasury stock method, the effect of which is that the shares issuable upon conversion of the Convertible Notes are not
included in the calculation of diluted earnings per share except to the extent that the conversion value of the Convertible Notes exceeds their principal
amount. Under the treasury stock method, for diluted earnings per share purposes, the transaction is accounted for as if the number of shares of common stock
that would be necessary to settle such excess, if we elected to settle such excess in shares, are issued. We cannot be sure that the accounting standards in the
future will continue to permit the use of the treasury stock method. If we are unable to use the treasury stock method in accounting for the shares issuable
upon conversion of the Convertible Notes, then our diluted earnings per share would be adversely affected.
In July 2019, the FASB issued an exposure draft that proposes to change the accounting for the convertible debt instruments described above. Under
the exposure draft, an entity may no longer be required to separately account for the liability and equity components of convertible debt instruments. This
could have the impact of reducing non-cash interest expense, and thereby increasing net income. Additionally, as currently proposed, the treasury stock
method for calculating earnings per share will no longer be allowed for convertible debt instruments whose principal amount may be settled using shares.
Rather, the if-converted method may be required, which would decrease our diluted weighted-average earnings per share. We cannot be sure that this
exposure draft will be issued or will be issued in its current format. We also cannot be sure whether other changes may be made to the current accounting
standards related to the Convertible Notes, or otherwise, that could have an adverse impact on our financial statements.
30
The accounting for the 1.25% Notes will result in our having to recognize interest expense significantly greater than the stated interest rate of the
notes and may result in volatility to our Consolidated Statements of Operations.
We are obligated to settle any conversions of the 1.25% Notes entirely in cash. In accordance with GAAP, the conversion option that is part of the
1.25% Notes is accounted for as a derivative pursuant to accounting standards relating to derivative instruments and hedging activities. In general, this
resulted in an initial valuation of the conversion option separate from the debt component of the 1.25% Notes, resulting in an original issue discount. The
original issue discount will be accreted to interest expense over the term of the 1.25% Notes, which will result in an effective interest rate reported in our
financial statements significantly in excess of the stated coupon rate of the 1.25% Notes. This accounting treatment will reduce our earnings and could
adversely affect the price at which our common stock trades.
For each financial statement period after the issuance of the 1.25% Notes, a hedge gain (or loss) will be reported in our financial statements to the
extent the valuation of the conversion option changes from the previous period. The 1.25% Call Option (as defined under Note 9, “Debt,” to our consolidated
financial statements included in Part II, Item 8, “Financial Statements and Supplementary Data” of this Form 10-K) is also accounted for as a derivative
instrument, substantially offsetting the gain (or loss) associated with changes to the valuation of the conversion option. This may result in increased volatility
to our operating results.
The convertible note hedge and warrant transactions we entered into in connection with the issuance of our 1.25% Notes may not provide the
benefits we anticipate, and may have a dilutive effect on our common stock.
Concurrently with the issuance of the 1.25% Notes, we entered into the 1.25% Call Option with, and issued the 1.25% Warrants (as defined under
Note 9, “Debt,” to our consolidated financial statements included in Part II, Item 8, “Financial Statements and Supplementary Data” of this Form 10-K) to
certain of the initial purchasers of the 1.25% Notes. We entered into the 1.25% Call Option transaction with the expectation that it would offset potential cash
payments in excess of the principal amount of the 1.25% Notes upon conversion of the 1.25% Notes. The hedge counterparties are financial institutions or
affiliates of financial institutions, and we are subject to the risk that these hedge counterparties may default under the 1.25% Call Option transactions. Our
exposure to the credit risk of the hedge counterparties is not secured by any collateral. If one or more of the hedge counterparties to the 1.25% Call Option
transactions becomes subject to any insolvency proceedings, we will become an unsecured creditor in those proceedings with a claim equal to our exposure at
the time under those transactions. Our exposure will depend on many factors but, generally, the increase in our exposure will be correlated to the increase in
our stock price and in the volatility of our stock price. In addition, upon a default by one of the hedge counterparties, we may suffer adverse tax consequences
and dilution with respect to our common stock. We can provide no assurances as to the financial stability or viability of any of the hedge counterparties.
Separately, we also issued the 1.25% Warrants to the hedge counterparties. The 1.25% Warrants could separately have a dilutive effect to the extent
that our stock price, as measured under the terms of the transaction, exceeds the strike price of the 1.25% Warrants.
Item 1B. Unresolved Staff Comments
None.
Item 2. Properties
Our corporate headquarters are located in Chicago, Illinois. As of December 31, 2019, we leased 1.3 million square feet of building space worldwide.
Our facilities are primarily located in the United States, although we also maintain facilities in Canada, India, Israel, Singapore and the United Kingdom. Our
facilities house various sales, services, support, development, and data processing functions, as well as certain ancillary functions and other back-office
functions related to our current operations. We believe that our existing facilities are adequate to meet our current business requirements. If we require
additional space, we believe that we will be able to obtain such space on acceptable, commercially reasonable terms.
Item 3. Legal Proceedings
Refer to Note 21, “Contingencies,” to our consolidated financial statements included in Part II, Item 8, “Financial Statements and Supplementary
Data” of this Form 10-K.
Item 4. Mine Safety Disclosures
Not applicable.
31
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Market Information for Common Stock
Our common stock is traded on the Nasdaq Global Select Market (“Nasdaq”) under the symbol “MDRX.”
Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities
PART II
On August 2, 2018, we announced that our Board approved a new stock purchase program (the “2018 Program”) under which we may repurchase up
to $250 million of our common stock through December 31, 2020. We repurchased 0.9 million shares of our common stock under the 2018 Program for a
total of $9.3 million during the fourth quarter of 2019. Any future stock repurchase transactions may be made through open market transactions, block trades,
privately negotiated transactions (including accelerated share repurchase transactions) or other means, subject to our working capital needs, cash requirements
for investments, debt repayment obligations, economic and market conditions at the time, including the price of our common stock, and other factors that we
consider relevant. Our stock repurchase program may be accelerated, suspended, delayed or discontinued at any time.
(In thousands, except per share amounts)
Period (Based on Trade Date)
10/01/19—10/31/19
11/01/19—11/30/19
12/01/19—12/31/19
Dividend Policy
Total
Number
Of Shares
Purchased
Average
Price
Paid Per
Share
857 $
0 $
0 $
857 $
10.84
0.00
0.00
10.84
Total Number
Of Shares
Purchased
As Part Of
Publicly
Announced
Plans Or
Programs
Approximate
Dollar Value
Of Shares
That May Yet
Be Purchased
Under The
Plans Or
Programs
857 $
0 $
0 $
857
101,800
101,800
101,800
We have not declared or paid cash dividends on our shares of common stock for the last two years and currently do not intend to declare or pay cash
dividends on our shares of common stock in the foreseeable future. Any future determination to pay cash dividends will be at the discretion of our Board and
will depend upon our results of operations, financial condition, current and anticipated cash needs, contractual restrictions, restrictions imposed by applicable
law and other factors that our Board deems relevant. The covenants in the Senior Secured Credit Facility (as defined below) include a restriction on our
ability to declare dividends and other payments in respect of our capital stock. See Note 9, “Debt,” to our consolidated financial statements included in Part II,
Item 8, “Financial Statements and Supplementary Data” of this Form 10-K for further information regarding our Senior Secured Credit Facility.
Stockholders
According to the records of our transfer agent, as of February 27, 2020, there were 362 holders of record of our common stock, including banks,
brokers and other nominees who hold shares of our common stock on behalf of an indeterminate number of beneficial owners.
32
Performance Graph
The following graph compares the cumulative 5-Year total return to stockholders on our common stock relative to the cumulative total returns of the
Nasdaq Composite index and the Nasdaq Health Services index for the period commencing on December 31, 2014 through December 31, 2019, and assuming
an initial investment of $100. Data for the Nasdaq Composite index and the Nasdaq Health Services index assumes reinvestment of dividends. The following
will not be deemed incorporated by reference into any of our other filings under the Exchange Act or the Securities Act of 1933, as amended, except to the
extent we specifically incorporate it by reference into such filings. Note that historic stock price performance is not necessarily indicative of future stock price
performance.
Allscripts Healthcare Solutions, Inc.
NASDAQ Composite
NASDAQ Health Services
2014
2015
2016
2017
2018
2019
100.00
100.00
100.00
120.44
106.96
107.35
79.95
116.45
86.83
113.94
150.96
109.24
75.49
146.67
123.53
76.86
200.49
160.42
33
Item 6. Selected Financial Data
The selected consolidated financial data shown below should be read in conjunction with Part II, Item 7, “Management’s Discussion and Analysis of
Financial Condition and Results of Operations” and Part II, Item 8, “Financial Statements and Supplementary Data” in this Form 10-K to fully understand
factors that may affect the comparability of the information presented below. The consolidated statements of operations data for the years ended
December 31, 2019, 2018 and 2017 and the balance sheet data as of December 31, 2019 and 2018 are derived from our audited consolidated financial
statements included elsewhere in this Form 10-K. The consolidated statements of operations data for the years ended December 31, 2016 and 2015 and the
balance sheet data as of December 31, 2017, 2016 and 2015 are derived from audited consolidated financial statements that are not included in this Form 10-
K. The historical results are not necessarily indicative of results to be expected for any future period.
(In thousands, except per share amounts)
Consolidated Statements of Operations Data:
Revenue
Cost of revenue
Gross profit
Selling, general and administrative expenses
Research and development
Asset impairment charges
Goodwill impairment charge
Amortization of intangible and
acquisition-related assets
(Loss) income from operations
Interest expense
Other (loss) income, net
Gain on sale of businesses, net
Impairment of long-term investments
Equity in net income (loss) of unconsolidated investments
(Loss) income from continuing operations before
income taxes
Income tax benefit (provision)
(Loss) income from continuing operations, net of tax
Loss from discontinued operations
Gain on sale of Netsmart
Income tax effect on discontinued operations
Income (loss) from discontinued operations,
net of tax
Net (loss) income
Net loss (income) attributable to non-controlling interest
Accretion of redemption preference on redeemable
convertible non-controlling interest -
discontinued operations
Net (loss) income attributable to Allscripts Healthcare
Solutions, Inc. stockholders
Net (loss) income attributable to Allscripts Healthcare
Solutions, Inc. stockholders per share:
Basic:
Continuing operations
Discontinued operations
Net (loss) income attributable to Allscripts Healthcare
Solutions, Inc. stockholders per share
Diluted:
Continuing operations
Discontinued operations
Net (loss) income attributable to Allscripts Healthcare
Solutions, Inc. stockholders per share
2019(1)
2018(2)
2017(3)
2016(4)
2015(5)
Year Ended December 31,
$
1,771,677
1,058,097
713,580
419,774
254,509
10,837
25,700
27,216
(24,456)
(43,172)
(138,902)
0
(651)
665
(206,516)
23,914
(182,602)
0
0
0
0
(182,602)
424
$
1,749,962 $
1,025,419
724,543
450,967
268,409
58,166
13,466
1,497,708 $
864,909
632,799
400,688
202,282
0
0
1,386,069 $
784,770
601,299
334,521
178,534
4,650
0
1,386,393
805,828
580,565
339,175
184,791
1,544
0
26,587
(93,052)
(50,914)
74
172,258
(15,487)
259
13,138
(469)
12,669
(72,836)
500,471
(32,497)
395,138
407,807
4,527
17,345
12,484
(37,540)
(512)
0
(165,290)
821
(190,037)
5,514
(184,523)
(11,915)
0
42,263
30,348
(154,175)
1,566
15,884
67,710
(29,478)
829
0
0
(7,501)
31,560
(309)
31,251
(46,344)
0
18,123
(28,221)
3,030
(146)
23,172
31,883
(31,396)
2,183
0
0
(2,100)
570
(2,626)
(2,056)
0
0
0
0
(2,056)
(170)
0
(48,594)
(43,850)
(28,536)
0
$
(182,178)
$
363,740 $
(196,459) $
(25,652) $
(2,226)
$
$
$
$
$
$
(1.10)
0.00
$
$
0.10 $
1.97 $
(1.02) $
(0.07) $
0.17 $
(0.31) $
(0.01)
0.00
(1.10)
$
2.07 $
(1.09) $
(0.14) $
(0.01)
(1.10)
0.00
$
$
0.10 $
1.94 $
(1.02) $
(0.07) $
0.17 $
(0.31) $
(0.01)
0.00
(1.10)
$
2.04
$
(1.09)
$
(0.14) $
(0.01)
(1) Results of operations for the year ended December 31, 2019 include the results of operations of (i) Pinnacle and Diabetes and Collaborative Registries subsequent to the
date of acquisition, which was July 2, 2019 and (ii) a third party engaged in a specialty prescription drug platform subsequent to the date of acquisition, which was June
10, 2019.
34
(2) Results of operations for the year ended December 31, 2018 include the results of operations of: (i) Health Grid Holding Company subsequent to the date of acquisition,
which was May 18, 2018 and (ii) Practice Fusion, Inc., subsequent to the date of acquisition, which was February 13, 2018.
(3) Results of operations for the year ended December 31, 2017 include the results of operations of: (i) Enterprise Information Solutions (“EIS”) subsequent to the date of
acquisition, which was October 2, 2017; and (ii) NantHealth’s patient/provider engagement solutions business for the period subsequent to the date of acquisition, which
was August 25, 2017.
(4) Results of operations for the year ended December 31, 2016 include the results of operations of: (i) a third party for the period subsequent to the date of acquisition, which
was December 2, 2016; (ii) a third party for the period subsequent to the date of acquisition, which was October 14, 2016; and (iii) a third party for the period subsequent
to the date of acquisition of a controlling interest, which was September 8, 2016.
(5) Results of operations for the year ended December 31, 2015 include the results of operations of a third party for the period subsequent to the date of acquisition of a
majority interest, which was April 17, 2015.
(In thousands)
Consolidated Balance Sheet Data:
Cash, cash equivalents and marketable securities
Working capital (deficit)
Goodwill and intangible assets, net
Total assets
Long-term debt
Total stockholders’ equity
2019
2018
As of December 31,
2017
2016
2015
$
$
137,539
(369,428)
1,736,159
3,205,739
551,004
1,285,188
184,795 $
61,235
1,804,825
3,181,484
647,539
1,580,427
130,994 $
(32,515)
1,728,320
4,230,150
906,725
1,160,072
71,545 $
(62,610)
1,584,542
3,832,159
717,853
1,273,201
116,873
25,389
1,570,247
2,681,948
612,405
1,419,073
35
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion should be read in conjunction with the consolidated financial statements and notes thereto included in Part II, Item 8,
“Financial Statements and Supplementary Data” of this Form 10-K under the heading “Financial Statements and Supplementary Data” and the other
financial information that appears elsewhere in this Form 10-K. We assume no obligation to revise or update any forward-looking statements for any reason,
except as required by law.
Overview
Our Business Overview and Regulatory Environment
We deliver information technology (“IT”) solutions and services to help healthcare organizations achieve optimal clinical, financial and operational
results. We sell our solutions to physicians, hospitals, governments, health systems, health plans, life-sciences companies, retail clinics, retail pharmacies,
pharmacy benefit managers, insurance companies, employer wellness clinics, and post-acute organizations, such as home health and hospice agencies. We
help our clients improve the quality and efficiency of health care with solutions that include electronic health records (“EHRs”), information connectivity,
private cloud hosting, outsourcing, analytics, patient access and population health management.
Our solutions empower healthcare professionals with the data, insights and connectivity to other caregivers they need to succeed in an industry that is
rapidly changing from fee-for-service models to fee-for-value advanced payment models. We believe we offer some of the most comprehensive solutions in
our industry today. Healthcare organizations can effectively manage patients and patient populations across all care settings using a combination of our
physician, hospital, health system, post-acute care and population health management products and services. We believe these solutions will help transform
health care as the industry seeks new ways to manage risk, improve quality and reduce costs.
Globally, healthcare providers face an aging population and the challenge of caring for an increasing number of patients with chronic diseases. At the
same time, practitioners worldwide are also under growing pressure to demonstrate the delivery of high-quality care at lower costs. Population health
management, analytics, connectivity based on open Application Programming Interfaces (“APIs”), and patient engagement are strategic imperatives that can
help address these challenges. In the United States, for example, such initiatives will be critical tools for success under the framework of the Quality Payment
Program (“QPP”), launched by the Centers for Medicare & Medicaid Services (“CMS”) in response to the passage of the Medicare Access and CHIP
Reauthorization Act (“MACRA”). As healthcare providers and payers migrate from volume-based to value-based care delivery, interoperable solutions that
are connected to the consumer marketplace are the key to market leadership in the new healthcare reality. Additionally, there is a small but growing portion of
the market interested in payment models not reliant on insurance, such as the direct primary care model, with doctors and other healthcare professionals
interested in the clinical value of the interoperable EHR separate and apart from payment mechanisms established by public or commercial payers or
associated reporting requirements.
We believe our solutions are delivering value to our clients by providing them with powerful connectivity, as well as increasingly robust patient
engagement and care coordination tools, enabling users to successfully participate in alternative payment models that reward high value care delivery.
Population health management is commonly viewed as one of the critical next frontiers in healthcare delivery, and we expect this rapidly emerging and
evolving area to be a key driver of our future growth, both domestically and globally.
Recent advances in molecular science and computer technology are creating opportunities for the delivery of personalized medicine solutions. We
believe these solutions will transform the coordination and delivery of health care, ultimately improving patient outcomes.
Specific to the United States, the healthcare IT industry in which we operate is in the midst of a period of rapid change, primarily due to new laws and
regulations, as well as modifications to industry standards. Various incentives that exist today (including alternative payment models that reward high value
care delivery) have been rapidly moving health care toward a time where EHRs are as common as practice management or other financial systems in all
provider offices. As a result, we believe that legislation, such as the aforementioned MACRA, as well as other government-driven initiatives (including at the
state level), will continue to affect healthcare IT adoption and expansion, including products and solutions like ours. We also believe that we are well-
positioned in the market to take advantage of the ongoing opportunity presented by these changes.
Given that CMS annually proposes further regulations, including payment rules for upcoming years, which require use of EHRs and other health
information technology even as we comply with previously published rules, our industry is preparing for additional areas in which we must execute
compliance. Similarly, our ability to achieve expanded applicable product certification requirements resulting from changing strategies at the Office of the
National Coordinator for Health Information Technology (“ONC”) and the scope of related development and other efforts required to meet regulatory
standards could both materially impact our capacity to maximize the market opportunity. All our market-facing EHR solutions and several other relevant
products have successfully completed the testing process and are certified as 2015 Edition-compliant by an ONC-Authorized Certification Body (the most
recent edition). Allscripts remains committed to satisfying evolving certification requirements and meeting conditions of certification, including those that are
expected to be finalized at the end of the review process by ONC later this year or early next.
36
The MACRA encouraged the adoption of health IT necessary to satisfy new requirements more closely associating the report of quality
measurements to Medicare payments. Following the finalization of the Physician Fee Schedule rule each year, providers accepting payment from Medicare
must select one of two payment models: the Merit-based Incentive Payment System (“MIPS”) or an Advanced Alternative Payment Model (“APM”). Both of
these approaches require substantive reporting on quality measures; additionally, the MIPS consolidated several preexisting incentive programs, including
Medicare Meaningful Use and Physician Quality Reporting System, under one umbrella, as required by statute. We believe the implementation of this law is
likely driving additional interest in our products among providers who were not eligible for or chose not to participate in the Health Information Technology
for Economic and Clinical Health Act (“HITECH”) incentive program but now need an EHR and other health IT solutions and among those looking to
purchase more robust systems to comply with increasingly complex MACRA requirements. Additional regulations continue to be released annually,
clarifying requirements related to reporting and quality measures, which will enable physician populations and healthcare organizations to make strategic
decisions about the purchase of analytic software or other solutions important to comply with the new law and associated regulations.
HITECH resulted in additional related new orders for our EHR products, and we believe that the MACRA could drive purchases of not only EHRs
but also additional technologies necessary in advanced payment models. Large physician groups will continue to purchase and enhance their use of EHR
technology; while the number of very large practices with over 100 physicians that have not yet acquired such technology is insignificant, those considering
replacement purchases are increasing. Such practices may choose to replace older EHR technology in the future as regulatory requirements (such as those
related to Advanced APMs) and business realities dictate the need for updates and upgrades, as well as additional features and functionality. As incentive
payment strategies shift in policies under the current Presidential Administration in the United States, the role of commercial payers and their continued
expansion of alternative payment models and interest in attaining larger volumes of clinical data, as well as the anticipated growth in Medicaid payment
models, are expected to provide additional incentives for purchase and expansion.
We also continue to see activity in local community-based buying, whereby individual hospitals, health systems and integrated delivery networks
subsidize the purchase of EHR licenses or related services for local, affiliated physicians and physicians across their employed physician base in order to
leverage buying power and to help those practices take advantage of payment reform opportunities. This activity has also resulted in a pull-through effect
where smaller practices affiliated with a community hospital are motivated to participate in a variety of incentive programs, while the subsidizing health
system expands connectivity within the local provider community. We believe that the new rules related to exceptions to the Stark Law and Anti-Kickback
Statute, which were recently released in proposed form and would continue to allow hospitals and other organizations to subsidize the purchase of EHRs, will
possibly further contribute to the growth of this market dynamic. We expect that these regulatory revisions from HHS will further support value-based
payment models and their associated purchasing arrangements between hospitals and physician practices, including allowing subsidization of replacement
EHRs and not just initial purchases. The associated challenge we face is to successfully position, sell, implement and support our products sold to hospitals,
health systems or integrated delivery networks that subsidize their affiliated physicians. We believe the community programs we have in place will help us
penetrate these markets.
We believe we have taken and continue to take the proper steps to maximize the opportunity presented by the QPP and other new payment programs,
including several announced recently, such as Primary Care First and the Pathways to Success overhaul of Medicare’s National ACO program. However,
given the effects the laws are having on our clients, there can be no assurance that they will result in significant new orders for us in the near term, and if they
do, that we will have the capacity to meet the additional market demand in a timely fashion.
Additionally, other public laws to reform the United States healthcare system contain various provisions, which may impact us and our clients.
Continued efforts by the current Presidential Administration and several state governments to alter aspects of the Patient Protection and Affordable Care Act
(as amended, the “PPACA”) or to make other policy changes through Executive Orders create uncertainty for us and for our clients. Certain lawsuits related
to the PPACA also create uncertainty for us and our clients. Some laws currently in place may have a positive impact by requiring the expanded use of EHRs,
quality measurement, prescription drug monitoring and analytics tools to participate in certain federal, state or private sector programs. Others, such as
adjustments made to the PPACA by the Administration, laws or regulations mandating reductions in reimbursement for certain types of providers, decreasing
insurance coverage of patients, state-level requests for waivers from CMS related to Medicaid modeling, or increasing regulatory oversight of our products or
our business practices, may have a negative impact by reducing the resources available to purchase our products. Increases in fraud and abuse enforcement
and payment adjustments for non-participation in certain programs or overpayment of certain incentive payments may also adversely affect participants in the
healthcare sector, including us.
Generally, Congressional oversight of EHRs and health information technology has increased in recent years, including a specific focus on perceived
interoperability failures and physician frustration with user burden, as well as contributing factors to such dissatisfaction. This increased oversight could
impact our clients and our business. The passage of the 21st Century Cures Act in December 2016 assuaged some concerns about interoperability and possible
FDA oversight of EHRs, and we await the final regulations on data blocking and interoperability that were released in proposed form by HHS in February
2019. Certain of these proposals may have a significant effect on our business processes and how our clients must exchange patient information. We will
respond as necessary to the finalized regulations on those topics, which are expected early this year.
37
Allscripts continues to see increased opportunities stemming from the large stores of patient data accumulated from our industry-leading client base
and partnerships with other EHR companies, including NextGen Healthcare Inc., a leading provider of ambulatory-focused healthcare technology solutions.
Through collaboration with researchers and life sciences companies, we believe Allscripts may play a role in the study of real-world evidence as it relates to
post-market surveillance of new medicines, as an example. We will closely monitor regulations and/or guidance from the FDA, as well as any new laws that
take shape in Congress that may touch third-party uses of patient data and/or any related privacy implications for patient consent.
Congressional focus on addressing the opioid epidemic in part through technological applications and reducing clinician burden is likely to continue.
The Administration is also taking action in some areas that may directly or indirectly affect Allscripts and our clients, including efforts to increase health-
related price transparency in order to support patients in applying market-based pressures to the nation’s challenge of health cost containment. Further, CMS
has finalized changes to the Evaluation & Management coding structure that ties closely to our clients’ requirements to document the care they are delivering
prior to payment. We expect these changes may have a positive effect on clinician satisfaction with our EHRs, though the fundamentals of payment will
remain in transition to value-based payment models.
New payment and delivery system reform programs, including those modeled after those of the Medicare program, are increasingly being rolled out
at the state level through Medicaid administrators, as well as through the private sector, presenting additional opportunities for us to provide software and
services to our clients who participate. We also must take steps to comply with state-specific laws and regulations governing companies in the health
information technology space.
We derive our revenues primarily from sales of our proprietary software (either as a perpetual license sale or under a subscription delivery model),
support and maintenance services, and managed services, such as outsourcing, private cloud hosting and revenue cycle management.
Summary of Results
During 2019, we continued to make progress on our key strategic, financial and operational imperatives aimed at driving higher client satisfaction,
improving our competitive positioning by expanding the depth and breadth of our products and, ultimately, positioning the Company for sustainable long-
term growth both domestically and globally. In that regard, we had success across the below key areas:
•
•
•
U.S. Core Solutions and Services: We expanded the breadth of our solutions through both internal innovation and acquisitions. During 2019, we
completed the acquisitions of Pinnacle and Diabetes Collaborative Registries from the American College of Cardiology and the assets of a
business engaged in the development, implementation, customization, marketing, licensing and sale of a specialty prescription drug platform
including software that collects, saves and transmits information required to fill a prescription.
Value-based Care: During 2019, as the healthcare industry continues its transition toward value-based care model, we launched our new
integrated data systems and services payer and life sciences business and brand Veradigm™, which combines data-driven clinical insights with
actionable tools for clinical workflow, research, analytics and media.
Capital Deployment and Operational Efficiency: During 2019, we completed the integration of Practice Fusion and Health Grid.
Total revenue for the year ended December 31, 2019 was $1.8 billion, an increase of 1% compared with the year ended December 31, 2018. For both
of the years ended December 31, 2019 and 2018, software delivery, support and maintenance revenue totaled $1.1 billion. Client services revenue totaled
$645 million in the year ended December 31, 2019, an increase of 4% compared to prior year.
Gross profit and margin decreased for the year ended December 31, 2019 compared to prior year. These decreases were primarily due to an increase
in hosting costs, higher amortization of software development costs, recognition of previously deferred costs and the sale of OneContent in 2018, which had
higher margins than our other businesses.
Our contract backlog as of December 31, 2019 was $4.4 billion, an increase of 13% compared with our contract backlog of $3.9 billion as of
December 31, 2018.
On December 31, 2018, we sold all of the Class A Common Units of Netsmart LLC (“Netsmart”) held by the Company for aggregate consideration
of $566 million in cash, plus a final settlement as determined following the closing. Netsmart was originally acquired in April 2016 and we realized a gain on
sale of $500.5 million. Prior to the sale, Netsmart comprised a separate reportable segment, which due to its significance to our historical consolidated
financial statements and results of operations, is now reported as a discontinued operation as a result of the sale for all periods presented.
Revenues and Expenses
Revenues are derived primarily from sales of our proprietary software (either under a perpetual or term license delivery model), subscription-based
software sales, post-contract client support and maintenance services, and managed services solutions, such as outsourcing, private cloud hosting and revenue
cycle management.
38
Cost of revenue consists primarily of salaries, incentive compensation and benefits for our billable professionals, third-party software costs, third-
party transaction processing and consultant costs, amortization of acquired proprietary technology and capitalized software development costs, depreciation
and other direct engagement costs.
Selling, general and administrative expenses consist primarily of salaries, incentive compensation and benefits for management and administrative
personnel, sales commissions and marketing expenses, facilities costs, depreciation and amortization and other general operating expenses.
Research and development expenses consist primarily of salaries, incentive compensation and benefits for our development personnel, third‑party
contractor costs and other costs directly or indirectly related to development of new products and upgrading and enhancing existing products.
Asset impairment charges consist primarily of non-cash charges relate to the retirement of hosting assets, our decision to discontinue several software
development projects and the impairment of several intangible assets. Goodwill impairment charges incurred related to our Hospital and Health System
business and to the acquisition of the patient/provider engagement solutions business from NantHealth during the years ended December 31, 2019 and 2018,
respectively.
Amortization of intangible and acquisition-related assets consists of amortization of customer relationships, tradenames and other intangibles
acquired through business combinations recorded under the purchase method of accounting.
Interest expense consists primarily of interest on the 1.25% Notes and on the outstanding debt under our senior secured credit facility, including the
amortization of debt discounts and debt issuance costs.
Gain on sale of businesses, net consists of net gains from the divestitures during 2018 of the OneContent and Strategic Sourcing businesses, both of
which were acquired as part of the EIS Business acquisition during the fourth quarter of 2017.
Other (loss) income, net included a settlement with the Department of Justice related to our Practice Fusion business.
Impairment of long-term investments primarily consists of other-than-temporary and realized losses associated with our available for sale marketable
securities.
Equity in net income (loss) of unconsolidated investments represents our share of the equity earnings (losses) of our investments in third parties
accounted for under the equity method, including the amortization of cost basis adjustments.
Income from discontinued operations during years ended December 31, 2018 and 2017 includes activity associated with Netsmart and of two
solutions acquired with the EIS Business, which were sunset in 2018.
Critical Accounting Policies and Estimates
The preparation of our consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that
affect the amounts reported and disclosed in our consolidated financial statements and the accompanying notes. The accounting policies and estimates
discussed in this section are those that we consider to be particularly critical to an understanding of our consolidated financial statements because their
application involves significant judgment regarding the effect of inherently uncertain matters on our financial results. Actual results could differ materially
from these estimates under different assumptions or conditions.
Revenue Recognition
Refer to Note 2, “Revenue from Contracts with Customers” to our consolidated financial statements included in Part II, Item 8, “Financial Statements
and Supplementary Data” of this Form 10-K for detailed discussion about our revenue recognition accounting policies.
Allowance for Doubtful Accounts Receivable
We rely on estimates to determine our bad debt expense and the adequacy of our allowance for doubtful accounts. These estimates are based on our
historical experience and management’s assessment of a variety of factors related to the general financial condition of our clients, the industry in which we
operate and general economic conditions. If the financial condition of our clients were to deteriorate, resulting in an impairment of their ability to make
payments, additional allowances and related bad debt expense may be required.
Business Combinations
Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets
acquired and the liabilities assumed. While we use our best estimates and assumptions as a part of the purchase price allocation process to accurately value
assets acquired, including intangible assets, and the liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement.
As a result, during the measurement period, which may be up to one year from the acquisition date, we may record adjustments to the fair values of the assets
acquired and the liabilities assumed, with a corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the
values of assets acquired or the liabilities assumed, whichever comes first, any subsequent adjustments are reflected in our consolidated statement of
operations.
39
Goodwill and Intangible Assets
Goodwill and intangible assets acquired in a business combination and determined to have an indefinite useful life are not amortized but are tested for
impairment annually or between annual tests when an impairment indicator exists. If an optional qualitative goodwill impairment assessment is not
performed, we are required to determine the fair value of each reporting unit. If a reporting unit’s fair value is lower than its carrying value, an impairment
loss equal to the excess will be recorded not to exceed the carrying amount of goodwill assigned to the reporting unit. The recoverability of indefinite-lived
intangible assets is assessed by comparison of the carrying value of an asset to its estimated fair value. If we determine that the carrying value of an asset
exceeds its estimated fair value, an impairment loss equal to the excess will be recorded.
The determination of the fair value of our reporting units is based on a combination of a market approach, that considers benchmark company market
multiples, and an income approach, that utilizes discounted cash flows for each reporting unit and other Level 3 inputs. Under the income approach, we
determine fair value based on the present value of the most recent cash flow projections for each reporting unit as of the date of the analysis, and calculate a
terminal value utilizing a terminal growth rate. The significant assumptions under this approach include, among others: income projections, which are
dependent on sales to new and existing clients, new product introductions, client behavior, competitor pricing, operating expenses, the discount rate and the
terminal growth rate. The cash flows used to determine fair value are dependent on a number of significant management assumptions such as our expectations
of future performance and the expected economic environment, which are partly based on our historical experience. Our estimates are subject to change given
the inherent uncertainty in predicting future results. Additionally, the discount rate and the terminal growth rate are based on our judgment of the rates that
would be utilized by a hypothetical market participant. As part of the goodwill impairment testing, we also consider our market capitalization in assessing the
reasonableness of the fair values estimated for our reporting units.
During 2019, we made organizational changes that affected our reportable segments. Refer to Note 18, “Business Segments” to our consolidated
financial statements included in Part II, Item 8, “Financial Statements and Supplementary Data” of this Form 10-K for detailed discussion about these
changes.
We performed our 2019 goodwill impairment test as of October 1, 2019. As a result of this test, we concluded that the carrying value of the Hospitals
and Health Systems (“HHS”) reporting unit exceeded its fair value. As a result, we recognized a goodwill impairment charge of $25.7 million. This goodwill
impairment charge is reflected on the “Goodwill impairment charge” line in our consolidated statements of operations. The fair values of all other reporting
units substantially exceeded their carrying values. As of December 31, 2019, the goodwill allocated to the HHS reporting unit was $485.5 million.
We performed our 2018 goodwill impairment test as of October 1, 2018. We concluded that the carrying value of the NantHealth reporting unit
exceeded its fair value as a result of this test. Our latest available financial forecasts at the time of the annual goodwill impairment test reflected that projected
future operating costs exceeded projected revenues resulting in negative operating margins for the NantHealth reporting unit. As a result, we recognized a
goodwill impairment charge of $13.5 million, representing the entire goodwill balance assigned to the NantHealth reporting unit.
In accordance with GAAP, definite-lived intangible assets are required to be amortized over their respective estimated useful lives and reviewed for
impairment whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. We estimate the useful lives of our
intangible assets and ratably amortize the value over the estimated useful lives of those assets. If the estimates of the useful lives should change, we will
amortize the remaining book value over the remaining useful lives or, if an asset is deemed to be impaired, a write-down of the value of the asset may be
required at such time.
Software Development Costs
We capitalize purchased software upon acquisition if it is accounted for as internal-use or if it meets the future alternative use criteria. We capitalize
incurred labor costs for software development from the time technological feasibility of the software is established, or when the preliminary project phase is
completed in the case of internal use software, until the software is available for general release. Research and development costs and other computer
software maintenance costs related to software development are expensed as incurred. We estimate the useful life of our capitalized software and amortize its
value over that estimated life. If the actual useful life is shorter than our estimated useful life, we will amortize the remaining book value over the remaining
useful life or the asset may be deemed to be impaired and, accordingly, a write-down of the value of the asset may be recorded as a charge to earnings.
The carrying value of capitalized software is dependent on the ability to recover its value through future revenue from the sale of the software. At
each balance sheet date, the unamortized capitalized costs of a software product are compared with the net realizable value of that product. The net realizable
value is the estimated future gross revenues from that product reduced by the estimated future costs of completing and disposing of that product, including the
costs of performing maintenance and client support required to satisfy our responsibility at the time of sale. The amount by which the unamortized capitalized
costs of a software product exceed the net realizable value of that asset is written off. If we determine that the value of the capitalized software could not be
recovered, a write-down of the value of the capitalized software to its recoverable value is recorded as a charge to earnings.
40
Income Taxes
We account for income taxes using the liability method, which requires the recognition of deferred tax assets or liabilities for the tax-effected
temporary differences between the financial reporting and tax bases of our assets and liabilities and for net operating loss and tax credit carryforwards. The
objectives of accounting for income taxes are to recognize the amount of taxes payable or refundable for the current year and deferred tax liabilities and assets
for the future tax consequences of events that have been recognized in an entity’s financial statements or tax returns. Judgment is required in addressing the
future tax consequences of events that have been recognized in our consolidated financial statements or tax returns. The deferred tax assets are recorded net of
a valuation allowance when, based on the weight of available evidence, we believe it is more likely than not that some portion or all of the recorded deferred
tax assets will not be realized in future periods. We consider many factors when assessing the likelihood of future realization of our deferred tax assets,
including recent cumulative earnings experience, expectations of future taxable income, the ability to carryback losses and other relevant factors.
In addition, we are subject to the continuous examination of our income tax returns by the Internal Revenue Service and other tax authorities. A
change in the assessment of the outcomes of such matters could materially impact our consolidated financial statements.
The calculation of tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for
anticipated tax audit issues based on our estimate of whether, and the extent to which, additional taxes may be required. If we ultimately determine that
payment of these amounts is unnecessary, then we reverse the liability and recognize a tax benefit during the period in which we determine that the liability is
no longer necessary. We also recognize tax benefits to the extent that it is more likely than not that our positions will be sustained if challenged by the taxing
authorities. To the extent we prevail in matters for which liabilities have been established, or are required to pay amounts in excess of our liabilities, our
effective tax rate in a given period may be materially affected. An unfavorable tax settlement would require cash payments and may result in an increase in
our effective tax rate in the year of resolution. A favorable tax settlement would be recognized as a reduction in our effective tax rate in the year of resolution.
We report interest and penalties related to uncertain income tax positions in the income tax (provision) benefit line of our consolidated statements of
operations.
We file income tax returns in the United States federal jurisdiction, numerous states in the United States and multiple countries outside of the United
States.
Fair Value Measurements
Fair value measurements are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent
sources, while unobservable inputs reflect our view of market participant assumptions in the absence of observable market information. We utilize valuation
techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. The fair values of assets and liabilities required to be
measured at fair value are categorized based upon the level of judgment associated with the inputs used to measure their value in one of three categories
(Levels 1 to 3). The values of assets and liabilities assigned to Level 3 require the most judgement and are based unobservable inputs or prices for which little
or no market data exists. Therefore, Level 3 values can be susceptible to significant fluctuations, both positive and negative, from changes in the underlying
assumption used by management. Refer to Note 5, “Fair Value Measurements” to our consolidated financial statements included in Part II, Item 8, “Financial
Statements and Supplementary Data” of this Form 10-K for detailed information about financial assets and liabilities measured at fair value on a recurring
basis.
Recent Accounting Pronouncements
For information with respect to recent accounting pronouncements and the impact of these pronouncements on our consolidated financial statements,
refer to Note 1, “Basis of Presentation and Significant Accounting Policies” to our consolidated financial statements included in Part II, Item 8, “Financial
Statements and Supplementary Data” of this Form 10-K.
41
Overview of Consolidated Results
(In thousands)
Revenue:
Software delivery, support and maintenance
Client services
Total revenue
Cost of revenue:
Software delivery, support and maintenance
Client services
Amortization of software development and
acquisition-related assets
Total cost of revenue
Gross profit
Gross margin %
Selling, general and administrative expenses
Research and development
Asset impairment charges
Goodwill impairment charge
Amortization of intangible and acquisition-related assets
(Loss) income from operations
Interest expense
Other (loss) income, net
Gain on sale of businesses, net
Impairment of long-term investments
Equity in net income of unconsolidated investments
(Loss) income from continuing operations
before income taxes
Income tax benefit (provision)
Effective tax rate
(Loss) income from continuing operations, net of tax
Loss from discontinued operations
Gain on sale of Netsmart
Income tax effect on discontinued operations
Income from discontinued operations, net of tax
Net (loss) income
Net loss attributable to non-controlling interests
Accretion of redemption preference on redeemable
convertible non-controlling interest -
discontinued operations
Net (loss) income attributable to Allscripts Healthcare
Solutions, Inc. stockholders
2019
Year Ended December 31,
2018
2017
2019 %
Change
from 2018
2018 %
Change
from 2017
$
$
1,126,486
645,191
1,771,677
$
1,128,263
621,699
1,749,962
958,187
539,521
1,497,708
358,946
583,111
116,040
1,058,097
713,580
40.3%
419,774
254,509
10,837
25,700
27,216
(24,456)
(43,172)
(138,902)
0
(651)
665
(206,516)
23,914
11.6%
(182,602)
0
0
0
0
(182,602)
424
357,039
565,504
102,876
1,025,419
724,543
41.4%
450,967
268,409
58,166
13,466
26,587
(93,052)
(50,914)
74
172,258
(15,487)
259
13,138
(469)
3.6%
12,669
(72,836)
500,471
(32,497)
395,138
407,807
4,527
295,593
484,591
84,725
864,909
632,799
42.3%
400,688
202,282
0
0
17,345
12,484
(37,540)
(512)
0
(165,290)
821
(190,037)
5,514
2.9%
(184,523)
(11,915)
0
42,263
30,348
(154,175)
1,566
(0.2%)
3.8%
1.2%
0.5%
3.1%
12.8%
3.2%
(1.5%)
(6.9%)
(5.2%)
(81.4%)
90.9%
2.4%
(73.7%)
(15.2%)
NM
(100.0%)
(95.8%)
156.8%
NM
NM
NM
(100.0%)
(100.0%)
(100.0%)
(100.0%)
(144.8%)
(90.6%)
17.7%
15.2%
16.8%
20.8%
16.7%
21.4%
18.6%
14.5%
12.5%
32.7%
NM
NM
53.3%
NM
35.6%
114.5%
NM
(90.6%)
(68.5%)
106.9%
(108.5%)
(106.9%)
NM
NM
(176.9%)
NM
NM
189.1%
0
(48,594)
(43,850)
(100.0%)
10.8%
$
(182,178) $
363,740
$
(196,459)
(150.1%)
NM
NM—We define “NM” as not meaningful for increases or decreases greater than 200%.
Revenue
Recurring revenue consists of subscription-based software sales, support and maintenance revenue, recurring transactions revenue and recurring
revenue from managed services solutions, such as outsourcing, private cloud hosting and revenue cycle management. Non-recurring revenue consists of
perpetual software licenses sales, hardware resale and non-recurring transactions revenue, and project-based client services revenue.
(In thousands)
Revenue:
Recurring revenue
Non-recurring revenue
Total revenue
2019
Year Ended December 31,
2018
2017
2019 %
Change
from 2018
2018 %
Change
from 2017
$
$
1,395,869 $
375,808
1,771,677 $
1,411,742
$
338,220
1,749,962 $
1,176,720
320,988
1,497,708
(1.1%)
11.1%
1.2%
20.0%
5.4%
16.8%
42
Year Ended December 31, 2019 Compared with the Year Ended December 31, 2018
Recurring revenue decreased during the year ended December 31, 2019 compared to prior year due to known attrition within the EIS and other
businesses partially offset with growth in subscription revenue. The sale of the OneContent business on April 2, 2018 also contributed to the decline in
recurring revenue. The OneContent business was acquired as part of the EIS Business acquisition on October 2, 2017, and it contributed $13 million of
recurring revenue during the first quarter of 2018, including $1 million of amortization of acquisition-related deferred revenue adjustments. Non-recurring
revenue increased due to higher sales of perpetual software licenses for our acute solutions and hardware in 2019 compared to 2018, partially offset by lower
client services revenue related to the timing of software activations.
The percentage of recurring and non-recurring revenue of our total revenue was 79% and 21%, respectively, during the year ended December 31,
2019 and 81% and 19%, respectively, during the year ended December 31, 2018.
Year Ended December 31, 2018 Compared with the Year Ended December 31, 2017
The increase in revenue for the year ended December 31, 2018 compared with the year ended December 31, 2017 was primarily driven by
incremental revenue from the acquisitions of the EIS Business in the fourth quarter of 2017 and Practice Fusion in the first quarter of 2018. Total revenue
includes the amortization of acquisition-related deferred revenue adjustments, which totaled $24 million and $29 million during the years ended December
31, 2018 and 2017, respectively. The growth in both recurring and non-recurring revenue for the year ended December 31, 2018 compared with the prior year
was also largely driven by incremental revenue from the previously mentioned acquisitions.
The percentage of recurring and non-recurring revenue of our total revenue was 81% and 19%, respectively, during the year ended December 31,
2018, compared with 79% and 21%, respectively, during the year ended December 31, 2017.
Gross Profit
(In thousands)
Total cost of revenue
Gross profit
Gross margin %
$
$
2019
1,058,097
713,580
Year Ended December 31,
2018
1,025,419
724,543
$
$
$
$
40.3%
41.4%
2019 %
Change
from 2018
2018 %
Change
from 2017
3.2%
(1.5%)
18.6%
14.5%
2017
864,909
632,799
42.3%
Year Ended December 31, 2019 Compared with the Year Ended December 31, 2018
Gross profit and margin decreased during the year ended December 31, 2019 compared to prior year primarily due to an increase in hosting migration
costs, higher amortization of software development, recognition of previously deferred costs and the sale of OneContent business on April 2, 2018, which
carried a higher gross margin compared with our other businesses. These were partially offset with an increase in organic sales for Veradigm and our acute
solutions in 2019.
Year Ended December 31, 2018 Compared with the Year Ended December 31, 2017
Gross profit increased during the year ended December 31, 2018 compared with the year ended December 31, 2017 primarily due to acquisitions.
From a revenue mix perspective, gross profit associated with our recurring revenue streams, which include the delivery of recurring subscription-based
software sales, support and maintenance, and recurring client services improved as we continued to expand our customer base for these services, particularly
those related to outsourcing and revenue cycle management. Gross profit associated with our non-recurring software delivery, support and maintenance
revenue stream decreased primarily due to fewer perpetual software license sales of our acute and population health management solutions. Gross profit
associated with our non-recurring client services revenue stream, which includes non-recurring project-based client services, decreased primarily driven by
higher internal personnel costs, including those related to incremental resources from recent acquisitions. Gross margin decreased primarily due to lower sales
of higher margin perpetual software licenses and higher amortization of software development and acquisition-related assets driven by additional amortization
expense associated with intangible assets acquired as part of recent acquisitions.
Selling, General and Administrative Expenses
(In thousands)
Selling, general and administrative expenses
2019
419,774 $
Year Ended December 31,
2018
450,967 $
$
2017
400,688
2019 %
Change
from 2018
2018 %
Change
from 2017
(6.9%)
12.5%
Year Ended December 31, 2019 Compared with the Year Ended December 31, 2018
Selling, general and administrative expenses decreased during the year ended December 31, 2019 compared with the prior year, primarily due to
headcount reduction actions taken during 2018 as part of the integration of EIS, Practice Fusion and Health Grid acquisitions. The sale of OneContent in 2018
contributed to the decrease because there were one-time incentive compensation expenses. These decreases were partially offset with an increase in legal
costs.
43
Year Ended December 31, 2018 Compared with the Year Ended December 31, 2017
Selling, general and administrative expenses increased during the year ended December 31, 2018 compared with the prior year, primarily due to
higher incentive-based compensation and incremental expenses from the acquisitions of the EIS Business, Practice Fusion and Health Grid, including
associated transaction-related, severance and legal expenses as a result of these acquisitions.
Research and Development
(In thousands)
Research and development
2019
254,509 $
Year Ended December 31,
2018
268,409 $
$
2017
202,282
2019 %
Change
from 2018
2018 %
Change
from 2017
(5.2%)
32.7%
Year Ended December 31, 2019 Compared with the Year Ended December 31, 2018
Research and development expenses decreased during the year ended December 31, 2019 compared with prior year. This decrease was primarily due
to the sale of OneContent on April 2, 2018, as there were $10 million of one-time incentive compensation costs recorded within Research and development
expense as a result of the sale.
Year Ended December 31, 2018 Compared with the Year Ended December 31, 2017
Research and development expenses increased during the year ended December 31, 2018 compared with the prior year, primarily due to higher
overall personnel costs, including higher incentive-based compensation and severance, and additional expenses from the acquisition of the EIS Business,
Practice Fusion and Health Grid, which were partly offset by an increase in the amount of capitalized software costs. The increase in capitalized software
development costs was primarily driven by our continued investment in expanding the capabilities and functionality of our traditional ambulatory, acute and
post-acute platforms as well as incremental investments in the emerging areas of precision medicine and cloud-based solution delivery. In addition, we
incurred costs to integrate the solutions acquired through the above noted acquisitions. The capitalization of software development costs is highly dependent
on the nature of the work being performed and the development status of projects and, therefore, it is common for the amount of capitalized software
development costs to fluctuate.
Asset Impairment Charges
(In thousands)
Asset impairment charges
2019
Year Ended December 31,
2018
2017
2019 %
Change
from 2018
2018 %
Change
from 2017
$
10,837 $
58,166 $
0
(81.4%)
NM
Year Ended December 31, 2019 Compared with the Years Ended December 31, 2018 and 2017
Asset impairment charges for the year ended December 31, 2019 was primarily the result of impairing the remaining NantHealth acquired customer
relationship intangible balance of $8.1 million. We also recognized non-cash impairment charges of $2.7 million on the retirement of certain hosting assets
due to data center migrations. We incurred non-cash asset impairment charges during the year ended December 31, 2018 of $33.2 million related to the write-
off of capitalized software as a result of our decision to discontinue several software development projects. We also recognized $22.9 million of non-cash
asset impairment charges in 2018 related to our acquisition of the patient/provider engagement solutions business from NantHealth in 2017, which included
the write-downs of $2.2 million of acquired technology and $20.7 million, representing the unamortized value assigned to the modification of our existing
commercial agreement with NantHealth, as we no longer expect to recover the value assigned to these assets. The remaining $2.1 million of non-cash asset
impairment charges recorded during the year ended December 31, 2018 relate to the disposal of fixed assets as a result of relocating and consolidating
business functions and locations from recent acquisitions.
Goodwill Impairment Charge
(In thousands)
Goodwill impairment charge
2019
Year Ended December 31,
2018
2017
2019 %
Change
from 2018
2018 %
Change
from 2017
$
25,700 $
13,466 $
0
90.9%
NM
44
Year Ended December 31, 2019 Compared with the Years Ended December 31, 2018 and 2017
We recorded a goodwill impairment charge of $25.7 million related to our Hospitals and Health Systems reporting unit during the year ended
December 31, 2019. We impaired all of the goodwill previously recognized as part of the acquisition of NantHealth’s patient/provider engagement solutions
business following the completion of our annual goodwill impairment during the year ended December 31, 2018. Refer to Note 7, “Goodwill and Intangible
Assets” to our consolidated financial statements included in Part II, Item 8, “Financial Statements and Supplementary Data” of this Form 10-K for further
information regarding these impairments.
Amortization of Intangible and Acquisition-Related Assets
(In thousands)
Amortization of intangible and acquisition-related
assets
2019
Year Ended December 31,
2018
2017
2019 %
Change
from 2018
2018 %
Change
from 2017
$
27,216
$
26,587 $
17,345
2.4%
53.3%
Year Ended December 31, 2019 Compared with the Year Ended December 31, 2018
The slight increase in amortization expense for the year ended December 31, 2019 compared with the prior year was due to incremental amortization
expense associated with intangible assets as part of business combinations completed during 2018.
Year Ended December 31, 2018 Compared with the Year Ended December 31, 2017
The increase in amortization expense for the year ended December 31, 2018 compared with the prior year was primarily due to incremental
amortization expense associated with intangible assets acquired as part of business acquisitions completed during the fourth quarter of 2017 and the first half
of 2018, the largest being the acquisitions of the EIS Business and Practice Fusion. Refer to Note 4, “Business Combinations” to our consolidated financial
statements included in Part II, Item 8, “Financial Statements and Supplementary Data” of this Form 10-K for additional information regarding business
acquisitions.
Interest Expense
(In thousands)
Interest expense
2019
Year Ended December 31,
2018
2017
2019 %
Change
from 2018
2018 %
Change
from 2017
$
43,172 $
50,914 $
37,540
(15.2%)
35.6%
Year Ended December 31, 2019 Compared with the Year Ended December 31, 2018
Interest expense during the year ended December 31, 2019 decreased compared to the prior year due to lower average outstanding borrowings
partially offset with higher interest rates.
Year Ended December 31, 2018 Compared with the Year Ended December 31, 2017
Interest expense during the year ended December 31, 2018 increased compared with the prior year primarily due to the combination of higher average
outstanding borrowings under Allscripts’ senior secured credit facility and higher interest rates. The higher average outstanding borrowings were largely due
to additional borrowings to finance the acquisition of the EIS Business during the fourth quarter of 2017 and the acquisitions of Practice Fusion and Health
Grid during 2018.
Other (loss) income, net
(In thousands)
Other (loss) income, net
$
Year Ended December 31,
2018
2019
(138,902) $
2017
2019 %
Change
from 2018
2018 %
Change
from 2017
74 $
(512)
NM
114.5%
Year Ended December 31, 2019 Compared with the Years Ended December 31, 2018 and 2017
Other (loss) income, net for the year ended December 31, 2019 consisted of (i) $145 million settlement with the DOJ related to its civil and criminal
investigations of Practice Fusion, Refer to Note 21, “Contingencies” of the Notes to our consolidated financial statements of this Form 10-K for further
information regarding the investigations and (ii) offset with a $5 million reversal of an earnout related to a prior acquisition. Other (loss) income, net also
consists of a combination of interest income and miscellaneous receipts and expenses.
Gain on Sale of Businesses, Net
(In thousands)
Gain on sale of businesses, net
Year Ended December 31,
2018
172,258 $
0 $
2017
2019 %
Change
from 2018
2018 %
Change
from 2017
0
(100.0%)
NM
$
2019
45
Year Ended December 31, 2019 Compared with the Years Ended December 31, 2018 and 2017
Gain on sale of businesses, net for the year ended December 31, 2018 consists of a gain of $177.9 million and a loss of $5.6 million from the
divestitures of the OneContent and Strategic Sourcing businesses, respectively, both of which were acquired as part of the EIS Business acquisition during the
fourth quarter of 2017.
Impairment of Long-term investments
(In thousands)
Impairment of long-term investments
2019
Year Ended December 31,
2018
$
(651) $
(15,487) $
2017
(165,290)
2019 %
Change
from 2018
2018 %
Change
from 2017
(95.8%)
(90.6%)
Year Ended December 31, 2019 Compared with the Year Ended December 31, 2018
Impairment of long-term investments during the year ended December 31, 2019 consisted of an impairment of $1.7 million associated with one of our
long-term equity investments partially offset with a $1.0 million recovery of a long-term equity investment that had previously been impaired.
Year Ended December 31, 2018 Compared with the Year Ended December 31, 2017
We recognized non-cash charges on two of our cost-method equity investments and a related note receivable during the year ended December 31,
2018. These charges equaled the cost bases of the investments and the related note receivable prior to the impairment. We recorded non-cash impairment
charges of $165.3 million associated with two of our long-term investments during 2017. The majority of these charges relate to our previous investment in
NantHealth common stock, which we fully disposed of in connection with our acquisition of certain assets related to NantHealth’s patient/provider
engagement solutions business in 2017.
Equity in Net Income of Unconsolidated Investments
(In thousands)
Equity in net income of unconsolidated
investments
2019
Year Ended December 31,
2018
2017
2019 %
Change
from 2018
2018 %
Change
from 2017
$
665
$
259 $
821
156.8%
(68.5%)
Year Ended December 31, 2019 Compared with the Years Ended December 31, 2018 and 2017
Equity in net income (loss) of unconsolidated investments represents our share of the equity earnings (losses) of our investments in third parties
accounted for under the equity method of accounting based on one quarter lag.
Income Tax Benefit (Provision)
(In thousands)
Income tax benefit (provision)
Effective tax rate
2019
Year Ended December 31,
2018
2017
$
23,914
$
11.6%
(469) $
3.6%
5,514
2.9%
2019 %
Change
from 2018
2018 %
Change
from 2017
NM
(108.5%)
Year Ended December 31, 2019 Compared with the Year Ended December 31, 2018
The United States Tax Cuts and Jobs Act (the “Tax Act”) was enacted on December 22, 2017 and introduced significant changes to the income tax
law in the United States. Effective in 2018, the Tax Act reduced the United States statutory tax rate from 35% to 21% and created new taxes on certain
foreign-sourced earnings and certain related-party payments, which are referred to as the Global Intangible Low-taxed Income ("GILTI") tax and Base
Erosion and Anti-Abuse Tax (“BEAT”) rules, respectively. In addition, in 2017 we were subject to a one-time transition tax on accumulated foreign subsidiary
earnings not previously subject to income tax in the United States.
Our provision for income taxes differs from the tax computed at the U.S. federal statutory income tax rate due primarily to valuation allowance,
permanent differences, income attributable to foreign jurisdictions taxed at rates different from the United States federal statutory income tax rate, state taxes,
tax credits and certain discrete items. Our effective tax rate for the year ended December 31, 2019, compared with the prior year, differs primarily due to the
fact that the permanent items, credits and the impact of foreign earnings had a greater impact on the pre-tax income of $13.1 million in the year ended
December 31, 2018, compared to the impacts of these items on a pre-tax loss of $206.5 million for the year ended December 31, 2019. In evaluating our
ability to recover our deferred tax assets within the jurisdictions from which they arise, we consider all available evidence, including scheduled reversals of
deferred tax liabilities, tax-planning strategies, and results of recent operations. In evaluating the objective evidence that historical results provide, we
consider three years of cumulative operating income (loss). In the year ended December 31, 2019, we recorded $0.9 million of valuation allowance, mostly
against foreign deferred tax assets.
46
Year Ended December 31, 2018 Compared with the Year Ended December 31, 2017
The United States Tax Cuts and Jobs Act (the “Tax Act”) was enacted on December 22, 2017 and introduced significant changes to the income tax
law in the United States. Effective in 2018, the Tax Act reduced the United States statutory tax rate from 35% to 21% and created new taxes on certain
foreign-sourced earnings and certain related-party payments, which are referred to as the Global Intangible Low-taxed Income ("GILTI") tax and Base
Erosion and Anti-Abuse Tax (“BEAT”) rules, respectively. In addition, in 2017 we were subject to a one-time transition tax on accumulated foreign subsidiary
earnings not previously subject to income tax in the United States.
Due to the timing of the enactment and the complexity involved in applying the provisions of the Tax Act, we made reasonable estimates of the
effects and recorded provisional expense of $15.3 million in our financial statements for the year ended December 31, 2017 in accordance with guidance in
Staff Accounting Bulletin No. 118 (“SAB 118”), which allowed a measurement period of up to one year after the enactment date of the Tax Act to finalize the
recording of the related tax impacts. This provisional benefit included $10.1 million expense for remeasurement of deferred tax balances to reflect the lower
federal rate and expense of $5.2 million for the one-time transition tax on accumulated foreign subsidiary earnings not previously subject to income tax in the
United States. Adjustments to these provisional amounts that we recorded in 2018 did not have a significant impact on our consolidated financial statements.
Our accounting for the effects of the enactment of United States Tax Reform is now complete. Due to our divestiture of our investment in Netsmart, the
amounts noted above do not include the provisional amounts recorded by Netsmart in 2017.
Our provision for income taxes differs from the tax computed at the U.S. federal statutory income tax rate due primarily to valuation allowance,
permanent differences, income attributable to foreign jurisdictions taxed at rates different from the United States federal statutory income tax rate, state taxes,
tax credits and certain discrete items. Our effective tax rate decreased for the year ended December 31, 2018, compared with the prior year, primarily due to
the effects of the stricter executive compensation deduction provisions of the Tax Act recorded in 2018, offset by the United States federal rate reduction of
21% versus 35% in 2017.
In evaluating our ability to recover our deferred tax assets within the jurisdictions from which they arise, we consider all available evidence, including
scheduled reversals of deferred tax liabilities, tax-planning strategies, and results of recent operations. In evaluating the objective evidence that historical
results provide, we consider three years of cumulative operating income (loss). In the year ended December 31, 2018, we released $64.8 million of valuation
allowance, mostly due to the utilization of capital loss carryforward against capital gain incurred during the year ended December 31, 2018 and the utilization
of federal credit carryforwards.
Discontinued Operations
(In thousands)
Loss from discontinued operations
Gain on sale of Netsmart
Income tax effect on discontinued operations
Income (loss) from discontinued operations, net of tax
2019
Year Ended December 31,
2018
2017
$
$
0 $
0
0
0 $
(72,836) $
500,471
(32,497)
395,138 $
(11,915)
0
42,263
30,348
2019 %
Change
from 2018
(100.0%)
(100.0%)
(100.0%)
(100.0%)
2018 %
Change
from 2017
NM
NM
(176.9%)
NM
Year Ended December 31, 2019 Compared with the Years Ended December 31, 2018 and 2017
On December 31, 2018, we sold all of the Class A Common Units of Netsmart owned by the Company. Prior to the sale, Netsmart comprised a
separate reportable segment, which due to its significance to our historical consolidated financial statements and results of operations, is now reported as a
discontinued operation as a result of the sale for all periods presented. The loss from discontinued operations represents the net of losses incurred by Netsmart
for the years ended December 31, 2018 and 2017 partly offset by earnings attributable to two solutions acquired during the fourth quarter of 2017 as part of
the EIS Business that we no longer support effective as of March 31, 2018. Refer to Note 17, “Discontinued Operations” to our consolidated financial
statements included in Part II, Item 8, “Financial Statements and Supplementary Data” of this Form 10-K for additional information regarding discontinued
operations.
Non-Controlling Interests
(In thousands)
Net loss attributable to non-controlling interests
Accretion of redemption preference on
redeemable convertible non-controlling interest
- discontinued operations
$
$
2019
Year Ended December 31,
2018
2017
2019 %
Change
from 2018
2018 %
Change
from 2017
424 $
4,527 $
1,566
(90.6%)
189.1%
0 $
(48,594) $
(43,850)
(100.0%)
10.8%
47
Year Ended December 31, 2019 Compared with the Years Ended December 31, 2018 and 2017
The net loss attributable to non-controlling interest represents the share of earnings of consolidated affiliates that is attributable to the affiliates’
common stock that is not owned by us for each of the periods presented. The remaining minority interest of Pulse8 was purchased during the first quarter of
2019. We have no remaining non-controlling interest activities to report. The accretion of redemption preference on redeemable convertible non-controlling
interest represents the accretion of liquidation preference at 11% per annum to the value of the preferred units of Netsmart, prior to the sale of our investment
in Netsmart on December 31, 2018.
Segment Operations
Overview of Segment Results
(In thousands)
Revenue:
Provider
Veradigm
Unallocated Amounts
Total revenue
Gross Profit:
Provider
Veradigm
Unallocated Amounts
Total gross profit
Income from operations:
Provider
Veradigm
Unallocated Amounts
Total (loss) income from operations
2019
Year Ended December 31,
2018
2017
2019 %
Change
from 2018
2018 %
Change
from 2017
$
$
$
$
$
$
1,597,115 $
161,216
13,346
1,771,677
$
672,206
104,896
(63,522)
713,580
396,724
43,996
(465,176)
(24,456)
$
$
$
$
1,616,022 $
140,326
(6,386)
1,749,962
710,063
100,708
(86,228)
724,543
402,544
43,641
(539,237)
(93,052)
$
$
$
$
$
1,441,212
69,879
(13,383)
1,497,708
(1.2%)
14.9%
NM
1.2%
12.1%
100.8%
(52.3%)
16.8%
674,112
43,817
(85,130)
632,799
426,099
23,816
(437,431)
12,484
(5.3%)
4.2%
(26.3%)
(1.5%)
5.3%
129.8%
1.3%
14.5%
(1.4%)
0.8%
(13.7%)
(73.7%)
(5.5%)
83.2%
23.3%
NM
The results for the years ended December 31, 2018 and 2017 have been recast to conform to the current year presentation, which reflects several
changes made to our organizational and reporting structure during the year ended December 31, 2019. Refer to Note 18, “Business Segments” to our
consolidated financial statements included in Part II, Item 8, “Financial Statements and Supplementary Data” of this Form 10-K for detailed discussion about
these changes to our segments.
Provider
Our Provider segment derives its revenue from the sale of integrated clinical software applications, financial management and patient engagement
solutions, which primarily include EHR-related software, connectivity and coordinated care solutions, financial and practice management software, related
installation, support and maintenance, outsourcing, private cloud hosting, revenue cycle management, training and electronic claims administration services.
(In thousands)
Revenue
Gross profit
Gross margin %
Income from operations
Operating margin %
2019
1,597,115
672,206
$
$
Year Ended December 31,
2018
1,616,022
710,063
$
$
$
$
2017
1,441,212
674,112
2019 %
Change
from 2018
2018 %
Change
from 2017
(1.2%)
(5.3%)
12.1%
5.3%
42.1%
$
396,724
$
24.8%
43.9%
402,544
$
24.9%
46.8%
426,099
29.6%
(1.4%)
(5.5%)
Year Ended December 31, 2019 Compared with the Year Ended December 31, 2018
Provider revenue decreased during the year ended December 31, 2019, compared with the prior year comparable period due to known attrition within
the EIS and other businesses and the sale of the OneContent and Strategic Sourcing businesses on March 15, 2018 and on April 2, 2018, respectively. These
businesses were acquired as part of the EIS business acquisition on October 2, 2017 and contributed $16 million of revenue during the first quarter of 2018,
including $1 million of amortization of acquisition-related deferred revenue adjustments. These decreases were partly offset by higher sales of perpetual
software licenses for our acute solutions in 2019 compared to 2018 and additional revenue from the 2018 acquisition of Health Grid.
48
Gross profit and margin decreased during the year ended December 31, 2019 compared with the prior year primarily due to the previously mentioned
attrition and increased hosting migration costs. These were partially offset with lower costs due to the decline in sales. The sale of OneContent, which had
higher overall profitability, compared with our other Provider businesses, contributed to the decline of gross profit and margin. Operating margin remained
consistent during the year ended December 31, 2019 compared with prior year, as the decline in gross profit was offset by lower selling, general and
administrative, and research and development expenses driven by headcount reduction actions taken during 2018 as part of the integration of the EIS and
Health Grid acquisitions.
Year Ended December 31, 2018 Compared with the Year Ended December 31, 2017
Provider revenue and gross profit increased during the year ended December 31, 2018 compared with the year ended December 31, 2017, primarily
due to acquisitions of the EIS business and Health Grid during the fourth quarter of 2017 and second quarter of 2018, respectively. The increase in revenue
due to acquisitions was partially offset by fewer perpetual software license sales of our acute and coordinated care solutions software as there were several
large transactions recorded in 2017 that did not recur in 2018.
Gross margin decreased during the year ended December 31, 2018 compared with the prior year primarily due to lower sales of higher margin
perpetual software licenses, higher internal personnel costs related to incremental resources from recent acquisitions and to support anticipated new hosting
client go-lives, and higher amortization of capitalized software development and acquired technology-related intangible assets.
Income from operations and operating margin decreased during the year ended December 31, 2018 compared with prior year due to increases in
selling, general and administrative, and research and development expenses, mostly driven by recent acquisitions, partly offset by higher capitalization of
internal software development expenses.
Veradigm
Our Veradigm segment derives its revenue from the provision of data-driven clinical insights with actionable tools for clinical workflow, research,
analytics and media. Its solutions, targeted at key healthcare stakeholders, help improve the quality, efficiency and value of healthcare delivery – from
biopharma to health plans, healthcare providers and patients, and health technology partners, among others.
(In thousands)
Revenue
Gross profit
Gross margin %
Income from operations
Operating margin %
$
$
$
2019
161,216
104,896
Year Ended December 31,
2018
140,326
100,708
$
$
$
$
65.1%
43,996
$
27.3%
71.8%
43,641
$
31.1%
2019 %
Change
from 2018
2018 %
Change
from 2017
14.9%
4.2%
100.8%
129.8%
0.8%
83.2%
2017
69,879
43,817
62.7%
23,816
34.1%
Year Ended December 31, 2019 Compared with the Year Ended December 31, 2018
Veradigm revenue increased during the year ended December 31, 2019 compared with the prior year comparable period due to an increase in organic
sales. Gross profit and income from operations increased for during the year ended December 31, 2019 due to an increase in organic sales and cost reductions
partially offset with headcount growth and hosting migration costs. The acquisition of Practice Fusion during the first quarter of 2018 also contributed to the
increases.
Gross margin and operating margin decreased during the year ended December 31, 2019, compared with the prior year comparable period, primarily
due to (i) an increase in hosting migration costs, (ii) costs associated with recent acquisitions, (iii) headcount growth and (iv) partially offset with other cost
reductions.
Year Ended December 31, 2018 Compared with the Year Ended December 31, 2017
Veradigm revenue, gross profit, gross margin and income from operations increased during the year ended December 31, 2018 compared with the
prior year comparable period primarily due to the acquisition of Practice Fusion during the first quarter of 2018. Operating margin decreased during 2018
primarily due to higher personnel costs related to incremental resources from the Practice Fusion acquisition and to support anticipated new hosting client go-
lives.
49
Unallocated Amounts
In determining revenue, gross profit and income from operations for our segments, we do not include in revenue the amortization of acquisition-
related deferred revenue adjustments, which reflect the fair value adjustments to deferred revenues acquired in a business acquisition. We also exclude the
amortization of intangible assets, stock-based compensation expense, expenses not reflective of our core business and transaction-related costs and non-cash
asset impairment charges from the operating segment data provided to our Chief Operating Decision Maker. Expenses not reflective of our core business
relate to certain severance, product consolidation, legal, consulting and other charges. Accordingly, these amounts are not included in our reportable segment
results and are included in the “Unallocated Amounts” category. The “Unallocated Amounts” category also includes (i) corporate general and administrative
expenses (including marketing expenses) and certain research and development expenses related to common solutions and resources that benefit all of our
business units, all of which are centrally managed, and (ii) revenue and the associated cost from the resale of certain ancillary products, primarily hardware.
(In thousands)
Revenue
Gross profit
Gross margin %
Loss from operations
Operating margin %
2019
Year Ended December 31,
2018
2017
$
$
13,346 $
$
(63,522)
NM
$
(465,176)
$
NM
(6,386) $
$
(86,228)
NM
(13,383)
(85,130)
NM
(539,237)
NM
$
(437,431)
NM
2019 %
Change
from 2018
NM
(26.3%)
2018 %
Change
from 2017
(52.3%)
1.3%
(13.7%)
23.3%
Year Ended December 31, 2019 Compared with the Year Ended December 31, 2018
Revenue from the resale of ancillary products, primarily consisting of hardware, is customer- and project-driven and, as a result, can fluctuate from
period to period. The increase in revenue for the year ended December 31, 2019 compared to the prior year was primarily due to only $2 million in
amortization of acquisition-related deferred revenue adjustments being recorded during 2019, compared to $24.3 million during 2018.
Gross unallocated expenses, which represent the unallocated loss from operations excluding the impact of revenue, totaled $478 million for the year
ended December 31, 2019 compared to $533 million for the year ended December 31, 2018. The decrease was primarily the result of (i) lower asset
impairment and goodwill charges of $35 million, (ii) lower net transaction-related severance and legal expenses of $16 million and (iii) lower acquisition-
related amortization of $1 million. These were partially offset with $3 million in additional stock-based compensation expense.
Year Ended December 31, 2018 Compared with the Year Ended December 31, 2017
Revenue from the resale of ancillary products, primarily consisting of hardware, is customer and project driven and, as a result, can fluctuate from
period to period. Revenue for the year ended December 31, 2018 compared with the prior year improved primarily due to lower recognition of amortization
of acquisition-related deferred revenue adjustments, which reflect the fair value adjustments to deferred revenues acquired in the EIS Business, Practice
Fusion, Health Grid and NantHealth provider/patient engagement acquisitions. Such adjustments totaled $24 million for the year ended December 31, 2018
compared with $29 million for the year ended December 31, 2017.
Gross unallocated expenses, which represent the unallocated loss from operations excluding the impact of revenue, totaled $533 million for the year
ended December 31, 2018 compared with $424 million for the prior year. The increase in the year ended December 31, 2018 compared with prior year was
primarily driven by higher transaction-related, severance and legal expenses, primarily related to the acquisitions of the EIS Business, Practice Fusion and
Health Grid, which included higher (i) asset impairment charges of $58 million, (ii) goodwill impairment charges of $14 million, (iii) transaction-related,
severance and legal expenses of $30 million, and (iv) amortization of intangible and acquisition-related asset of $9 million. The increase in amortization
expense was primarily due to additional amortization expense associated with intangible assets acquired as part of business acquisitions completed since the
third quarter of 2017.
Contract Backlog
Contract backlog represents the value of bookings and support and maintenance contracts that have not yet been recognized as revenue. A summary
of contract backlog by revenue category is as follows:
(In millions)
Software delivery, support and maintenance
Client services
Total contract backlog
As of December 31,
2019
2018
% Change
$
$
2,519
1,848
4,367
$
$
2,507
1,350
3,857
0.5%
36.9%
13.2%
Total contract backlog as of December 31, 2019 increased compared with December 31, 2018. Total contract backlog can fluctuate between periods
based on the level of revenue and bookings as well as the timing and mix of renewal activity and periodic revalidations.
50
We estimate that the aggregate contract backlog as of December 31, 2019 will be recognized as revenue in future years as follows:
Year Ended December 31,
2020
2021
2022
2023
2024
Thereafter
Total
Liquidity and Capital Resources
(Percentage of
Total Backlog)
35%
19%
14%
10%
7%
15%
100%
The primary factors that influence our liquidity include, but are not limited to, the amount and timing of our revenues, cash collections from our
clients, capital expenditures and investments in research and development efforts, including investments in or acquisitions of third parties. As of December
31, 2019, our principal sources of liquidity consisted of cash and cash equivalents of $138 million and available borrowing capacity of $819 million under our
revolving credit facility. The change in our cash and cash equivalents balance is reflective of the following:
Operating Cash Flow Activities
(In thousands)
Net (loss) income
Less: Loss from discontinued operations
(Loss) income from continuing operations
Non-cash adjustments to net (loss) income
Cash impact of changes in operating assets and liabilities
Net cash provided by operating activities -
continuing operations
Net cash (used in) provided by operating activities -
discontinued operations
Net cash provided by operating activities
2019
(182,602) $
$
Year Ended December 31,
2018
407,807 $
395,138
12,669
136,651
(60,086)
0
(182,602)
277,217
(18,361)
2017
(154,175) $
30,348
(184,523)
351,835
57,746
2019 $
Change
from 2018
2018 $
Change
from 2017
$
(590,409)
(395,138)
(195,271)
140,566
41,725
561,982
364,790
197,192
(215,184)
(117,832)
76,254
89,234
225,058
(12,980)
(135,824)
(30,000)
46,254 $
(21,343)
67,891 $
54,357
279,415 $
(8,657)
(21,637)
$
(75,700)
(211,524)
$
Year Ended December 31, 2019 Compared with the Year Ended December 31, 2018
Net cash provided by operating activities – continuing operations decreased during the year ended December 31, 2019 compared with prior year. The
decrease in income from operations and the increase in non-cash adjustments to net income in 2019 partially related to the absence in the gains on sale of
divestitures, such as OneContent in 2018. The increase in non-cash adjustments to net loss in 2019 also related to higher depreciation and the amortization of
right-to-use assets. The net loss and the cash impact of changes in operating assets and liabilities during 2019 reflects the $145 million settlement with the
DOJ in connection with the Practice Fusion investigations.
Net cash used in operating activities – discontinued operations during the year ended December 31, 2019 reflects an advance income tax payment
related to the gain realized on the sale of our investment in Netsmart on December 31, 2018.
Year Ended December 31, 2018 Compared with the Year Ended December 31, 2017
Net cash provided by operating activities – continuing operations decreased during the year ended December 31, 2018 compared with the prior year
primarily due to working capital changes and higher costs during the year ended December 31, 2018 compared with the prior year, which primarily included
higher interest expense, transaction-related and legal expenses, and incentive-based compensation payments. The decrease in non-cash adjustments to net loss
was primarily driven by lower non-cash impairment charges associated with long-term investments, intangibles and goodwill during the year ended
December 31, 2018 compared with the prior year.
Net cash provided by operating activities – discontinued operations decreased during the year ended December 31, 2018 compared with the prior year
primarily driven by the additional tax provision relating to the gain from the sale of our investment in Netsmart on December 31, 2018. Netsmart generated
cash from operations during both 2018 and 2017. During 2018, Netsmart’s cash provided by operations decreased by approximately $16 million primarily
driven by higher interest expenses paid attributable to Netsmart’s credit facilities.
51
Investing Cash Flow Activities
(In thousands)
Capital expenditures
Capitalized software
Cash paid for business acquisitions, net of cash acquired
Cash received from sale of businesses, net
Purchases of equity securities, other investments and
related intangible assets, net
Other proceeds from investing activities
Net cash (used in) provided by investing activities -
continuing operations
Net cash used in investing activities -
discontinued operations
$
2019
(16,600) $
(113,836)
(23,443)
0
Year Ended December 31,
2018
(31,309) $
(113,308)
(177,233)
807,764
2017
(38,759) $
(118,241)
(169,823)
0
$
14,709
(528)
153,790
(807,764)
2019 $
Change
from 2018
2018 $
Change
from 2017
(7,191)
14
(16,934)
54
(5,606)
215
9,743
(40)
(161,056)
469,034
(332,214)
(630,090)
801,248
0
(221,021)
248,013 $
(80,758)
(412,972) $
221,021
(409,069)
$
(140,263)
660,985
7,450
4,933
(7,410)
807,764
(11,328)
(161)
Net cash (used in) provided by investing activities
$
(161,056) $
Year Ended December 31, 2019 Compared with the Year Ended December 31, 2018
Net cash used in investing activities – continuing operations during the year ended December 31, 2019 resulted from the absence of the sale of
businesses compared to prior year. The sale of Netsmart and OneContent produced significant investing cash inflows during 2018, which was partially offset
with cash paid for the acquisitions of Practice Fusion and Health Grid. Capital expenditures also decreased in 2019 compared with prior year.
Year Ended December 31, 2018 Compared with the Year Ended December 31, 2017
We had cash inflows from investing activities – continuing operations during the year ended December 31, 2018 compared with cash outflows from
investing activities – continuing operations during the year ended December 31, 2017, which was primarily driven by cash proceeds of $567 million from the
sale of our investment in Netsmart and $241 million of net cash proceeds from the divestiture of the OneContent business during 2018. Cash used in investing
activities also included the purchase of Practice Fusion and Health Grid, which were mostly offset by lower overall capital expenditures during 2018.
Net cash used in investing activities – discontinued operations increased during the year ended December 31, 2018 compared with the prior year,
primarily due to larger business acquisitions completed by Netsmart during 2018.
Financing Cash Flow Activities
(In thousands)
Proceeds from sale or issuance of common stock
Taxes paid related to net share settlement of equity awards
Proceeds from issuance of 0.875%
Convertible Senior Notes
Payments for issuance costs on 0.875%
Convertible Senior Notes
Payments for capped call transaction on 0.875%
Convertible Senior Notes
Credit facility payments
Credit facility borrowings, net of issuance costs
Repurchase of common stock
Payment of acquisition and other financing obligations
Purchases of subsidiary shares owned by
non-controlling interest
Net cash provided by (used in) financing activities -
continuing operations
Net cash provided by financing activities -
discontinued operations
2019
Year Ended December 31,
2018
2017
2019 $
Change
from 2018
2018 $
Change
from 2017
$
0 $
(7,286)
1,283 $
(9,466)
1,568 $
(7,269)
(1,283) $
2,180
(285)
(2,197)
218,000
(5,445)
(17,222)
(220,000)
279,241
(111,460)
(14,685)
0
0
0
0
0
(713,751)
430,843
(138,928)
(5,198)
0
(138,139)
325,001
(12,077)
(1,283)
218,000
(5,445)
(17,222)
493,751
(151,602)
27,468
(9,487)
0
0
0
(575,612)
105,842
(126,851)
(3,915)
(53,800)
(7,198)
0
(46,602)
(7,198)
67,343
(442,415)
167,801
509,758
(610,216)
0
149,432
(292,983) $
30,784
198,585 $
(149,432)
360,326 $
118,648
(491,568)
Net cash provided (used in) by financing activities
$
67,343 $
52
Year Ended December 31, 2019 Compared with the Year Ended December 31, 2018
Net cash provided by financing activities – continuing operations increased during the year ended December 31, 2019 primarily due to inflows
resulting from (i) the issuance of the 0.875% Convertible Senior Notes, (ii) lower credit facility payments, partially offset with less credit facility borrowings
and (iii) a decrease in the repurchase of common stock. These were partially offset by the purchase of the remaining minority interest in Pulse8 during 2019.
Year Ended December 31, 2018 Compared with the Year Ended December 31, 2017
We used cash in financing activities – continuing operations during the year ended December 31, 2018 compared with cash inflows from financing
activities – continuing operations during the year ended December 31, 2017, which was primarily driven by higher repayments of borrowings outstanding
under our senior secured credit facility and higher common stock repurchases. We used a portion of the proceeds from the sale of our investment in Netsmart
to repay balances outstanding under our senior secured credit facilities at the end of 2018. We borrowed funds in 2018 to purchase Practice Fusion and Health
Grid and to acquire the remaining outstanding minority interest in which we initially acquired a controlling interest in April 2015.
Net cash provided by financing activities – discontinued operations increased during the year ended December 31, 2018 compared with the prior year
primarily due to higher borrowings by Netsmart used to finance business acquisitions.
Future Capital Requirements
The following table summarizes future payments under our 0.875% Convertible Senior Notes, 1.25% Cash Convertible Senior Notes and Senior
Secured Credit Facility as of December 31, 2019:
Total
2020
2021
2022
2023
2024
Thereafter
$
218,000 $
0 $
0 $
0 $
0 $
0 $
218,000
345,000
410,000
973,000
345,000
27,500
372,500
0
30,000
30,000
0
37,500
37,500
0
315,000
315,000
0
0
0
0
0
218,000
13,469
1,070
1,908
1,907
1,908
1,907
4,769
(In thousands)
Principal payments:
0.875% Convertible Senior Notes (1)
1.25% Cash Convertible Senior
Notes (2)
Senior Secured Credit Facility (3)
Total principal payments
Interest payments:
0.875% Convertible Senior Notes
1.25% Cash Convertible Senior
Notes (3)
Senior Secured Credit Facility (3) (4)
Total interest payments
Total future debt payments
$ 1,039,674 $
4,313
48,892
66,674
4,313
16,267
21,650
394,150 $
0
15,225
17,133
47,133 $
0
14,093
16,000
53,500 $
0
3,307
5,215
320,215 $
0
0
1,907
1,907 $
0
0
4,769
222,769
(1) Assumes no cash conversions of the 1.25% Cash Convertible Senior Notes prior to their maturity on July 1, 2020.
(2) Amount represents the face value of the 0.875% Convertible Senior Notes, which includes both the liability and equity portions.
(3) Assumes no additional borrowings after December 31, 2019 and that all drawn amounts are repaid upon maturity.
(4) Assumes LIBOR plus the applicable margin remain constant at the rate in effect on December 31, 2019, which was 3.55%.
Revolving Credit Facilities
We have a $900 million senior secured revolving facility (the “Revolving Facility”) that expires on February 15, 2023. A total of up to $50 million of
the Revolving Facility is available for the issuance of letters of credit, up to $10 million of the Revolving Facility is available for swingline loans, and up to
$100 million of the Revolving Facility could be borrowed under certain foreign currencies. We had no borrowings and $1.0 million of letters of credit
outstanding under the Revolving Facility as of December 31, 2019. We had $819 million available, net of outstanding letters of credit, under the Revolving
Facility as of December 31, 2019. There can be no assurance that we will be able to draw on the full available balance of the Revolving Facility if the
financial institutions that have extended such credit commitments become unwilling or unable to fund such borrowings. Refer to Note 9, “Debt” to our
consolidated financial statements included in Part II, Item 8, “Financial Statements and Supplementary Data” of this Form 10-K for further information.
Other Matters Affecting Future Capital Requirements
We completed renegotiations with Atos to improve the operating cost structure of our private cloud hosting operations during 2019. The new
agreement also provides for the payment of initial annual base fees of $35 million per year (an increase from $30 million) plus charges for volume-based
services currently projected using volumes estimated based on historical actuals and forecasted projections. We incurred $100 million and $56 million during
2019 and 2018, respectively, of expenses under our agreements with Atos. These costs are included in cost of revenue in our consolidated statements of
operations.
Our total investment in research and development efforts during 2019 increased compared to 2018, as we continue to build and expand capabilities
and functionality in Veradigm and our Consumer Health offerings while reducing investment in traditional ambulatory, acute and post-acute platforms. Our
total spending consists of research and development costs directly recorded to expense, which are offset by the capitalization of eligible development costs.
53
We believe that our cash and cash equivalents of $138 million as of December 31, 2019, our future cash flows, and our borrowing capacity under our
Revolving Facility, taken together, provide adequate resources to fund our ongoing cash requirements for the next twelve months. We cannot provide
assurance that our actual cash requirements will not be greater than we expect as of the date of this Form 10-K. We will, from time to time, consider the
acquisition of, or investment in, complementary businesses, products, services and technologies, and the repurchase of our common stock under our stock
repurchase program, each of which might impact our liquidity requirements or cause us to borrow under our credit facilities or issue additional equity or debt
securities.
If sources of liquidity are not available or if we cannot generate sufficient cash flow from operations during the next twelve months, we might be
required to obtain additional sources of funds through additional operating improvements, capital market transactions, asset sales or financing from third
parties, a combination thereof or otherwise. We cannot provide assurance that these additional sources of funds will be available or, if available, would have
reasonable terms.
Contractual Obligations and Commitments
We enter into obligations with third parties in the ordinary course of business. The following table summarizes our significant contractual obligations
as of December 31, 2019 and the effect such obligations are expected to have on our liquidity and cash in future periods, assuming all obligations reach
maturity. We do not believe that our cash flow requirements can be assessed based upon this analysis of these obligations as the funding of these future cash
obligations will be from future cash flows from the sale of our products and services that are not reflected in the following table.
(In thousands)
Balance sheet obligations: (1)
Debt:
Principal payments
Interest payments
Finance leases
Other obligations: (2)
Non-cancelable operating leases
Purchase obligations (3)
Agreement with Atos
Letters of credit
Total contractual obligations
Total
2020
2021
Payments due by period
2023
2022
2024
Thereafter
$
973,000 $ 372,500 $
66,674
132
21,650
85
30,000 $
17,133
40
37,500 $ 315,000 $
16,000
7
5,215
0
0 $ 218,000
4,769
0
1,907
0
134,503
66,844
451,049
1,015
27,647
37,097
95,301
1,015
23,277
18,734
86,808
0
21,640
11,013
82,101
0
19,497
0
75,995
0
$ 1,693,217 $ 555,295 $ 175,992 $ 168,261 $ 415,707 $
13,862
0
74,375
0
28,580
0
36,469
0
90,144 $ 287,818
(1) Our liability for uncertain tax positions was $21 million as of December 31, 2019. Liabilities that may result from this exposure have been excluded from the table above
since we cannot predict, with reasonable reliability, the outcome of discussions with the respective taxing jurisdictions, which may or may not result in cash settlements.
We have also excluded net deferred tax liabilities of $15 million from the amounts presented in the table as the future amounts that will be settled in cash are uncertain.
(2) We have no off-balance sheet arrangements as defined in Item 303 of Regulation S-K as of December 31, 2019. We have obligations to pay contingent consideration
associated with acquisitions of $19.5 million as of December 31, 2019. Such contingent consideration obligations are excluded from the above table since their payment is
based on future financial objectives, the achievement of which we cannot predict.
(3) Purchase obligations consist of minimum purchase commitments for telecommunication services, computer equipment, maintenance, consulting and other commitments.
54
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
We are exposed to interest rate risk, primarily changes in United States interest rates and changes in LIBOR (including the transition away from
LIBOR), and primarily due to our borrowing under the Senior Secured Credit Facility. Based on the principal balance of $410 million of debt outstanding
under the Senior Secured Credit Facility as of December 31, 2019, an increase in interest rates of 1.0% will cause a corresponding increase in annual interest
expense of approximately $4.1 million.
We have global operations; therefore, we are exposed to risks related to foreign currency fluctuations. Foreign currency fluctuations through
December 31, 2019 have not had a material impact on our financial position or operating results. We believe most of our global operations are naturally
hedged for foreign currency risk as our foreign subsidiaries invoice their clients and satisfy their obligations primarily in their local currencies. An exception
to this is our development and shared services center in India and our local operations in Israel, where we are required to make payments in local currency but
which we fund in United States dollars. We have entered into non-deliverable forward foreign currency exchange contracts with reputable banking
counterparties in order to hedge a portion of our forecasted future Indian Rupee-denominated (“INR”) expenses against foreign currency fluctuations between
the United States dollar and the INR. We had no outstanding forward contracts as of December 31, 2019. In the future, we may enter into additional forward
contracts to increase the amount of hedged monthly INR expenses or initiate hedges for monthly periods beyond December 2019. The forward contracts
resulted in net gains of $0.3 million and $0.5 million during the years ended December 31, 2019 and 2018, respectively.
We continually monitor our exposure to foreign currency fluctuations and may use additional derivative financial instruments and hedging
transactions in the future if, in our judgment, circumstances warrant. There can be no guarantee that the impact of foreign currency fluctuations in the future
will not be significant and will not have a material impact on our financial position or results of operations.
55
Item 8. Financial Statements and Supplementary Data
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Board of Directors and Shareholders
Allscripts Healthcare Solutions, Inc.
Opinion on the financial statements
We have audited the accompanying consolidated balance sheets of Allscripts Healthcare Solutions, Inc. (a Delaware corporation) and subsidiaries (the
“Company”) as of December 31, 2019 and 2018, the related consolidated statements of operations, comprehensive income, stockholders’ equity, and cash
flows for each of the three years in the period ended December 31, 2019, and the related notes and financial statement schedules included under Item 15(a)
(collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of
the Company as of December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended December
31, 2019, in conformity with accounting principles generally accepted in the United States of America.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the
Company’s internal control over financial reporting as of December 31, 2019, based on criteria established in the 2013 Internal Control—Integrated
Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”), and our report dated March 2, 2020 expressed an
unqualified opinion.
Change in Accounting Principle
As discussed in Note 3 to the consolidated financial statements, the Company has changed its method of accounting for leases in 2019 due to the
adoption of FASB Accounting Standards Codification (Topic 842), Leases.
Basis for opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s
financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the
Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the
PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing
procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to
those risks. Such procedures included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. Our audits also
included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the
financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical audit matters
The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or
required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved
our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the
financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit
matters or on the accounts or disclosures to which they relate.
Revenue Recognition - Determination of distinct performance obligations and application of stand-alone selling prices
56
As discussed in Note 2 to the consolidated financial statements, the Company enters into contracts with customers that often include multiple
promises to transfer products and services including sales of proprietary software, support and maintenance, as well as client services including managed
services solutions, such as private cloud hosting, outsourcing and revenue cycle management, as well as other client services or project-based revenue from
implementation, training, consulting, and outsourced IT services. Given the nature and volume of the Company’s product and service offerings included in a
single contract, there is complexity related to the determination of which of these promises result in distinct performance obligations within the context of the
contract. Judgment is required by management to determine the various performance obligations and to allocate the transaction price in each contract to these
distinct performance obligations using the relative stand-alone selling prices as well as a residual allocation approach for certain software licenses. We
identified the determination of distinct performance obligations and application of stand-alone selling prices as a critical audit matter.
The principal consideration for our determination that the identification of distinct performance obligations and the application of stand-alone selling
prices is a critical audit matter is the especially challenging auditor judgment required when evaluating the determination of distinct performance obligations
and execution of the allocation of transaction price using stand-alone selling prices due to the mix and volume of products and services offered with terms that
are specific to each contract.
Our audit procedures related to the identification of distinct performance obligations and the application of stand-alone selling prices included the
following, among others:
• We tested the design and operating effectiveness of controls relating to the identification of performance obligations, the determination of stand-
alone selling prices and the allocation of the contractual transaction price to each distinct performance obligation.
• We inspected a sample of contracts with customers and performed the following procedures:
•
•
•
•
Obtained and read all selected contracts, contract amendments and sales orders for each selected arrangement and tested the
identification of significant terms;
Evaluated management’s identification of all distinct performance obligations in each arrangement and recalculated management’s
allocation of the contract’s transaction price to each distinct performance obligation;
Evaluated management’s estimate of stand-alone selling prices for reasonableness;
Evaluated the timing of revenue recognition for each performance obligation and tested the accuracy of management’s computations of
revenue recognized in the financial statements.
Assessment of the carrying value of goodwill
As further discussed in Notes 1 and 7 to the financial statements, the Company has approximately $1.3 billion of goodwill on the balance sheet. The
Company performs goodwill impairment testing annually, or more frequently if events or circumstances indicate the carrying value of a reporting unit that
includes goodwill might exceed the fair value of that reporting unit. The determination of the fair value of each reporting unit is based on a combination of a
market approach, that considers guideline public company market multiples, and an income approach, that utilizes discounted cash flows specific to each
reporting unit as well as other Level 3 inputs. We identified the estimation of the fair value of each reporting unit included in the Company’s annual goodwill
impairment test as a critical audit matter.
The principal considerations for our determination that annual impairment testing is a critical audit matter is the significant amount of management
and auditor judgement utilized in assessing the fair value of the reporting units. The key assumptions utilized by management in the determination of the fair
value under the income approach include long-term projected revenue growth rates, operating expenses, profit margins terminal value and discount rates for
each of the Company’s reporting units. Additionally, assessment of guideline public companies utilized in the market approach required significant
management and auditor judgment. Changes to these assumptions can have a significant impact on the fair value of each reporting unit.
Our audit procedures related to the estimation of the fair value of each reporting unit included the following, among others:
• We tested the design and operating effectiveness of controls relating to management’s goodwill impairment tests, including controls over the
development and review of significant assumptions used in the determination of the fair value of each reporting unit.
• We tested management’s process for determining the fair value of the reporting units, including evaluating significant projected financial
information by comparing such projections to the publicly available industry data and market conditions found in industry reports as well as
comparing historical operating results to prior forecasts and actual results of each reporting unit.
57
• We involved a valuation specialist to evaluate:
•
•
•
•
The methodologies used and whether they were acceptable for the underlying assets or operations as well as applied in accordance with
valuation standards and from a market participant perspective;
The reasonableness of the discount rates by reporting unit by independently recalculating the weighted average costs of capital and
evaluating future market conditions;
The guideline public companies and transactions utilized by management in comparison to Capital IQ data, examination of financial
metrics of the comparable public companies and other transactions within the industry;
Other significant assumptions, including the terminal growth rate.
/s/ GRANT THORNTON LLP
We have served as the Company’s auditor since 2014.
Raleigh, North Carolina
March 2, 2020
58
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Board of Directors and Shareholders
Allscripts Healthcare Solutions, Inc.
Opinion on internal control over financial reporting
We have audited the internal control over financial reporting of Allscripts Healthcare Solutions, Inc., a Delaware corporation and subsidiaries (the
“Company”) as of December 31, 2019, based on criteria established in the 2013 Internal Control—Integrated Framework issued by the Committee of
Sponsoring Organizations of the Treadway Commission (“COSO”). In our opinion, the Company maintained, in all material respects, effective internal
control over financial reporting as of December 31, 2019, based on criteria established in the 2013 Internal Control—Integrated Framework issued by COSO.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the
consolidated financial statements of the Company as of and for the year ended December 31, 2019, and our report dated March 2, 2020 expressed an
unqualified opinion on those financial statements.
Basis for opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the
effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control over Financial Reporting
(“Management’s Report”). Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a
public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an
understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating
effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We
believe that our audit provides a reasonable basis for our opinion.
Definition and limitations of internal control over financial reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal
control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and
fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to
permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are
being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention
or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any
evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree
of compliance with the policies or procedures may deteriorate.
/s/ GRANT THORNTON LLP
Raleigh, North Carolina
March 2, 2020
59
ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except per share amounts)
ASSETS
Current assets:
Cash and cash equivalents
Restricted cash
Accounts receivable, net of allowance of $44,944 and $50,406 as of
December 31, 2019 and December 31, 2018, respectively
Contract assets
Prepaid expenses and other current assets
Total current assets
Fixed assets, net
Software development costs, net
Intangible assets, net
Goodwill
Deferred taxes, net
Contract assets - long-term
Right-of-use assets - operating leases
Other assets
Total assets
60
December 31, 2019
December 31, 2018
$
$
129,668 $
7,871
459,751
95,982
147,990
841,262
88,339
243,929
374,142
1,362,017
5,704
67,559
98,020
124,767
3,205,739 $
174,243
10,552
465,264
66,451
142,455
858,965
121,913
209,660
431,081
1,373,744
5,036
71,879
0
109,206
3,181,484
ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
CONSOLIDATED BALANCE SHEETS (CONTINUED)
$
(In thousands, except per share amounts)
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable
Accrued expenses
Accrued compensation and benefits
Income tax payable
Deferred revenue
Current maturities of long-term debt
Current operating lease liabilities
Current liabilities attributable to discontinued operations
Total current liabilities
Long-term debt
Deferred revenue
Deferred taxes, net
Long-term operating lease liabilities
Other liabilities
Total liabilities
Commitments and contingencies
Stockholders’ equity:
Preferred stock: $0.01 par value, 1,000 shares authorized,
no shares issued and outstanding as of December 31, 2019 and December 31, 2018
Common stock: $0.01 par value, 349,000 shares authorized as of December 31, 2019
and December 31, 2018; 272,609 and 162,475 shares issued and outstanding
as of December 31, 2019, respectively; 270,955 and 171,224 shares issued
and outstanding as of December 31, 2018, respectively
Treasury stock: at cost, 110,134 and 99,731 shares as of December 31, 2019 and
December 31, 2018, respectively
Additional paid-in capital
(Accumulated deficit) retained earnings
Accumulated other comprehensive loss
Total Allscripts Healthcare Solutions, Inc.'s stockholders' equity
Non-controlling interest
Total stockholders’ equity
Total liabilities and stockholders’ equity
$
December 31, 2019
December 31, 2018
104,014 $
270,662
68,569
0
379,843
364,465
23,137
0
1,210,690
551,004
12,337
21,038
95,162
30,320
1,920,551
73,166
107,068
100,076
29,644
466,797
20,059
0
920
797,730
647,539
15,984
58,470
0
81,334
1,601,057
0
0
2,725
2,709
(571,157)
1,907,348
(49,336)
(4,392)
1,285,188
0
1,285,188
3,205,739 $
(460,543)
1,881,494
132,842
(5,389)
1,551,113
29,314
1,580,427
3,181,484
The accompanying notes are an integral part of these consolidated financial statements.
61
ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
Revenue:
Software delivery, support and maintenance
Client services
Total revenue
Cost of revenue:
Software delivery, support and maintenance
Client services
Amortization of software development and
acquisition-related assets
Total cost of revenue
Gross profit
Selling, general and administrative expenses
Research and development
Asset impairment charges
Goodwill impairment charge
Amortization of intangible and acquisition-related assets
(Loss) income from operations
Interest expense
Other (loss) income, net
Gain on sale of businesses, net
Impairment of long-term investments
Equity in net income of unconsolidated investments
(Loss) income from continuing operations before income taxes
Income tax benefit (provision)
(Loss) income from continuing operations, net of tax
Loss from discontinued operations
Gain on sale of Netsmart
Income tax effect on discontinued operations
Income from discontinued operations, net of tax
Net (loss) income
Net loss attributable to non-controlling interests
Accretion of redemption preference on redeemable
convertible non-controlling interest - discontinued operations
Net (loss) income attributable to Allscripts Healthcare
Solutions, Inc. stockholders
Net (loss) income attributable to Allscripts Healthcare
Solutions, Inc. stockholders per share:
Basic
Continuing operations
Discontinued operations
Net (loss) income attributable to Allscripts Healthcare
Solutions, Inc. stockholders per share
Diluted
Continuing operations
Discontinued operations
Net (loss) income attributable to Allscripts Healthcare
Solutions, Inc. stockholders per share
2019
Year Ended December 31,
2018
2017
$
1,126,486 $
645,191
1,771,677
1,128,263 $
621,699
1,749,962
958,187
539,521
1,497,708
358,946
583,111
116,040
1,058,097
713,580
419,774
254,509
10,837
25,700
27,216
(24,456)
(43,172)
(138,902)
0
(651)
665
(206,516)
23,914
(182,602)
0
0
0
0
(182,602)
424
357,039
565,504
102,876
1,025,419
724,543
450,967
268,409
58,166
13,466
26,587
(93,052)
(50,914)
74
172,258
(15,487)
259
13,138
(469)
12,669
(72,836)
500,471
(32,497)
395,138
407,807
4,527
295,593
484,591
84,725
864,909
632,799
400,688
202,282
0
0
17,345
12,484
(37,540)
(512)
0
(165,290)
821
(190,037)
5,514
(184,523)
(11,915)
0
42,263
30,348
(154,175)
1,566
0
(48,594)
(43,850)
$
(182,178) $
363,740
$
(196,459)
$
(1.10) $
0.00
0.10 $
1.97
$
(1.10) $
2.07
$
$
(1.10) $
0.00
0.10 $
1.94
$
(1.10) $
2.04
$
(1.02)
(0.07)
(1.09)
(1.02)
(0.07)
(1.09)
The accompanying notes are an integral part of these consolidated financial statements.
62
ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In thousands)
Net (loss) income
Other comprehensive (loss) income:
Foreign currency translation adjustments
Unrealized gain on available-for-sale securities
Change in fair value of derivatives qualifying as cash flow hedges
Other comprehensive income (loss) before income
tax (expense) benefit
Income tax benefit related to items in
other comprehensive (loss) income
Total other comprehensive income (loss)
Comprehensive (loss) income
Comprehensive loss attributable to non-controlling interests
Comprehensive (loss) income, net
$
2019
Year Ended December 31,
2018
2017
$
(182,602) $
407,807 $
(154,175)
1,192
0
(262)
930
67
997
(181,605)
424
(181,181) $
(2,908)
0
(873)
(3,781)
377
(3,404)
404,403
4,527
408,930 $
3,352
56,359
114
59,825
19
59,844
(94,331)
1,566
(92,765)
The accompanying notes are an integral part of these consolidated financial statements.
63
ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In thousands)
Number of Common Shares Issued
Balance at beginning of year
Common stock issued under stock compensation plans, net of shares
withheld for employee taxes
Balance at end of year
Common Stock
Balance at beginning of year
Common stock issued under stock compensation plans, net of shares
withheld for employee taxes
Balance at end of year
Number of Treasury Stock Shares Purchased
Balance at beginning of year
Issuance of treasury stock
Purchase of treasury stock
Balance at end of year
Treasury Stock
Balance at beginning of year
Issuance of treasury stock
Purchase of treasury stock
Balance at end of year
Additional Paid-In Capital
Balance at beginning of year
Stock-based compensation
Common stock issued under stock compensation plans, net of shares
withheld for employee taxes
Issuance of 0.875% Convertible Senior Notes
Capped call transactions
Allocation of discounts and debt issuance costs for issuance of 0.875%
Convertible Senior Notes
Accretion of redemption preference on redeemable convertible
non-controlling interest - discontinued operations
Subsidiary issuance of common stock
Issuance of treasury stock
Warrants issued
Acquisition of non-controlling interest
Balance at end of year
Accumulated Deficit
Balance at beginning of year
Net (loss) income less net loss attributable to non-controlling interests
Recognition of previously unrecognized excess tax benefits
ASC 606 implementation adjustments
Balance at end of year
Accumulated Other Comprehensive Loss
Balance at beginning of year
Foreign currency translation adjustments, net
Unrecognized (loss) gain on derivatives qualifying as cash flow
hedges, net of tax
Unrecognized gain on available for sale securities, net of tax
Balance at end of year
Non-controlling interest
Balance at beginning of year
Acquisition of non-controlling interest
Net loss attributable to non-controlling interests
Balance at end of year
Total Stockholders’ Equity at beginning of year
Total Stockholders’ Equity at end of year
2019
Year Ended December 31,
2018
2017
270,955
269,335
267,997
1,654
272,609
1,620
270,955
2,709 $
2,693 $
16
2,725 $
16
2,709 $
(99,731)
61
(10,464)
(110,134)
(460,543) $
846
(111,460)
(571,157) $
(88,504)
76
(11,303)
(99,731)
(322,735) $
1,121
(138,929)
(460,543) $
1,338
269,335
2,680
13
2,693
(87,487)
22
(1,039)
(88,504)
(310,993)
335
(12,077)
(322,735)
1,881,494 $
38,713
1,781,059 $
34,638
1,789,959
35,337
(7,227)
40,058
(17,222)
(1,140)
0
0
(144)
2,729
(29,913)
1,907,348 $
132,842 $
(182,178)
0
0
(49,336) $
(5,389) $
1,192
(195)
0
(4,392) $
29,314 $
(28,890)
(424)
0 $
1,580,427 $
1,285,188 $
(8,197)
0
0
0
72,386
0
(61)
2,729
(1,060)
1,881,494 $
(338,150) $
412,334
0
58,658
132,842 $
(1,985) $
(2,908)
(496)
0
(5,389) $
39,190 $
(5,349)
(4,527)
29,314 $
1,160,072 $
1,580,427 $
(5,767)
0
0
0
(43,850)
1,473
(76)
3,983
0
1,781,059
(187,351)
(152,609)
1,810
0
(338,150)
(61,829)
3,352
72
56,420
(1,985)
40,735
21
(1,566)
39,190
1,273,201
1,160,072
$
$
$
$
$
$
$
$
$
$
$
$
$
$
The accompanying notes are an integral part of these consolidated financial statements.
64
ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
Cash flows from operating activities:
Net (loss) income
Less: Loss from discontinued operations
(Loss) income from continuing operations
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization
Operating right-of-use asset amortization
Stock-based compensation expense
Deferred taxes
Asset impairment charges
Goodwill impairment charge
Impairment of long-term investments
Gain on sale of businesses, net
Other loss (income), net
Changes in operating assets and liabilities (net of businesses acquired):
Accounts receivable and contract assets, net
Prepaid expenses and other assets
Accounts payable
Accrued expenses
Accrued compensation and benefits
Deferred revenue
Other liabilities
Operating leases
Net cash provided by operating activities - continuing operations
Net cash (used in) provided by operating activities - discontinued operations
Net cash provided by operating activities
Cash flows from investing activities:
Capital expenditures
Capitalized software
Cash paid for business acquisitions, net of cash acquired
Cash received from sale of businesses, net
Purchases of equity securities, other investments and related intangible assets, net
Other proceeds from investing activities
Net cash (used in) provided by investing activities - continuing operations
Net cash used in investing activities - discontinued operations
Net cash (used in) provided by investing activities
Cash flows from financing activities:
Proceeds from sale or issuance of common stock
Taxes paid related to net share settlement of equity awards
Proceeds from issuance of 0.875% Convertible Senior Notes
Payments for issuance costs on 0.875% Convertible Senior Notes
Payments for capped call transaction on 0.875% Convertible Senior Notes
Credit facility payments
Credit facility borrowings, net of issuance costs
Repurchase of common stock
Payment of acquisition and other financing obligations
Purchases of subsidiary shares owned by non-controlling interest
Net cash provided by (used in) financing activities - continuing operations
Net cash provided by financing activities - discontinued operations
Net cash provided (used in) by financing activities
Effect of exchange rate changes on cash and cash equivalents
Net (decrease) increase in cash and cash equivalents
Cash, cash equivalents and restricted cash, beginning of period
Cash, cash equivalents and restricted cash, end of period
Less: Cash and cash equivalents within current assets attributable to discontinued operations
Cash, cash equivalents and restricted cash, end of period, excluding discontinued operations
2019
Year Ended December 31,
2018
2017
$
(182,602) $
0
(182,602)
407,807 $
395,138
12,669
(154,175)
30,348
(184,523)
207,106
22,534
38,982
(37,970)
10,837
25,700
651
0
9,377
(13,273)
(15,374)
27,799
141,407
(32,471)
(94,353)
(7,746)
(24,350)
76,254
(30,000)
46,254
(16,600)
(113,836)
(23,443)
0
(7,191)
14
(161,056)
0
(161,056)
0
(7,286)
218,000
(5,445)
(17,222)
(220,000)
279,241
(111,460)
(14,685)
(53,800)
67,343
0
67,343
203
(47,256)
184,795
137,539
0
192,346
0
34,638
4,144
58,166
13,466
15,487
(172,258)
(9,338)
(109,134)
(55,818)
(19,159)
40,484
13,440
58,010
12,091
0
89,234
(21,343)
67,891
(31,309)
(113,308)
(177,233)
807,764
(16,934)
54
469,034
(221,021)
248,013
1,283
(9,466)
0
0
0
(713,751)
430,843
(138,928)
(5,198)
(7,198)
(442,415)
149,432
(292,983)
(624)
22,297
162,498
184,795
0
$
137,539 $
184,795 $
157,328
0
36,540
(10,228)
0
0
165,290
0
2,905
(95,189)
13,219
(19,785)
10,131
18,717
112,684
17,969
0
225,058
54,357
279,415
(38,759)
(118,241)
(169,823)
0
(5,606)
215
(332,214)
(80,758)
(412,972)
1,568
(7,269)
0
0
0
(138,139)
325,001
(12,077)
(1,283)
0
167,801
30,784
198,585
860
65,888
96,610
162,498
(31,504)
130,994
The accompanying notes are an integral part of these consolidated financial statements.
65
ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Basis of Presentation and Significant Accounting Policies
Principles of Consolidation
The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. (“Allscripts”) and its wholly-owned subsidiaries
and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company”
as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and controlled affiliates, unless otherwise stated.
Use of Estimates
The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the United States of America
(“GAAP”) requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the
accompanying notes. Actual results could differ materially from these estimates.
Cash and Cash Equivalents
We consider all highly liquid investments with an original maturity of three months or less, when purchased, to be cash equivalents. The fair values of
these investments approximate their carrying values.
Other Financial Assets and Liabilities
We have investments in equity investments for which it is not practicable to estimate fair value primarily because of their illiquidity and restricted
marketability. Such investments for initially at cost, less impairment and changes resulting from observable price changes and equity methods of accounting.
Refer to Note 4, “Business Combinations and Other Investments” for additional information about these investments.
Our long-term financial liabilities include borrowings outstanding under our Senior Secured Credit Facility (as defined in Note 9, “Debt”), with
carrying values that approximate fair value since the variable interest rates approximate current market rates. In addition, as of December 31, 2019, the fair
value of the 1.25% Notes (as defined in Note 9, “Debt”) was approximately equal to the 1.25% Notes’ principal balance (or par). We utilized the 1.25%
Notes’ market trading prices near December 31, 2019 in making this fair value assessment. See Note 9, “Debt” for further information regarding our long-
term financial liabilities.
Derivative Financial Instruments
Derivative instruments are recognized as either assets or liabilities and are measured at fair value. The accounting for changes in the fair value of a
derivative depends on the intended use of the derivative and the resulting designation. See Note 15, “Derivative Financial Instruments” for information
regarding gains and losses from derivative instruments during the years ended December 31, 2019, 2018 and 2017.
Allowance for Doubtful Accounts Receivable
Accounts receivable are recorded at the invoiced amounts and do not bear interest. An allowance for doubtful accounts is recorded to provide for
estimated losses resulting from uncollectible accounts and is based principally on specifically identified amounts where collection is deemed doubtful.
Additional non-specific allowances are recorded based on historical experience and management’s assessment of a variety of factors related to the general
financial condition of our clients, the industry in which we operate and general economic conditions. We regularly review the collectability of individual
accounts and assess the adequacy of the allowance for doubtful accounts. Account balances are charged off against the allowance after all means of collection
have been exhausted and the potential for recovery is considered remote. If the financial condition of our clients were to deteriorate, resulting in an
impairment of their ability to make payments, additional allowance and related bad debt expense may be required.
Contingent Liabilities
A liability is contingent if the amount is not presently known but may become known in the future as a result of the occurrence of some uncertain
future event. We accrue a liability for an estimated loss if we determine that the potential loss is probable of occurring and the amount can be reasonably
estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is
reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made.
The assessment of contingent liabilities, including legal and income tax contingencies, involves the use of estimates, assumptions and judgments. Our
estimates are based on our belief that future events will validate the current assumptions regarding the ultimate outcome of these exposures. However, there
can be no assurance that future events, such as court decisions or Internal Revenue Service (“IRS”) positions, will not differ from our assessments.
66
Fixed Assets
Fixed assets are stated at cost. Depreciation and amortization are computed under the straight-line method over the estimated useful lives of the
related assets. The depreciable life of leasehold improvements is the shorter of the lease term or the useful life. Upon asset retirement or other disposition, the
fixed asset cost and the related accumulated depreciation or amortization are removed from the accounts, and any gain or loss is included in the consolidated
statements of operations. Amounts incurred for repairs and maintenance are expensed as incurred.
Business Combinations
Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets
acquired and the liabilities assumed. While we use our best estimates and assumptions as a part of the purchase price allocation process to accurately value
the assets acquired, including intangible assets, and the liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to
refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we may record adjustments to the fair values
of the assets acquired and the liabilities assumed, with a corresponding offset to goodwill. Upon the conclusion of the measurement period or final
determination of the values of assets acquired or the liabilities assumed, whichever comes first, any subsequent adjustments are reflected in our consolidated
statements of operations.
Goodwill and Intangible Assets
Goodwill and intangible assets acquired in a business combination and determined to have an indefinite useful life are not amortized but are tested for
impairment annually or between annual tests when an impairment indicator exists. If an optional qualitative goodwill impairment assessment is not
performed, we are required to determine the fair value of each reporting unit. If a reporting unit’s fair value is lower than the carrying value, an impairment
loss equal to the excess will be recorded not to exceed the carrying amount of goodwill assigned to the reporting unit. The recoverability of indefinite-lived
intangible assets is assessed by comparison of the carrying value of an asset to its estimated fair value. If we determine that the carrying value of an asset
exceeds its estimated fair value, an impairment loss equal to the excess will be recorded.
The determination of the fair value of our reporting units is based on a combination of a market approach, that considers benchmark company market
multiples, and an income approach, that utilizes discounted cash flows for each reporting unit and other Level 3 inputs. Under the income approach, we
determine fair value based on the present value of the most recent cash flow projections for each reporting unit as of the date of the analysis and calculate a
terminal value utilizing a terminal growth rate. The significant assumptions under this approach include, among others: income projections, which are
dependent on sales to new and existing clients, new product introductions, client behavior, competitor pricing, operating expenses, the discount rate, and the
terminal growth rate. The cash flows used to determine fair value are dependent on a number of significant management assumptions such as our expectations
of future performance and the expected future economic environment, which are partly based upon our historical experience. Our estimates are subject to
change given the inherent uncertainty in predicting future results. Additionally, the discount rate and the terminal growth rate are based on our judgment of
the rates that would be utilized by a hypothetical market participant. As part of the goodwill impairment testing, we also consider our market capitalization in
assessing the reasonableness of the combined fair values estimated for our reporting units.
In accordance with GAAP, definite-lived intangible assets are required to be amortized over their respective estimated useful lives and reviewed for
impairment whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. We estimate the useful lives of our
intangible assets and ratably amortize their value over the estimated useful lives of those assets. If the estimates of the useful lives should change, we will
amortize the remaining book value over the remaining useful lives or, if an asset is deemed to be impaired, a write-down of the value of the asset may be
required at such time.
Long-Lived Assets and Long-Lived Assets to Be Disposed Of
We review our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be
recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to
be generated by the asset. If assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount
of the assets exceeds the fair value of the assets.
67
Software Development Costs
We capitalize purchased software upon acquisition if it is accounted for as internal-use software or if it meets the future alternative use criteria. We
capitalize incurred labor costs for software development from the time technological feasibility of the software is established, or when the preliminary project
phase is completed in the case of internal-use software, until the software is available for general release. Research and development costs and other computer
software maintenance costs related to software development are expensed as incurred. We estimate the useful life of our capitalized software and amortize its
value over that estimated life. If the actual useful life is shorter than our estimated useful life, we will amortize the remaining book value over the remaining
useful life or the asset may be deemed to be impaired and, accordingly, a write-down of the value of the asset may be recorded as a charge to earnings. Upon
the availability for general release, we commence amortization of the capitalized software costs on a product by product basis. Amortization of capitalized
software is recorded using the greater of (i) the ratio of current revenues to total and anticipated future revenues for the applicable product or (ii) the straight-
line method over the remaining estimated economic life, which is estimated to be three to five years.
At each balance sheet date, the unamortized capitalized costs of a software product are compared with the net realizable value of that product. The net
realizable value is the estimated future gross revenues from that product reduced by the estimated future costs of completing and disposing of that product,
including the costs of performing maintenance and client support required to satisfy our responsibility set forth at the time of sale. The amount by which the
unamortized capitalized costs of a software product exceed the net realizable value of that asset is written off. If we determine that the value of the capitalized
software could not be recovered, a write-down of the value of the capitalized software to its recoverable value is recorded as a charge to earnings.
The unamortized balances of capitalized software were as follows:
(In thousands)
Software development costs
Less: accumulated amortization
Software development costs, net
December 31,
2019
428,641 $
(184,712)
243,929 $
2018
317,637
(107,977)
209,660
$
$
Capitalized software development costs, write-offs included in asset impairment changes and amortization of capitalized software development costs
included in cost of revenue are illustrated in the following table:
(In thousands)
Capitalized software development costs
Write-offs and divestitures of capitalized software development costs
Amortization of capitalized software development costs
Income Taxes
2019
Year Ended December 31,
2018
2017
$
$
$
113,836 $
0 $
79,567 $
113,308 $
34,083 $
64,409 $
94,740
0
51,589
We account for income taxes using the liability method, which requires the recognition of deferred tax assets or liabilities for the tax-effected
temporary differences between the financial reporting and tax bases of our assets and liabilities and for net operating loss and tax credit carryforwards. The
objectives of accounting for income taxes are to recognize the amount of taxes payable or refundable for the current year and deferred tax liabilities and assets
for the future tax consequences of events that have been recognized in an entity’s financial statements or tax returns. Judgment is required in addressing the
future tax consequences of events that have been recognized in our consolidated financial statements or tax returns. The deferred tax assets are recorded net of
a valuation allowance when, based on the weight of available evidence, we believe it is more likely than not that some portion or all of the recorded deferred
tax assets will not be realized in future periods. We consider many factors when assessing the likelihood of future realization of our deferred tax assets,
including recent cumulative earnings experience, expectations of future taxable income, the ability to carryback losses and other relevant factors.
In addition, we are subject to the continuous examination of our income tax returns by the IRS and other tax authorities. A change in the assessment
of the outcomes of such matters could materially impact our consolidated financial statements.
68
The calculation of tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for
anticipated tax audit issues based on our estimate of whether, and the extent to which, additional taxes may be required. If we ultimately determine that
payment of these amounts is unnecessary, then we reverse the liability and recognize a tax benefit during the period in which we determine that the liability is
no longer necessary. We also recognize tax benefits to the extent that it is more likely than not that our positions will be sustained if challenged by the taxing
authorities. To the extent we prevail in matters for which liabilities have been established or are required to pay amounts in excess of our liabilities, our
effective tax rate in a given period may be materially affected. An unfavorable tax settlement would require cash payments and may result in an increase in
our effective tax rate in the year of resolution. A favorable tax settlement would be recognized as a reduction in our effective tax rate in the year of resolution.
We report interest and penalties related to uncertain income tax positions in the income tax (provision) benefit line of our consolidated statements of
operations.
We file income tax returns in the United States federal jurisdiction, numerous states in the United States and multiple countries outside of the United
States.
Stock-Based Compensation
We account for stock-based compensation in accordance with GAAP, which requires the measurement and recognition of compensation expense for
all share-based payment awards made to employees and non-employee directors based on their estimated fair value. We measure stock-based compensation
cost at the grant date based on the fair value of the award and recognize the expense over the requisite service period typically on a straight-line basis, net of
estimated forfeitures. We recognize stock-based compensation cost for awards with performance conditions if and when we conclude that it is probable that
the performance conditions will be achieved. The fair value of service-based restricted stock units and restricted stock awards is measured at their underlying
closing share price on the date of grant. The fair value of market-based restricted stock units is measured using the Monte Carlo pricing model. The net
proceeds from stock-based compensation activities are reflected as a financing activity within the accompanying consolidated statements of cash flows. We
settle employee stock option exercises and stock awards with newly issued common shares. Refer to Note 11, “Stock Award Plans” for detailed discussion
about our stock-based incentive plans.
Employee Benefit Plans
We provide employees with defined contribution savings plans. We recognize expense for our contributions to the savings plans at the time employees
make contributions to the plans and we contributed the following amounts to these plans:
(In thousands)
Company contributions to employee benefit plans
Foreign Currency
2019
Year Ended December 31,
2018
2017
$
24,782 $
29,393 $
18,861
The determination of the functional currency of our foreign subsidiaries is made based on the appropriate economic and management indicators. Our
foreign subsidiaries use the local currency of their respective countries as the functional currency, with the exception of our operating subsidiaries in India and
Israel which use the United States dollar as a functional currency. The assets and liabilities of foreign subsidiaries whose functional currency is the local
currency are translated into United States dollars at the exchange rates in effect at the consolidated balance sheet date, while revenues and expenses are
translated at the average rates of exchange during the year. Translation gains and losses are not included in determining net income or loss but are included as
a separate component of accumulated other comprehensive loss. Gains and losses resulting from foreign currency transactions are included in determining net
income or loss and have not been material in any years presented in the accompanying consolidated statements of operations. We periodically enter into non-
deliverable forward foreign currency exchange contracts in order to hedge a portion of our forecasted future Indian Rupee-denominated (“INR”) expenses
against foreign currency fluctuations between the United States dollar and the INR. See Note 15, “Derivative Financial Instruments,” for information
regarding these foreign currency exchange contracts.
Concentrations of Credit Risk
Financial instruments that potentially subject us to a concentration of credit risk consist of cash, cash equivalents, marketable securities and trade
receivables. We primarily maintain our cash balances with one major commercial bank domestically and several commercial banks internationally.
We sell our products and services to healthcare providers. Credit risk with respect to trade receivables is generally diversified due to the large number
of clients and their geographic dispersion. To reduce credit risk, we perform ongoing credit evaluations of significant clients and their payment histories. In
general, we do not require collateral from our clients, but we do enter into advance deposit agreements, if appropriate.
69
The majority of our revenue is derived from clients located in the United States. The majority of long-lived assets are also located in the United
States. No single client accounted for more than 10% of our revenue in the years ended December 31, 2018 and 2017. No client represented more than 10%
of accounts receivable as of December 31, 2019 and 2018.
Recently Adopted Accounting Pronouncements
We adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”) on
January 1, 2019 using the cumulative-effect adjustment transition method. This method requires us to recognize an adoption impact as a cumulative-effect
adjustment to the January 1, 2019 retained earnings balance. Prior period balances were not adjusted upon adoption of this standard. The standard requires
that leased assets and corresponding lease liabilities be recognized within the consolidated balance sheets as right-of-use assets and operating or financing
lease liabilities. Please refer to Note 3 “Leases” for further discussion on the impact of adoption.
In August 2017, the FASB issued Accounting Standards Update No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to
Accounting for Hedging Activities” (“ASU 2017-12”), which provides new accounting guidance to simplify and improve the reporting of hedging
relationships to better portray the economic results of an entity’s risk management activities in its financial statements. In addition to that main objective, the
amendments in ASU 2017-12 make certain targeted improvements to simplify the application of the hedge accounting guidance in current GAAP. We adopted
ASU 2017-12 on January 1, 2019, and the adoption did not have any effect on our consolidated financial statements.
In June 2018, the FASB issued Accounting Standards Update No. 2018-07, “Compensation-Stock Compensation (Topic 718): Improvements to
Nonemployee Share-Based Payment Accounting” (“ASU 2018-07”), which expands the scope of Topic 718 to include share-based payment transactions for
acquiring goods and services from nonemployees. ASU 2018-07 specifies that Topic 718 applies to all share-based payment transactions in which a grantor
acquires goods or services to be used or consumed in its own operations by issuing share-based payment awards. ASU 2018-07 also clarifies that Topic 718
does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or
services to customers. We adopted this standard on January 1, 2019, and the adoption did not have any effect on our consolidated financial statements.
We adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update 2014-09, Revenue from Contracts with Customers: Topic
606 (“ASU 2014-09”) effective on January 1, 2018 using the modified retrospective method. ASU 2014-09 superseded nearly all previously existing revenue
recognition guidance under GAAP. Refer to Note 2, “Revenue from Contracts with Customers” for detailed discussion about our revenue recognition
accounting policies.
Accounting Pronouncements Not Yet Adopted
In June 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of
Credit Losses on Financial Instruments (“ASU 2016-13”). The guidance in ASU 2016-13 replaces the incurred loss impairment methodology under current
GAAP. The new impairment model requires immediate recognition of estimated credit losses expected to occur for most financial assets and certain other
instruments. For available-for-sale debt securities with unrealized losses, the losses will be recognized as allowances rather than reductions in the amortized
cost of the securities. ASU 2016-13 is effective for annual periods beginning after December 15, 2019, and interim periods within those annual periods. We
are adopting the provisions of ASU 2016-13 on January 1, 2020 and currently expect to record a minimum of $20 million in additional reserves for estimated
credit losses.
In August 2018, the FASB issued Accounting Standards Update No. 2018-13, “Fair Value Measurement (Topic 820) – Disclosure Framework –
Changes to the Disclosure Requirements for Fair Value Measurement” (“ASU 2018-13”), which eliminates, adds and modifies certain disclosure
requirements for fair value measurements. Entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2
of the fair value hierarchy, but public companies will be required to disclose the range and weighted average used to develop significant unobservable inputs
for Level 3 fair value instruments. ASU 2018-13 will be effective for all entities for interim and annual periods beginning after December 15, 2019, with early
adoption permitted. We are currently evaluating the impact of this accounting guidance.
In December 2019, the FASB issued Accounting Standards Update No. 2019-12, “Income Taxes (Topic 740)” (‘ASU 2019-12”), which is part of the
FASB’s overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the
information provided to users of financial statements. ASU 2019-12 simplifies accounting guidance for intraperiod allocations, deferred tax liabilities, year-
to-date losses in interim periods, franchise taxes, step-up in tax basis of goodwill, separate entity financial statements and interim recognition of tax laws or
rate changes. ASU 2019-12 is effective for public business entities for annual reporting periods beginning after December 15, 2020, with early adoption
permitted. We are currently evaluating the impact of this accounting guidance.
We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, would have a material impact on our
consolidated financial statements.
70
2. Revenue from Contracts with Customers
Our two primary revenue streams are (i) software delivery, support and maintenance and (ii) client services. Software delivery, support and
maintenance revenue consists of all of our proprietary software sales (either under a perpetual or term license delivery model), subscription-based software
sales, transaction-related revenue, the resale of hardware and third-party software and revenue from post-contract client support and maintenance services,
which include telephone support services, maintaining and upgrading software and ongoing enhanced maintenance. Client services revenue consists of
revenue from managed services solutions, such as private cloud hosting, outsourcing and revenue cycle management, as well as other client services and
project-based revenue from implementation, training and consulting services. For other clients, we offer an outsourced service in which we assume partial to
total responsibility for a healthcare organization’s IT operations using our employees.
Costs to Obtain or Fulfill a Contract
Capitalized costs to obtain or fulfill a contract are amortized over periods ranging from two to six years which represent the initial contract term or a
longer period, if renewals are expected and the renewal commission, if any, is not commensurate with the initial commission. We classify such capitalized
costs as current or non-current based on the expected timing of expense recognition. The current and non-current portions are included in Prepaid expenses
and other current assets, and Other assets, respectively, in our consolidated balance sheets.
At December 31, 2019 and 2018, we had capitalized costs to obtain or fulfill a contract of $20.8 million and $24.7 million, respectively, in Prepaid
and other current assets and $32.9 million and $33.8 million, respectively, in Other assets. During the year ended December 31, 2019 and 2018, we
recognized $33.8 million and $29.7 million, respectively, of amortization expense related to such capitalized costs, which is included in selling, general and
administrative expenses.
Contract Balances
The timing of revenue recognition, billings and cash collections results in billed and unbilled accounts receivables, contract assets and customer
advances and deposits. Accounts receivable, net includes both billed and unbilled amounts where the right to receive payment is unconditional and only
subject to the passage of time. Contract assets include amounts where revenue recognized exceeds the amount billed to the customer and the right to payment
is not solely subject to the passage of time. Deferred revenue includes advanced payments and billings in excess of revenue recognized. Our contract assets
and deferred revenue are reported in a net position on an individual contract basis at the end of each reporting period. Contract assets are classified as current
or long-term based on the timing of when we expect to complete the related performance obligations and bill the customer. Deferred revenue is classified as
current or long-term based on the timing of when we expect to recognize revenue.
In general, with the exception of fixed fee project-based client service offerings (such as implementation services), we sell our software solutions on
date-based milestone events where control transfers and use of the software occurs on the delivery date but the associated payments for the software license
occur on future milestone dates. In such instances, unbilled amounts are included in contract assets since our right to receive payment is conditional upon the
continued functionality of the software and the provision of ongoing support and maintenance. Our fixed fee project-based client service offerings typically
require us to provide the services with either a significant portion or all amounts due prior to service completion. Since our right to payment is not
unconditional, amounts associated with work prior to the completion date are also deemed to be contract assets.
Performance Obligations
A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account in ASC 606. A
performance obligation is considered distinct when both (i) a customer can benefit from the product or service either on its own or together with other
resources that are readily available to the customer and (ii) the promised product or service is separately identifiable from other promises in the contract.
Activities related to the fulfillment of a contract that do not transfer products or services to a customer, such as contract preparation or legal review of contract
terms, are not deemed to be performance obligations. Based on the similarities in the definitions of a “deliverable” under ASC 605 and “performance
obligation” under ASC 606, our identification of performance obligations under ASC 606 did not result in a significant divergence from our existing
identification approach.
We generally sell our solutions through multi-element arrangements where we provide the customer with (1) software licenses, (2) support and
maintenance, (3) embedded content such as third-party software and (4) client services. Incremental solutions, such as hardware and managed services are
also provided based upon a customer’s preferences and requirements. We deem that a customer is typically able to benefit from a product or service on its
own or together with readily available resources when we sell such product or service on a standalone basis. We have historically sold the majority of our
performance obligations, with the exception of software licenses, on a standalone basis. Incremental solutions, such as hardware, client services and managed
services, are often negotiated and fulfilled on an independent sales order basis as customer needs and requirements change over the course of a relationship
period. In addition, support and maintenance and embedded content are provided on a stand-alone basis through the renewal process.
71
One of the product offerings under our CareInMotionTM platform requires significant client service customization to enable the functionality of the
software before the customer can obtain benefit from using the product. The significant customization cannot be performed by a third party. Software
products and client services are separately identifiable in these contracts, but the performance obligations are not considered distinct in the context of the
contract. Therefore, these products and services are treated as a combined performance obligation.
Our support and maintenance obligations include multiple discrete performance obligations, with the two largest being unspecified product upgrades
or enhancements, and technical support, which can be offered at various points during a contract period. We believe that the multiple discrete performance
obligations within our overall support and maintenance obligations can be viewed as a single performance obligation since both the unspecified product
upgrades and technical support are activities to fulfill the maintenance performance obligation and are rendered concurrently.
The breakdown of revenue recognized based on the origination of performance obligations and elected accounting expedients is presented in the table
below:
(In thousands)
Revenue related to deferred revenue balance at
beginning of period
Revenue related to new performance obligations satisfied
during the period
Revenue recognized under "right-to-invoice" expedient
Reimbursed travel expenses, shipping and other revenue
Total revenue
(In thousands)
Revenue related to deferred revenue balance at
beginning of period
Revenue related to new performance obligations satisfied
during the period
Revenue recognized under "right-to-invoice" expedient
Reimbursed travel expenses, shipping and other revenue
Total revenue
Three Months
Ended
March 31, 2019
Three Months
Ended
June 30, 2019
Three Months
Ended
September 30, 2019
Three Months
Ended
December 31, 2019
$
126,184 $
146,150 $
151,543 $
171,799
248,221
55,923
1,721
432,049 $
233,696
62,245
2,369
444,460 $
228,927
61,814
1,900
444,184 $
216,072
60,826
2,287
450,984
$
Three Months
Ended
March 31, 2018
Three Months
Ended
June 30, 2018
Three Months
Ended
September 30, 2018
Three Months
Ended
December 31, 2018
$
181,398 $
196,163 $
153,151 $
141,127
200,232
49,403
2,689
433,722 $
180,001
62,533
2,767
441,464 $
225,641
51,288
2,350
432,430 $
237,963
60,593
2,663
442,346
$
The aggregate amount of contract transaction price related to remaining unsatisfied performance obligations (commonly referred to as “backlog”)
represents contracted revenue that has not yet been recognized and includes both deferred revenue and amounts that will be invoiced and recognized as
revenue in future periods. Total backlog equaled $4.4 billion as of December 31, 2019, of which we expect to recognize approximately 35% over the next 12
months, and the remaining 65% thereafter.
Transaction price and allocation
Our contracts with customers often include multiple distinct performance obligations such as software licenses, software support and maintenance,
hardware, client services, private cloud hosting and Software-as-a-Service. We adjust the transaction price on a contract-by-contract basis for (i) the effect of
the time value of money when a contract has a significant financing component and/or (ii) customer discounts and incentives deemed to be variable
consideration. We then allocate the contract transaction price to the distinct performance obligations in the contract. Such allocation is based on the stand-
alone selling price (“SSP”) of each distinct performance obligation. The transaction price allocated to each distinct performance obligation is adjusted for
discounts offered to customers that are outside of the Company’s established sufficiently narrow ranges for distinct performance obligations’ SSPs on a
relative SSP basis.
We use observable stand-alone pricing to determine the SSP for each distinct performance obligation. Such observable SSPs are based upon our listed
sales prices and consider discounts offered to customers. In instances where SSP is not directly observable because we do not sell the product or service
separately, we determine the SSP through the residual approach or cost-plus margin models using information that includes market conditions and other
observable inputs. Such instances primarily relate to sales of new products and service offerings and our acute suite of software licenses. Our acute suite of
software licenses is sold to a diverse set of customers for a broad range of amounts and, therefore, SSP is not discernible from past transactions due to the
high variability of selling prices.
72
Our products and services are generally not sold with a right of return, except for certain hardware sales, which are not material to our consolidated
revenue. We may provide credits or incentives on a contract-by-contract basis which are accounted for either as a material right or as variable consideration,
respectively, when allocating the transaction price. Such credits and incentives have historically not been significant. We do not provide additional warranties
to clients above and beyond warranties that the solutions purchased will perform in accordance with the agreed-upon specifications. On rare occasions, when
additional warranties are granted, we evaluate on a case-by-case basis whether the additional warranty granted represents a separate performance obligation.
Accounting Policy Elections and Practical Expedients
We have elected to exclude from the measurement of the transaction price all taxes (e.g., sales, use, value-added) assessed by government authorities
and collected from a customer. Therefore, revenue is recognized net of such taxes.
We contract with customers to deliver and ship tangible products within the normal course of business, such as computer hardware. The control of the
products transfers to the customer when the product reaches the shipper based on free on board (FOB) shipping clauses in these situations. We have elected to
use the practical expedient allowed under ASC 606 to account for shipping and handling activities that occur after the customer has obtained control of a
promised good as fulfillment costs rather than as an additional promised service and, therefore, we do not allocate a portion of the transaction price to a
shipping service obligation. We record as revenue any amounts billed to customers for shipping and handling costs and record as cost of revenue the actual
shipping costs incurred.
Our standard contract terms allow for the reimbursement by a customer for certain travel expenses necessary to provide on-site services to the
customer, such as implementation and training. Such reimbursed travel expenses are reported on a gross basis. Since such reimbursed travel expenses do not
represent a distinct good or service nor incremental value provided to a customer, a performance obligation is deemed not to exist. In certain situations,
however, when the allowable reimbursable expenses amount is capped, we believe that such cap represents the most likely amount of variable consideration
and the capped amount is included in the total contract transaction price.
In accordance with ASC 606, if an entity has a right to consideration from a customer in an amount that corresponds directly with the value to the
customer of the entity’s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice (“right-to-
invoice” practical expedient). We have elected to utilize this expedient as it relates to transaction-based services (such as revenue cycle management) and
electronic data interchange transactions.
73
Revenue Recognition
We recognize revenue only when we satisfy an identified performance obligation (or bundle of obligations) by transferring control of a promised
product or service to a customer. We consider a product or service to be transferred when a customer obtains control because a customer has sole possession
of the right to use (or the right to direct the use of) the product or service for the remainder of its economic life or to consume the product or service in its own
operations. We evaluate the transfer of control primarily from the customer’s perspective as this reduces the risk that revenue is recognized for activities that
do not transfer control to the customer.
The majority of our revenue is recognized over time because a customer continuously and simultaneously receives and consumes the benefits of our
performance. The exceptions to this pattern are our sales of perpetual and term software licenses, and hardware, where we determined that a customer obtains
control of the asset upon granting of access, delivery or shipment. The following table summarizes the pattern of revenue recognition for our most significant
performance obligations:
Recurring or Non-
recurring Nature
Recurring
Revenue
Recognition Pattern Measure of progress
Over time
Performance Obligation
Support and maintenance
("SMA")
Software as a service
("SaaS")
Private cloud hosting
Revenue Type
Software delivery, support and
maintenance
Software delivery, support and
maintenance
Client services
Recurring
Over time
Recurring
Over time
Client/Education services
Client services
Non-recurring
Over time
Outsourcing services
Client services
Recurring
Over time
Payerpath
(transaction volume)
Software delivery, support and
maintenance
Recurring
Over time
Output method (time elapsed) – revenue is
recognized ratably over the contract term
Output method (time elapsed) – revenue is
recognized ratably over the contract term
Output method (time elapsed) – revenue is
recognized ratably over the contract term
Input method (cost to cost) – revenue is recognized
proportionally over the service implementation
based on hours
Input method (cost to cost) – revenue is recognized
proportionally over the outsourcing period
Output method ("right-to-invoice" practical
expedient) – value transferred to the customer is
reflected on invoicing.
Upon electronic delivery
Software licenses
Hardware
Software delivery, support and
maintenance
Software delivery, support and
maintenance
Non-recurring
Point in time
Non-recurring
Point in time
Upon shipment
Recurring software delivery, support and maintenance revenue consists of recurring subscription-based software sales, support and maintenance
revenue, and recurring transaction-related revenue. Non-recurring software delivery, support and maintenance revenue consists of perpetual software licenses
sales, resale of hardware and non-recurring transaction-related revenue. Recurring client services revenue consists of revenue from managed services
solutions, such as outsourcing, private cloud hosting and revenue cycle management. Non-recurring client services revenue consists of project-based client
services revenue.
SMA, SaaS and private cloud hosting performance obligations are deemed to be performance obligations satisfied evenly over time as these are
fulfilled as stand-ready obligations to perform. Client services, such as those relating to implementation, consulting, training or education, are generally not
fulfilled evenly over the contract period, but rather over a shorter timeline where work effort can increase, or decline based upon stages of the project work
effort. These client services are typically quoted to a customer as a fixed fee amount that covers the implementation effort. Delivery progress for these
services is measured by establishing an approved cost budget with labor hour inputs utilized to gauge percentage of completion of the work effort. Therefore,
revenue for our client, education and outsourcing services is recognized proportionally with the progress of the implementation work effort.
Payerpath transaction volume and other transaction-based service obligations, such as revenue cycle management services, are fulfilled over time but
are not provided evenly over the contract period and reliable inputs are not available to track progress of completion. We determined that value is provided to
the customer throughout the contract period and the pricing charged to the customer varies on a monthly basis, based upon the volume of the customer’s
transactions processed in that respective period. The invoiced amount to the customer represents this value and, accordingly, the practical expedient to
recognize revenue based upon invoicing is most appropriate.
74
We considered the specific implementation guidance for accounting for licenses of intellectual property (“IP”) to determine if point in time or over
time recognition was more appropriate. The first step in the licensing framework is to determine whether the license is distinct or combined with other goods
and services. For most of our software licensing products, the licenses are distinct, with the exception of one of our product offerings under
our CareInMotionTM platform, which requires a significant client service customization. In all instances, we determined that we are offering functional IP as
compared with a symbolic IP. Functional IP is a right to use IP because the IP has standalone functionality and a customer can use the IP as it exists at a point
in time.
Disaggregation of Revenue
We disaggregate our revenue from contracts with customers based on the type of revenue and nature of revenue stream, as we believe those categories
best depict how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. The below tables summarize
revenue by type and nature of revenue stream as well as by our reportable segments:
(In thousands)
Revenue:
Recurring revenue
Non-recurring revenue
Total revenue
(In thousands)
Software delivery, support and maintenance
Client services
Total revenue
(In thousands)
Software delivery, support and maintenance
Client services
Total revenue
(In thousands)
Software delivery, support and maintenance
Client services
Total revenue
3. Leases
2019
Year Ended December 31,
2018
2017
$
$
1,395,869 $
375,808
1,771,677 $
1,411,742
338,220
1,749,962
$
$
1,176,720
320,988
1,497,708
Provider
965,925 $
631,190
1,597,115
$
Year Ended December 31, 2019
Veradigm
Unallocated
148,352 $
12,864
161,216 $
12,209 $
1,137
13,346
$
Provider
995,193 $
620,829
1,616,022
$
Year Ended December 31, 2018
Veradigm
Unallocated
130,945 $
9,381
140,326 $
2,125 $
(8,511)
(6,386) $
Provider
904,391 $
536,821
1,441,212
$
Year Ended December 31, 2017
Veradigm
Unallocated
64,360 $
5,519
69,879 $
(10,564) $
(2,819)
(13,383) $
$
$
$
$
$
$
Total
1,126,486
645,191
1,771,677
Total
1,128,263
621,699
1,749,962
Total
958,187
539,521
1,497,708
We adopted ASU 2016-02 on January 1, 2019 using the cumulative-effect adjustment transition method. The new guidance requires the recognition of
leased arrangements on the balance sheet as right-of-use assets and liabilities pertaining to the rights and obligations created by the leased assets.
We determine whether an arrangement is a lease at inception. Assets leased under an operating lease arrangement are recorded in Right-of-use assets
– operating leases, and the associated lease liabilities are included in Current operating lease liabilities and Long-term operating lease liabilities within the
consolidated balance sheets. Assets leased under finance lease arrangements are recorded within fixed assets and the associated lease liabilities are recorded
within Accrued expenses and Other liabilities within the consolidated balance sheets.
Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease
payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease
payments over the expected lease term. Since our lease arrangements do not provide an implicit rate, we use our incremental borrowing rate in conjunction
with the market swap rate for the expected remaining lease team at commencement date for new leases, or as of January 1, 2019 for existing leases, in
determining the present value of future lease payments. Our expected lease terms may include options to extend or terminate the lease when it is reasonably
certain that we will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term.
75
We have elected the group of practical expedients under ASU 2016-02 to forego assessing upon adoption: (1) whether any expired contracts are or
contain leases; (2) the lease classification for any existing or expired leases and (3) any indirect costs that would have qualified for capitalization for any
existing leases. We have lease agreements with lease and non-lease components, which are generally accounted for separately except for real estate and
vehicle leases, which we have elected to combine through a practical expedient under ASU 2016-02. Non-lease components for our leases typically comprise
of executory costs, which under the practical expedient allows for all executory costs to be recorded as lease payments. Additionally, for certain equipment
leases, we apply a portfolio approach to effectively record right-of-use assets and liabilities.
Our operating leases mainly include office leases, and our finance leases include office and computer equipment leases. Our leases have remaining
lease terms of approximately 1 year to 9 years, some of which include options to extend the leases for up to 5 years, which may include options to terminate
the leases within 1 year. Total costs associated with leased assets are as follows:
(In thousands)
Operating lease cost (1)
Less: Sublease income
Total operating lease costs
Finance lease costs:
Amortization of right-of-use assets (2)
Interest on lease liability (3)
Total finance lease costs
Year Ended
December 31, 2019
27,962
(3,265)
24,697
157
9
166
$
$
$
$
(1) Operating lease costs are recognized on a straight-line basis and are included in Selling, general and administrative expenses within the consolidated statement of
operations.
(2) Amortization of finance right-of-use assets is recognized on a straight-line basis and is included in in Selling, general and administrative expenses within the consolidated
statement of operations.
Interest on finance lease liabilities is recorded as Interest expense within the consolidated statement of operations.
(3)
Supplemental information for operating and finance leases is as follows:
(In thousands)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases
Operating cash flows from finance leases
Financing cash flows from finance leases
Right-of-use assets obtained in exchange for lease obligations:
Operating leases
Finance leases
76
Year Ended
December 31, 2019
$
$
$
$
$
30,039
9
158
143,602
263
(In thousands, except lease term and discount rate)
Operating leases:
Right-of-use assets - operating leases
Current operating lease liabilities
Long-term operating lease liabilities
Finance leases:
Fixed assets, gross
Less: Accumulated depreciation
Fixed assets, net
Current finance lease liabilities (1)
Long-term finance lease liabilities (2)
Weighted average remaining lease term (in years)
Operating leases
Finance leases
Weighted average discount rate
Operating leases
Finance leases
(1) Current finance lease liabilities are included in Accrued expenses within the consolidated balance sheets.
(2) Long-term finance lease liabilities are included in Other liabilities within the consolidated balance sheets.
$
$
$
$
$
$
$
December 31, 2019
98,020
23,137
95,162
524
(392)
132
82
45
6
2
4.4%
5.1%
The future maturities of our leasing arrangements including lease and non-lease components are shown in the below table. The maturities are
calculated using foreign currency exchange rates in effect as of December 31, 2019.
(In thousands)
2020
2021
2022
2023
2024
Thereafter
Total lease liabilities
Less: Amount representing interest
Less: Short-term lease liabilities
Total long-term lease liabilities
December 31, 2019
Operating Leases
Finance Leases
$
$
27,647
23,277
21,640
19,497
13,862
28,580
134,503
(16,204)
(23,137)
95,162
$
$
85
40
7
0
0
0
132
(5)
(82)
45
4. Business Combinations and Other Investments
2019 Business Combinations
We acquired the Pinnacle and Diabetes Collaborative Registries from the American College of Cardiology (“ACC”) as part of our broader strategic
partnership with the ACC on July 2, 2019. The total purchase price was $19.7 million, consisting of an initial payment of $11.7 million plus up to an
aggregate of $8.0 million pending the attainment certain milestones over the next 18 months. The contingent consideration of up to $8.0 million was valued at
$5.0 million at the time of closing. As part of this partnership, we operate Pinnacle and Diabetes Collaborative Registries, which extends our EHR-enabled
ambulatory network to create a large-scale chronic disease network. The business is included in our Veradigm business segment.
We acquired the assets of a business engaged in the development, implementation, customization, marketing, licensing and sale of a specialty
prescription drug platform including software that collects, saves and transmits information required to fill a prescription on June 10, 2019. The drug platform
and software will enable healthcare providers, pharmacists and payors to digitally interact with one another to fill a prescription. The business is included in
our Veradigm business segment.
77
We acquired all of the outstanding minority interest in Pulse8, Inc. on March 1, 2019 for $53.8 million (subject to adjustments for net working capital
and a contingency holdback), plus up to a $5.0 million earnout based upon revenue targets through 2019. Pulse8, Inc. is a healthcare analytics and technology
company that provides business intelligence software solutions for health plans and at-risk providers to enable them to analyze their risk adjustment and
quality management programs. We initially acquired a controlling stake in Pulse 8, Inc. on September 8, 2016. This transaction was treated as an equity
transaction, and the cash payment is reported as part of cash flow from financing activities in the consolidated statement of cash flows for the year ended
December 31, 2019.
2018 Business Combinations and Divestitures
Acquisition of Health Grid
On May 18, 2018, we acquired all the capital stock of Health Grid Holding Company, a Delaware corporation (“Health Grid”), for a total price of
$110.0 million, consisting of an initial payment of $60.0 million plus up to an aggregate of $50.0 million in future earnout payments based on Health Grid
achieving certain revenue targets over the three years following the acquisition. At the time of closing, we pre-paid $10.0 million of the earnout payments and
the remaining contingent consideration of up to $40.0 million was valued at $23.9 million. Health Grid is a patient engagement solutions provider that assists
independent providers, hospitals and health systems to improve patient interactions and satisfaction. We have integrated the capabilities of Health Grid into
our FollowMyHealth® platform. The consideration paid for Health Grid is shown below:
Aggregate purchase price
First earnout payment paid by Allscripts
Fair value of contingent consideration payment
Closing purchase price adjustments
Total consideration paid for Health Grid
(In thousands)
60,000
10,000
23,915
2,009
95,924
$
$
The allocation of the fair value of the consideration transferred as of the acquisition date of May 18, 2018 is shown in the table below. The allocation
of purchase price was finalized in the fourth quarter of 2018. The goodwill is not deductible for tax purposes.
Cash and cash equivalents
Accounts receivable, net
Prepaid expenses and other assets
Fixed assets
Intangible assets
Goodwill
Accounts payable and accrued expenses
Deferred revenue
Long-term deferred tax liability
Net assets acquired
(In thousands)
1,783
3,968
185
200
41,000
53,953
(478)
(700)
(3,987)
95,924
$
$
The following table summarizes the preliminary fair values of the identifiable intangible assets and their estimated useful lives:
Description
Customer Relationships
Technology
Useful Life
(In years)
15
8
Fair Value
(In thousands)
$
$
28,000
13,000
41,000
78
We incurred $0.5 million of acquisition costs which are included in selling, general and administrative expenses in the accompanying consolidated
statement of operations for the year ended December 31, 2018. The results of operations of Health Grid were not material to our consolidated results of
operations for the year ended December 31, 2018.
Acquisition of Practice Fusion, Inc.
On February 13, 2018, we completed the acquisition of Practice Fusion, Inc., a Delaware corporation (“Practice Fusion”), for aggregate consideration
of $113.6 million paid in cash. Practice Fusion offers an affordable certified cloud-based electronic health record (“EHR”) for traditionally hard-to-reach
small, independent physician practices. The consideration paid for Practice Fusion is shown below:
Aggregate purchase price
Add: Net working capital surplus
Add: Closing cash
Less: Adjustment to assumed indebtedness
Total consideration paid for Practice Fusion
(In thousands)
100,000
373
14,951
(1,684)
113,640
$
$
The allocation of the fair value of the consideration transferred as of the acquisition date of February 13, 2018 is shown in the table below. The
allocation of the purchase price was finalized during the fourth quarter of 2018. The goodwill is not deductible for tax purposes.
Cash and cash equivalents
Accounts receivable, net
Prepaid expenses and other current assets
Fixed assets
Intangible assets
Goodwill
Other assets
Accounts payable and accrued expenses
Deferred revenue
Long-term deferred tax liability
Other liabilities
Net assets acquired
(In thousands)
14,951
13,328
809
1,764
67,100
35,092
42
(7,378)
(2,400)
(8,853)
(815)
113,640
$
$
The following table summarizes the fair values of the identifiable intangible assets and their estimated useful lives:
Description
Customer Relationships - Physician Practices
Customer Relationships - Pharmaceutical Partners
Technology
Tradenames
79
Useful Life
(In years)
15
20
8
10
Fair Value
(In thousands)
$
$
29,000
19,400
14,800
3,900
67,100
We incurred $1.2 million of acquisition costs which are included in selling, general and administrative expenses in the consolidated statement of
operations for the year ended December 31, 2018. The results of operations of Practice Fusion were not material to our consolidated results of operations for
the year ended December 31, 2018.
Netsmart LLC Divestiture
On December 31, 2018, we sold all of the Class A Common Units of Netsmart LLC, a Delaware limited liability company (“Netsmart”), owned by
the Company in exchange for $566.6 million, plus a final settlement as determined following the closing pursuant to the terms of the sales agreement.
Netsmart was originally acquired in April 2016 and we realized a pre-tax gain on sale of $500.5 million, which is included on the “Gain on sale of Netsmart”
line in our consolidated statements of operations for the year ended December 31, 2018. The divestiture of Netsmart is being treated as a discontinued
operation as of December 31, 2018 and has been reported as a discontinued operation for all periods presented. Refer to Note 17, “Discontinued operations”
for further details regarding the historical assets, liabilities and results of operations of Netsmart.
Other Acquisitions, Divestitures and Investments
On June 15, 2018, we acquired all the outstanding minority interests in a third party for $6.9 million. We initially acquired a controlling interest in the
third party in April 2015. Therefore, this transaction was treated as an equity transaction, and the cash payment is reported as part of cash flow from financing
activities in the consolidated statement of cash flows for the year ended December 31, 2018.
On April 2, 2018, we sold substantially all of the assets of the Allscripts’ business providing hospitals and health systems document and other content
management software and services generally known as “OneContent” to Hyland Software, Inc., an Ohio corporation (“Hyland”). Allscripts acquired the
OneContent business during the fourth quarter of 2017 through the acquisition of the EIS Business (as defined below). Certain assets of Allscripts relating to
the OneContent business were excluded from the transaction and retained by Allscripts. In addition, Hyland assumed certain liabilities related to the
OneContent business. The total consideration for the OneContent business was $260 million, which was subject to certain adjustments for liabilities assumed
by Hyland and net working capital. We realized a pre-tax gain upon sale of $177.9 million which is included in the “Gain on sales of businesses, net” line in
our consolidated statements of operations for the year ended December 31, 2018.
On March 15, 2018, we contributed certain assets and liabilities of our Strategic Sourcing business unit, acquired as part of the acquisition of the EIS
Business in 2017, into a new entity together with $2.7 million of cash as additional consideration. In exchange for our contributions, we obtained a 35.7%
interest in the new entity, which was valued at $4.0 million, and is included in Other assets in our consolidated balance sheet as of December 31, 2018. This
investment is accounted for under the equity method of accounting. As a result of this transaction, we recognized an initial pre-tax loss of $0.9 million and
$4.7 million in additional losses due to measurement period adjustments upon the finalization of carve-out balances, mainly related to accounts receivable.
These losses are included on the “Gain on sale of businesses, net” line in our consolidated statements of operations for the year ended December 31, 2018.
On February 6, 2018, we acquired all of the common stock of a cloud-based analytics software platform provider for a purchase price of $8.0 million
in cash. The allocation of the consideration is as follows: $1.1 million of intangible assets related to technology; $0.6 million to customer relationships; $6.6
million of goodwill; $0.8 million to accounts receivable; deferred revenue of $0.6 million and $0.5 million of long-term deferred income tax liabilities. The
allocation was finalized in the fourth quarter of 2018. The acquired intangible asset related to technology will be amortized over 8 years using a method that
approximates the pattern of economic benefits to be gained from the intangible asset. The customer relationship was amortized over one year. The goodwill is
not deductible for tax purposes. The results of operations of this acquisition were not material to our consolidated financial statements.
The following table summarizes our other equity investments which are included in other assets in the accompanying consolidated balance sheets:
(In thousands, except for number of investees)
Equity method investments (1)
Cost less impairment
Total long-term equity investments
Number of Investees
at December 31, 2019
Original
Cost
Carrying Value at
December 31, 2019
December 31, 2018
5 $
9
14 $
7,407 $
43,874
51,281 $
11,332 $
32,462
43,794 $
10,667
25,923
36,590
(1) Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.
80
During 2018, we acquired certain non-marketable equity securities of two third parties and entered into a commercial agreement with one of the third
parties for total consideration of $11.7 million. During 2018, we also acquired a $1.8 million non-marketable convertible note of a third party. These
investments are recorded in the Other asset caption within the consolidated balance sheets.
It is not practicable to estimate the fair value of our equity investments primarily because of their illiquidity and restricted marketability as of
December 31, 2019. The factors we considered in trying to determine fair value include, but are not limited to, available financial information, the issuer’s
ability to meet its current obligations and the issuer’s subsequent or planned raises of capital.
Impairment of and Losses on Long-Term Investments
We recognized non-cash impairment charges of $1.7 million in 2019 related to one of our long-term equity investments. We also recognized $1.0
million recovery of an equity investment that we had previously impaired. We recognized non-cash impairment charges of $15.5 million during 2018 related
to two of long-term equity investments and a related note receivable. The charges in 2018 equaled the cost bases of the investments and the related note
receivable prior to the impairment. The non-cash impairment charges are included on the Impairment of long-term investments line in our consolidated
statements of operations for the year ended December 31, 2019 and 2018.
Management performs a quarterly assessment of each of our investments on an individual basis to determine if there are any declines in fair value.
The Company determined that the decline in fair value of our marketable securities and impairment charges of $142.2 million on available for sale marketable
securities during the year ended December 31, 2017 as a result. The cost basis of these marketable securities prior to recognizing the impairment charges was
approximately $205.6 million. The Company determined the fair value of these securities based on Level 1 inputs. The Company recognized an additional
$20.7 million loss during 2017 upon the final disposition of these securities in connection with the NantHealth provider/patient solutions business acquisition.
The Company also recognized charges of $2.1 million on a cost method equity investment during the year ended December 31, 2017, which equaled its
aggregate carrying value. These impairment charges are included on the Impairment of long-term investments line in our consolidated statement of operations
for the year ended December 31, 2017.
5. Fair Value Measurements
Fair value measurements are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent
sources, while unobservable inputs reflect our view of market participant assumptions in the absence of observable market information. We utilize valuation
techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. The fair values of assets and liabilities required to be
measured at fair value are categorized based upon the level of judgment associated with the inputs used to measure their value in one of the following three
categories:
Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities. We held no Level 1 financial instruments at December
31, 2019 or 2018.
Level 2: Quoted prices for similar instruments in active markets with inputs that are observable, either directly or indirectly. Our Level 2 derivative
financial instruments include foreign currency forward contracts valued based upon observable values of spot and forward foreign currency exchange rates.
Refer to Note 15, “Derivative Financial Instruments,” for further information regarding these derivative financial instruments.
81
Level 3: Unobservable inputs or prices for which little or no market data exists. Our Level 3 financial instruments include derivative financial
instruments comprising the 1.25% Call Option asset and the 1.25% embedded cash conversion option liability (together the “1.25% Notes Call Spread
Overlay” as further described in Note 9, “Debt”) that are not actively traded. These derivative instruments were designed with the intent that changes in their
fair values would substantially offset, with limited net impact to our earnings. The sensitivity of changes in the unobservable inputs to the valuation pricing
model used to value these instruments is not material to our consolidated results of operations. Refer to Note 15, “Derivative Financial Instruments,” for
further information regarding these derivative financial instruments. Our Level 3 financial liabilities also include the estimated fair value of contingent
consideration related to completed acquisitions. Such fair values are based on discounted cash flow analyses reflecting the likelihood of achieving specified
performance measures or events and captures the contractual nature of the contingencies, commercial risk and the time value of money. Changes in fair value
for contingent consideration adjustments are recorded in Other(loss) income, net in the consolidated statements of operations.
The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates:
(In thousands)
Foreign exchange
derivative assets
1.25% Call Option
Total assets
Contingent consideration
- current
Contingent consideration
- long-term
1.25% Embedded
cash conversion
option
Total liabilities
Balance Sheet
Classifications
Prepaid expenses
and other
current assets
Other assets
Accrued
expenses
Level 1
Level 2
Level 3
Total
Level 1
Level 2
Level 3
Total
December 31, 2019
December 31, 2018
$
$
0 $
0
0 $
0 $
0
0 $
0 $
84
84 $
0 $
84
84 $
0 $
0
0 $
262 $
0
262 $
0 $
9,104
9,104 $
262
9,104
9,366
$
0 $
0 $ 17,116 $ 17,116 $
0 $
0 $ 10,528 $ 10,528
Other liabilities
0
0
2,415
2,415
0
0
15,317
15,317
Other liabilities
0
0 $
$
0
0 $ 19,716 $ 19,716 $
185
185
0
0 $
0
9,974
9,974
0 $ 35,819 $ 35,819
The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at December 31, 2019 are summarized as follows:
(In thousands)
Balance at December 31, 2017
Additions
Payments/write-downs
Fair value adjustments
Balance at December 31, 2018
Additions
Payments/write-downs (1)
Fair value adjustments
Balance at December 31, 2019
Contingent Consideration
1.25% Notes Call Spread Overlay
$
$
$
7,036
24,551
(6,067)
325
25,845
12,144
(18,900)
442
19,531
$
$
$
(1,199)
0
0
329
(870)
0
0
769
(101)
(1) Payments and write-downs for the year-ended December 31, 2019 primarily consisted of $10.0 million payment for the Health Grid earnout and $5.0 million write-down
related to the Pulse8 earnout.
82
6. Fixed Assets
Fixed assets consist of the following:
(Dollar amounts in thousands)
Computer equipment and software
Facility furniture, fixtures and equipment
Leasehold improvements
Assets under finance leases
Fixed assets, gross
Less: Accumulated depreciation and amortization
Fixed assets, net
Estimated
Useful Life
3 to 10 years
5 to 7 years
Shorter of 7 years or life of lease
1 to 3 years
December 31,
2019
December 31,
2018
$
$
344,127 $
24,704
39,335
524
408,690
(320,351)
88,339 $
332,826
21,300
37,555
9,435
401,116
(279,203)
121,913
Accumulated amortization for assets under finance leases totaled $0.4 million and $7.3 million as of December 31, 2019 and 2018, respectively.
(In thousands)
Fixed assets depreciation and amortization expense, including finance leases
2019
Year Ended December 31,
2018
2017
$
47,419 $
47,567 $
40,717
7. Goodwill and Intangible Assets
Goodwill and intangible assets consist of the following:
(In thousands)
Intangibles subject to amortization:
Proprietary technology
Customer contracts and relationships
Total
Intangibles not subject to amortization:
Registered trademarks
Goodwill
Total
December 31 2019
December 31, 2018
Gross
Carrying
Amount
Accumulated
Amortization
Intangible
Assets, Net
Gross
Carrying
Amount
Accumulated
Amortization
Intangible
Assets, Net
$
$
546,373 $
702,034
1,248,407 $
(437,640) $
(488,625)
(926,265) $
108,733 $
213,409
322,142 $
537,834 $
704,808
1,242,642 $
(401,093) $
(462,468)
(863,561) $
136,741
242,340
379,081
$
$
52,000
1,362,017
1,414,017
$
$
52,000
1,373,744
1,425,744
We performed our 2019 goodwill impairment test as of October 1, 2019. As a result of this test, we concluded that the carrying value of the Hospitals
and Health Systems (“HHS”) reporting unit exceeded its fair value. As a result, we recognized a goodwill impairment charge of $25.7 million. This goodwill
impairment charge is reflected on the “Goodwill impairment charge” line in our consolidated statements of operations. The fair values of all other reporting
units substantially exceeded their carrying values. As of December 31, 2019, the goodwill allocated to the HHS reporting unit was $485.5 million.
We performed our 2018 goodwill impairment test as of October 1, 2018. We concluded that the carrying value of the NantHealth reporting unit
exceeded its fair value as a result of this test. Our latest available financial forecasts at the time of the annual goodwill impairment test reflected that projected
future operating costs exceeded projected revenues resulting in negative operating margins for the NantHealth reporting unit. We recognized a goodwill
impairment charge of $13.5 million as a result, representing the entire goodwill balance assigned to the NantHealth reporting unit. This goodwill impairment
charge is reflected on the “Goodwill impairment charge” line in our consolidated statements of operations for the year ended December 31, 2018.
83
The determination of the fair value of our reporting units is based on a combination of a market approach, that considers benchmark company market
multiples, and an income approach, that utilizes discounted cash flows for each reporting unit and other Level 3 inputs. We determine fair value based on the
present value of the most recent cash flow projections for each reporting unit as of the date of the analysis and calculate a terminal value utilizing a terminal
growth rate under the income approach. The significant assumptions under this approach include, among others: income projections, which are dependent on
sales to new and existing clients, new product introductions, client behavior, competitor pricing, operating expenses, the discount rate, and the terminal
growth rate. The cash flows used to determine fair value are dependent on a number of significant management assumptions such as our expectations of
future performance and the expected future economic environment, which are partly based upon our historical experience. Our estimates are subject to change
given the inherent uncertainty in predicting future results. The discount rate and the terminal growth rate are based on our judgment of the rates that would be
utilized by a hypothetical market participant. We also consider our market capitalization in assessing the reasonableness of the combined fair values estimated
for our reporting units as part of goodwill impairment testing.
We recognized an intangible asset impairment charge of $8.1 million relating to NantHealth’s remaining customer relationship intangible balance
during 2019. We also recognized an intangible asset impairment charge of $2.2 million during 2018 relating to NantHealth’s acquired proprietary technology
because the carrying value of this definite-lived intangible assets no longer appeared recoverable based on latest available financial forecasts at the time of the
annual goodwill impairment test. These impairment charges are included in the “Asset impairment charges” line in our consolidated statements of operations
for the years ended December 31, 2019 and 2018.
Accumulated impairment losses associated with goodwill totaled $39.2 million and $13.5 million as of December 31, 2019 and 2018, respectively.
There were no accumulated impairment losses associated with our goodwill as of December 31, 2017. Changes in the carrying amounts of goodwill by
reportable segment for the years ended December 31, 2019 and 2018 were as follows:
(In thousands)
Balance as of December 31, 2017
Additions from the Practice Fusion acquisition
Additions from the Health Grid acquisition
Additions from other acquisitions
Total arising from business acquisitions
Changes due to measurement period adjustments
related to prior year acquisitions:
NantHealth provider/patient solutions business
Enterprise Information Solutions business
Other acquisitions
Total increases due to measurement
period adjustments:
Total additions to goodwill
Divestitures
Goodwill impairment charge
Foreign exchange translation
Balance as of December 31, 2018
Additions
Goodwill impairment charge
Foreign exchange translation
Balance as of December 31, 2019
Provider
Veradigm
Total
$
1,214,979 $
0
53,953
0
53,953
116
32,049
(205)
31,960
85,913
(32,306)
(13,466)
(840)
1,254,280 $
0
(25,700)
289
$
$
1,228,869 $
84
77,768 $
35,092
0
6,604
41,696
0
0
0
0
41,696
0
0
0
119,464 $
13,684
0
0
133,148 $
1,292,747
35,092
53,953
6,604
95,649
116
32,049
(205)
31,960
127,609
(32,306)
(13,466)
(840)
1,373,744
13,684
(25,700)
289
1,362,017
Additions to goodwill in 2019 resulted from the purchase of the Pinnacle and Diabetes Collaborative Registries and a prescription drug software
company. The goodwill for both purchases is expected to be deductible for tax purposes. Other additions of $6.4 million during 2018 primarily resulted from
the acquisition of a cloud-based analytics software platform provider. Goodwill was reduced in 2018 by $2.2 million due to the divestiture of our Strategic
Sourcing business unit and by $30.1 million related to the OneContent divestiture. Refer to Note 4, “Business Combinations and Other Investments” for
additional information regarding these transactions.
Intangible assets are being amortized over their estimated useful lives, and amortization expense related to intangible assets was as follows:
(In thousands)
Proprietary technology amortization included in cost of revenue
Intangible amortization included in operating expenses
Total intangible amortization expense
2019
Year Ended December 31,
2018
2017
$
$
36,472
27,216
63,688
$
$
38,467
26,587
65,054
$
$
33,137
17,345
50,482
Future amortization expense for the intangible assets as of December 31, 2019, based on foreign currency exchange rates in effect as of such date, is
as follows:
Year Ended December 31,
2020
2021
2022
2023
2024
Thereafter
Total
8. Asset Impairment Charges
$
$
(In thousands)
59,226
53,808
47,407
31,222
26,803
103,676
322,142
Asset impairment charges incurred during the year ended December 31, 2019 were primarily the result of impairing the remaining NantHealth
acquired customer relationship intangible balance of $8.1 million. We also recognized non-cash impairment charges of $2.7 million on the retirement of
certain hosting assets due to data center migrations. Impairment of long-term investments during the year ended December 31, 2019 consisted of an
impairment of $1.7 million associated with one of our long-term equity investments. We also recovered $1.0 million from one of our long-term equity
investments investment that we had previously impaired. We also recorded a goodwill impairment charge of $25.7 million related to our HHS reporting unit.
Refer to Note 7, “Goodwill and Intangible Assets” for further information regarding this impairment.
We incurred several non-cash asset impairment charges during the year ended December 31, 2018. We recorded non-cash asset impairment charges of
$33.2 million related to the write-off of capitalized software as a result of our decision to discontinue several software development projects. We also
recorded $22.9 million of non-cash asset impairment charges related to our acquisition of the patient/provider engagement solutions business from
NantHealth in 2017, which included the write-downs of $2.2 million of acquired technology and $20.7 million, representing the unamortized value assigned
to the modification of our existing commercial agreement with NantHealth, as we no longer expect to recover the value assigned to these assets. The
remaining $2.1 million of non-cash asset impairment charges recorded during the year ended December 31, 2018 relate to the disposal of fixed assets as a
result of relocating and consolidating business functions and locations from recent acquisitions.
We recorded a goodwill impairment charge of $13.5 million related to NantHealth during the year ended December 31, 2018. Refer to Note 7,
“Goodwill and Intangible Assets” for further information regarding this impairment. We recognized non-cash impairment charges of $15.5 million in 2018
related to two of our cost-method equity investments and a related note receivable. These charges equaled the cost bases of the investments and the related
note receivable prior to the impairment.
We recorded non-cash charges of $165.3 million during the year ended December 31, 2017, including impairment charges of $144.6 million
associated with two of the Company’s long-term investments based on management’s assessment of the likelihood of near-term recovery of the investments’
value. The majority of the impairment charges related to our investment in NantHealth common stock. We realized an additional $20.7 million loss upon the
final disposition of the NantHealth common stock in connection with our acquisition of certain assets related to NantHealth’s provider/patient engagement
solutions business. Refer to Note 4, “Business Combinations and Other Investments” and Note 14, “Accumulated Other Comprehensive Loss,” for further
information regarding these impairments.
85
The following table summarizes the non-cash asset impairment charges recorded during the periods indicated and where they appear in the
corresponding consolidated statements of operations:
(In thousands)
Asset impairment charges
Goodwill impairment charge
Impairment of long-term investments
Year Ended December 31,
$
$
$
2019
2018
2017
10,837 $
25,700 $
651 $
58,166 $
13,466 $
15,487 $
0
0
165,290
9. Debt
Debt outstanding, excluding finance lease obligations, consisted of the following:
(In thousands)
0.875% Convertible Senior Notes
1.25% Cash Convertible
Senior Notes
Senior Secured Credit Facility
Other debt
Total debt
Less: Debt payable within
one year
Total long-term debt, less
current maturities
December 31, 2019
Unamortized
Discount and
Debt Issuance
Costs
Net Carrying
Amount
Principal Balance
December 31, 2018
Unamortized
Discount and
Debt Issuance
Costs
Net Carrying
Amount
5,019 $
173,245 $
0 $
0 $
0
Principal Balance
$
178,264 $
345,000
410,000
0
7,552
5,224
0
337,448
404,776
0
$
933,264 $
17,795 $
915,469 $
345,000
350,000
748
695,748 $
22,112
6,038
0
28,150 $
322,888
343,962
748
667,598
364,653
188
364,465
20,538
479
20,059
$
568,611 $
17,607 $
551,004 $
675,210 $
27,671 $
647,539
Interest expense consisted of the following:
(In thousands)
Interest expense
Amortization of discounts and debt issuance costs
Total interest expense
2019
Year Ended December 31,
2018
2017
$
$
26,648
16,524
43,172
$
$
35,366
15,548
50,914
$
$
23,001
14,539
37,540
Interest expense related to the 0.875% Convertible Senior Notes and the 1.25% Cash Convertible Senior Notes, which is included in total interest
expense above, was comprised of the following:
(In thousands)
Coupon interest
Amortization of discounts and debt issuance costs
Total interest expense related to the convertible notes
Allscripts 0.875% Convertible Senior Notes
2019
Year Ended December 31,
2018
2017
$
$
4,429
14,926
19,355
$
$
4,312
13,867
18,179
$
$
4,312
13,208
17,520
On December 9, 2019, we issued $200.0 million aggregate principal amount of Allscripts’ 0.875% Convertible Senior Notes due 2027 (the “0.875%
Notes”) in a private offering. The 0.875% Notes are Allscripts’ senior, unsecured obligations that bear interest at a rate of 0.875% per year, payable
semiannually in arrears on January 1 and July 1 of each year, commencing on July 1, 2020. The 0.875% Notes will mature on January 1, 2027, unless earlier
repurchased by us or converted in accordance with their terms prior to such date.
86
The 0.875% Notes are convertible at the option of the holders (in whole or in part) at any time prior to the close of business on the business day
immediately preceding July 1, 2026 only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on
December 31, 2019 (and only during such calendar quarter), if the last reported sale price of Allscripts’ common stock for at least 20 trading days (whether or
not consecutive) during the period of 30 consecutive trading days ending on and including the last trading day of the immediately preceding calendar quarter
is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any five consecutive
trading day period (the “measurement period”) in which the trading price per $1,000 principal amount of 0.875% Notes for each trading day of the
measurement period was less than 98% of the product of the last reported sale price of Allscripts’ common stock and the conversion rate on each such trading
day; or (3) upon the occurrence of certain corporate events as specified in the indenture governing the 0.875% Notes (the “0.875% Notes Indenture”). On or
after July 1, 2026 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any
portion of their 0.875% Notes at any time, regardless of the foregoing conditions. Upon conversion, Allscripts will pay or deliver, as the case may be, cash,
shares of Allscripts’ common stock, or a combination of cash and shares of Allscripts’ common stock, at Allscripts’ election, in amounts determined in the
manner set forth in the 0.875% Notes Indenture.
The initial conversion rate for the 0.875% Notes will be 75.0962 shares of Allscripts’ common stock per $1,000 principal amount of the 0.875%
Notes, which is equivalent to an initial conversion price of approximately $13.32 per share of Allscripts’ common stock. The initial conversion price of the
0.875% Notes represents a premium of approximately 32.5% to $10.05 per share last reported sale price of Allscripts’ common stock on December 4, 2019.
The conversion rate will be subject to adjustment upon the occurrence of certain specified events, but will not be adjusted for any accrued and unpaid interest.
In addition, upon the occurrence of a “make-whole fundamental change” (as defined in Section 1.01 of the 0.875% Notes Indenture), Allscripts’ will, in
certain circumstances, increase the conversion rate by a number of additional shares of Allscripts’ common stock for a holder that elects to convert its 0.875%
Notes in connection with such make-whole fundamental change. We may not redeem the 0.875% Notes prior to the maturity date, and no sinking fund is
provided for the 0.875% Notes.
Upon the occurrence of a “fundamental change” (as defined in Section 1.01 of the 0.875% Notes Indenture), holders of the 0.875% Notes may require
us to repurchase all or any portion of their 0.875% Notes in principal amounts of $1,000 or an integral multiple thereof at a fundamental change repurchase
price in cash equal to 100% of the principal amount of the 0.875% Notes to be repurchased, plus any accrued and unpaid interest, if any, to, but excluding, the
fundamental change repurchase date.
The 0.875% Notes Indenture contains customary terms and covenants, including that upon certain events of default, including cross acceleration to
certain other indebtedness of Allscripts and its subsidiaries, either the trustee under the 0.875% Notes Indenture or the holders of not less than 25% in
aggregate principal amount of the 0.875% Notes then outstanding may declare the unpaid principal of the 0.875% Notes and accrued and unpaid interest, if
any, thereon immediately due and payable.
In December 2019, in connection with the 0.875% Notes offering, we entered into privately negotiated capped call transactions with JPMorgan Chase
Bank, National Association, New York Branch, Wells Fargo Bank, National Association, Bank of America, N.A. and Deutsche Bank AG, London Branch
(the “option counterparties”). The capped call transactions are expected generally to reduce the potential dilution to Allscripts’ common stock upon any
conversion of 0.875% Notes and/or offset any cash payments Allscripts is required to make in excess of the principal amount of the converted 0.875% Notes
upon conversion of the 0.875% Notes, as the case may be, in the event that the market price of Allscripts’ common stock is greater than the strike price of the
capped call transactions (which initially corresponds to the initial conversion price of the 0.875% Notes of approximately $13.32 per share of Allscripts’
common stock and is subject to certain adjustments under the terms of the capped call transactions), with such reduction and/or offset subject to a cap based
on the cap price of the capped call transactions. The cap price of the capped call transactions is initially $17.5875 per share, representing a premium of 75%
above the last reported sale price of $10.05 per share of Allscripts’ common stock on December 4, 2019, and is subject to certain adjustments under the terms
of the capped call transactions. The capped call transactions cover, subject to anti-dilution adjustments substantially similar to those applicable to the 0.875%
Notes, the number of shares of Allscripts’ common stock that underlie the 0.875% Notes. The capped call transactions are not part of the terms of the 0.875%
Notes and will not affect any holder’s rights under the 0.875% Notes. Holders of the 0.875% Notes will not have any rights with respect to the capped call
transactions.
The aggregate net proceeds of the 0.875% Notes were $195.0 million after deducting $5.0 million for the initial purchasers’ discount but before
deducting other estimated expenses. On December 9, 2019, we used $15.8 million of the net proceeds to pay the cost of the capped call transactions and the
remainder of $179.2 million to repay outstanding borrowings under our senior secured revolving credit facility.
87
On December 18, 2019, the initial purchasers notified us of the partial exercise of their option to purchase additional 0.875% Notes. On December 20,
2019 we issued an additional $18.0 million in aggregate principal amount of the 0.875% Notes (the “Option Notes”) pursuant to a partial exercise of the
initial purchasers’ option to purchase additional 0.875% Notes. The Option Notes have the same terms as the 0.875% Notes previously described and are
issued pursuant to the same 0.875% Notes Indenture. The net proceeds from the sale of the Option Notes totaled $17.5 million after deducting $0.5 million in
debt issuance costs. In connection with the initial purchasers’ exercise of their option to purchase the Option Notes, we entered into additional privately
negotiated capped call transactions (the “additional capped call transactions”) with each of the option counterparties. On December 20, 2019, we used $1.4
million of the net proceeds to pay the cost of additional capped call transactions and the remainder to repay additional outstanding borrowings under our
senior secured revolving credit facility.
The issuance in December 2019 of the combined $218.0 million aggregate purchase amount of the 0.875% Notes and the Option Notes (collectively,
the “0.875% Convertible Senior Notes”) incurred $0.7 in debt issuance costs. We have separately recorded liability and equity components of the 0.875%
Convertible Senior Notes including any discounts and issuance costs by allocating the proceeds from the issuance between the liability component and the
embedded conversion option, or equity component. This allocation was completed by first estimating an interest rate at the time of issuance for similar notes
that do not include an embedded conversion option. The interest rate of 1.95% was used to compute the initial fair value of the liability component, which
totaled $177.9 million at the time of issuance. The excess of the initial proceeds received from the 0.875% Convertible Senior Notes and the $177.9 million
liability component was allocated to the equity component, which totaled $40.1 million at the time of issuance before deducting any paid capped call fees.
The equity component of $40.1 million, the $17.2 million in paid capped call fees and an allocation of $1.1 million in combined discounts and issuance costs
were recorded in Additional paid-in capital within the consolidated balance sheets in December 2019. These were recorded as a discount that will be accreted
into interest expense through January 1, 2027 using the interest method.
Allscripts Senior Secured Credit Facility
On February 15, 2018, Allscripts and Healthcare LLC entered into a Second Amended and Restated Credit Agreement (the “Second Amended Credit
Agreement”), with JPMorgan Chase Bank, N.A., as administrative agent. The Second Amended Credit Agreement provides for a $400 million senior secured
term loan (the “Term Loan”) and a $900 million senior secured revolving facility (the “Revolving Facility”), each with a five-year term. Collectively, the
Term Loan and the Revolving Facility are referred to herein as the “Senior Secured Credit Facility.” The Term Loan is repayable in quarterly installments,
which commenced on June 30, 2018. A total of up to $50 million of the Revolving Facility is available for the issuance of letters of credit, up to $10 million
of the Revolving Facility is available for swingline loans, and up to $100 million of the Revolving Facility could be borrowed under certain foreign
currencies.
On August 7, 2019, we entered into a First Amendment to the Second Amended Credit Agreement in order to remain compliant with the covenants of
our Second Amended Credit Agreement. The First Amendment provides the financial flexibility to settle the U.S. Department of Justice’s investigations as
discussed in Note 21, “Contingencies” while maintaining our compliance with the covenants of our Second Amended Credit Agreement. None of the original
terms of our Second Amended Credit Agreement relating to scheduled future principal payments, applicable interest rates and margins or borrowing capacity
under our Revolving Facility were amended. In connection with this amendment, we incurred fees and other costs totaling $0.8 million, of which a majority
was capitalized.
The proceeds of the Revolving Facility can be used to finance Allscripts’ working capital needs and for general corporate purposes, including, without
limitations, for financing permitted acquisitions, and for share repurchases. Allscripts is also permitted to add one or more incremental revolving and/or term
loan facilities in an aggregate amount of up to $600 million, subject to certain conditions.
The initial applicable interest rate margin for Base Rate borrowings is 1.00%, and for Eurocurrency Rate borrowings is 2.00%. On and after
December 31, 2019, the interest rate margins will be determined from a pricing table and will depend upon Allscripts’ total leverage ratio. The applicable
margins for Base Rate borrowings under the Second Amended Credit Agreement range from 0.50% to 1.25% depending on Allscripts’ total leverage ratio
range. The applicable margins for Eurocurrency Rate loans range from 1.50% to 2.25%, depending on Allscripts’ total leverage ratio.
Subject to certain agreed upon exceptions, all obligations under the Senior Secured Credit Facility remain guaranteed by each of our existing and
future direct and indirect material domestic subsidiaries other than Coniston Exchange LLC and certain domestic subsidiaries owned by our foreign
subsidiaries (the “Guarantors”) pursuant to a related Guarantee and Collateral Agreement among Allscripts Healthcare Solutions, Inc., Allscripts Healthcare,
LLC, certain of our other subsidiaries, and JPMorgan Chase Bank, N.A., as administrative agent. Our obligations under the Senior Secured Credit Facility,
any swap agreements and any cash management arrangements provided by any lender, remain secured, subject to permitted liens and other agreed upon
exceptions, by a perfected first priority security interest in all of the tangible and intangible assets (including, without limitation, intellectual property, material
owned real property and all of the capital stock of each Guarantor and, in the case of foreign subsidiaries, up to 65% of the capital stock of first tier material
foreign subsidiaries) of Allscripts Healthcare Solutions, Inc. and certain of our subsidiary guarantors.
88
The Second Amended Credit Agreement requires us to maintain a minimum interest coverage ratio of 3.5 to 1.0 and a maximum total net leverage
ratio of 4.25 to 1.0. The minimum interest coverage ratio is calculated by dividing earnings before interest expense, income tax expense, depreciation and
amortization expense by cash interest expense, subject to various agreed upon adjustments. The total net leverage ratio is calculated by dividing total
indebtedness reduced by a portion of domestic unrestricted cash, by earnings before interest expense, income tax expense, depreciation and amortization
expense, subject to various agreed upon adjustments. The Second Amended Credit Agreement also provides that during the four-quarter period following
permitted acquisitions that are financed in whole or in part with indebtedness and the consideration paid by us is $100 million or more, we are required to
maintain a maximum total leverage ratio of 4.5 to 1.0. In addition, the Second Amended Credit Agreement requires mandatory prepayments of the debt
outstanding under the Senior Secured Credit Facility in certain specific circumstances, and contains a number of covenants which, among other things, restrict
our ability to incur additional indebtedness, engage in mergers, or declare dividends or other payments in respect of our capital stock.
The Second Amended Credit Agreement also contains certain customary events of default, including relating to non-payment, breach of covenants,
cross-default, bankruptcy and change of control.
As of December 31, 2019, $330 million under the Term Loan, $80 million under the Revolving Facility, and $1.0 million in letters of credit were
outstanding under the Second Amended Credit Agreement.
As of December 31, 2019, the interest rate on the Senior Secured Credit Facility was LIBOR plus 1.75%, which totaled 3.55%. We were in
compliance with all financial covenants under the Second Amended Credit Agreement as of December 31, 2019.
As of December 31, 2019, we had $819.0 million available borrowing capacity, net of outstanding letters of credit, under the Revolving Facility.
There can be no assurance that we will be able to draw on the full available balance of the Revolving Facility if the financial institutions that have extended
such credit commitments become unwilling or unable to fund such borrowings.
Allscripts 1.25% Cash Convertible Senior Notes due 2020
On June 18, 2013, we issued $345.0 million aggregate principal amount of Allscripts' 1.25% Cash Convertible Senior Notes due 2020 (the “1.25%
Notes”). The aggregate net proceeds of the 1.25% Notes were $305.1 million, after payment of the net cost of the 1.25% Notes Call Spread Overlay (as
described below) and transaction costs.
Interest on the 1.25% Notes is payable semiannually in arrears on January 1st and July 1st of each year, at a fixed annual rate of 1.25%. The 1.25%
Notes will mature on July 1, 2020 unless repurchased or converted in accordance with their terms prior to such date.
The 1.25% Notes are convertible only into cash, and not into shares of our common stock or any other securities. Holders may convert their 1.25%
Notes solely into cash at their option at any time prior to the close of business on the business day immediately preceding January 1, 2020 only under the
following circumstances: (1) during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at
least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding
calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period immediately
after any five consecutive trading day period in which the trading price per $1,000 principal amount of the 1.25% Notes for each trading day of the
measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; or
(3) upon the occurrence of specified corporate events. On or after January 1, 2020 until the close of business on the second scheduled trading day immediately
preceding the maturity date, holders may convert their 1.25% Notes solely into cash at any time, regardless of the foregoing circumstances. Upon conversion,
in lieu of receiving shares of our common stock, a holder will receive an amount in cash, per $1,000 principal amount of the 1.25% Notes, equal to the
settlement amount, determined in the manner set forth in the indenture governing the 1.25% Notes (the 1.25% Notes Indenture”).
The initial conversion rate will be 58.1869 shares of our common stock per $1,000 principal amount of the 1.25% Notes (equivalent to an initial
conversion price of approximately $17.19 per share of common stock). The conversion rate will be subject to adjustment in some events but will not be
adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date, we will pay a cash make-
whole premium by increasing the conversion rate for a holder who elects to convert such holder’s 1.25% Notes in connection with such a corporate event in
certain circumstances. We may not redeem the 1.25% Notes prior to the maturity date, and no sinking fund is provided for the 1.25% Notes.
If we undergo a fundamental change (as defined in the 1.25% Notes Indenture), holders may require us to repurchase for cash all or part of their
1.25% Notes at a repurchase price equal to 100% of the principal amount of the 1.25% Notes to be repurchased, plus accrued and unpaid interest to, but
excluding, the fundamental change repurchase date. The 1.25% Notes Indenture provides for customary events of default, including cross acceleration to
certain other indebtedness of ours, and our subsidiaries.
89
The 1.25% Notes are senior unsecured obligations, and rank senior in right of payment to any of our indebtedness that is expressly subordinated in
right of payment to the 1.25% Notes; equal in right of payment to any of our unsecured indebtedness that is not so subordinated; effectively junior in right of
payment to any of our secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and
other liabilities (including trade payables) of our subsidiaries.
The 1.25% Notes contain an embedded cash conversion option. We have determined that the embedded cash conversion option is a derivative
financial instrument, required to be separated from the 1.25% Notes and accounted for separately as a derivative liability, with changes in fair value reported
in our consolidated statements of operations until the cash conversion option transaction settles or expires. The initial fair value liability of the embedded cash
conversion option was $82.8 million, which simultaneously reduced the carrying value of the 1.25% Notes (effectively an original issuance discount). For
further discussion of the derivative financial instruments relating to the 1.25% Notes, refer to Note 15, “Derivative Financial Instruments.”
The reduced carrying value of the 1.25% Notes resulted in a debt discount that is amortized to the 1.25% Notes’ principal amount through the
recognition of non-cash interest expense over the expected term of the 1.25% Notes, which extends through their maturity date of July 1, 2020. This has
resulted in our recognition of interest expense on the 1.25% Notes at an effective rate approximating what we would have incurred had nonconvertible debt
with otherwise similar terms been issued. The effective interest rate of the 1.25% Notes at issuance was 5.4%, which was imputed based on the amortization
of the fair value of the embedded cash conversion option over the remaining term of the 1.25% Notes. As of December 31, 2019, we expect the 1.25% Notes
to be outstanding until their July 1, 2020 maturity date, for a remaining amortization period of approximately six months. As of December 31, 2019, the if-
converted value of the 1.25% Notes did not exceed the 1.25% Notes’ principal amount.
In connection with the settlement of the 1.25% Notes, we paid $8.4 million in transaction costs. Such costs were allocated to the 1.25% Notes, the
1.25% Call Option (as defined below) and the 1.25% Warrants (as defined below). The amount allocated to the 1.25% Notes, or $8.3 million, was capitalized
and is being amortized over the expected term of the 1.25% Notes. The outstanding capitalized amount of transaction costs related to the 1.25% Notes was
$1.8 million and is reported as a reduction of long-term debt on our consolidated balance sheet as of December 31, 2019.
Accrued and unpaid interest on the 1.25% Notes of $2.2 million is included in accrued expenses in the accompanying consolidated balance sheet as of
December 31, 2019.
1.25% Notes Call Spread Overlay
In June 2013, concurrent with the issuance of the 1.25% Notes, we entered into privately negotiated hedge transactions (collectively, the “1.25% Call
Option”) and warrant transactions (collectively, the “1.25% Warrants”), with certain of the initial purchasers of the 1.25% Notes (collectively, the “Call
Spread Overlay”). Assuming full performance by the counterparties, the 1.25% Call Option is intended to offset cash payments in excess of the principal
amount due upon any conversion of the 1.25% Notes. We used $82.8 million from the initial proceeds of the 1.25% Notes to pay for the 1.25% Call Option,
and simultaneously received $51.2 million from the sale of the 1.25% Warrants, for a net cash outlay of $31.6 million for the Call Spread Overlay. The 1.25%
Call Option is a derivative financial instrument and is discussed further in Note 15, “Derivative Financial Instruments.” The 1.25% Warrants are equity
instruments and are further discussed in Note 12, “Stockholders’ Equity.”
The following table summarizes future debt payments as of December 31, 2019:
(In thousands)
0.875% Convertible Senior Notes (1)
1.25% Cash Convertible Senior Notes (2)
Term Loan
Revolving Facility (2)
Other debt
Total
$ 218,000 $
345,000
330,000
80,000
0
2020
2021
2022
2023
2024
0 $
345,000
27,500
0
0
0 $
0
30,000
0
0
0 $
0
37,500
0
0
0 $
0
235,000
80,000
0
Total debt
$ 973,000 $ 372,500 $
30,000 $
37,500 $ 315,000 $
Thereafter
218,000
0
0
0
0
218,000
0 $
0
0
0
0
0 $
(1) Amount represents the face value of the 0.875% Convertible Senior Notes, which includes both the liability and equity portions.
(2) Assumes no cash conversion of the 1.25% Cash Convertible Senior Notes prior to their maturity on July 1, 2020.
10. Income Taxes
The following is a geographic breakdown of (loss) income before income tax benefits:
(In thousands)
United States
Foreign
(Loss) income from continuing operations before income taxes
$
$
90
Year Ended December 31,
2018
2019
(211,853) $
5,337
(206,516) $
14,045 $
(907)
13,138 $
2017
(190,053)
16
(190,037)
The following is a summary of the components of the (benefit) provision for income taxes:
(In thousands)
Current tax provision
Federal
State
Foreign
Deferred tax provision
Federal
State
Foreign
Income tax (benefit) provision
2019
Year Ended December 31,
2018
2017
$
$
6,607
2,778
5,054
14,439
(28,732)
(8,763)
(858)
(38,353)
(23,914)
$
$
838
737
5,015
6,590
(5,781)
236
(576)
(6,121)
469
$
$
407
1,796
5,091
7,294
2,800
(12,695)
(2,913)
(12,808)
(5,514)
Taxes computed at the statutory federal income tax rate of 21% for the years ended December 31, 2019 and 2018 and 35% for the year ended
December 31, 2017 are reconciled to the provision for income taxes as follows:
(In thousands)
United States federal tax at statutory rate
Items affecting federal income tax rate
Non-deductible acquisition and reorganization expenses
Non-deductible portion of Department of Justice Settlement
Research credits
Change in unrecognized tax benefits
State income taxes, net of federal benefit
Compensation
Meals and entertainment
Impact of foreign operations
Provision-to-Return adjustments
Deemed Dividends
Federal, state and local rate changes
US Tax reform impact
One time Mandatory Repatriation Toll Charge
Goodwill impairment
Non-deductible items
Noncontrolling interest
True-up of prior year income of Consolidated Investment
Valuation allowance
Other
Income tax (benefit) provision
$
91
2019
Year Ended December 31,
2018
2017
$
(43,368) $
2,759
$
(66,523)
31
18,546
(6,126)
1,046
(3,787)
4,664
549
3,079
(383)
473
(630)
(2,972)
0
5,397
43
0
0
922
(1,398)
(23,914) $
291
0
(6,185)
3
715
3,213
616
3,627
(2,140)
373
0
0
0
0
34
951
913
(5,208)
507
469
$
0
0
(3,200)
395
(7,121)
2,950
991
730
(1,413)
1,289
185
10,189
5,155
0
33
0
0
47,959
2,867
(5,514)
Significant components of our deferred tax assets and liabilities consist of the following:
(In thousands)
Deferred tax assets
Accruals and reserves, net
Allowance for doubtful accounts
Stock-based compensation, net
Deferred revenue
Operating and finance lease liabilities
Net operating loss carryforwards
Research and development tax credit
Other
Less: Valuation Allowance
Total deferred tax assets
Deferred tax liabilities
Prepaid expense
Property and equipment, net
Acquired intangibles, net
Operating and finance right-to-use assets
Other
Total deferred tax liabilities
Net deferred tax liabilities
The deferred tax assets (liabilities) are classified in the consolidated balance sheets as follows:
(In thousands)
Non-current deferred tax assets, net
Non-current deferred tax liabilities, net
Non-current deferred tax liabilities, net
December 31,
2019
2018
$
29,627 $
11,507
10,382
21,786
22,085
37,717
899
7,488
(19,219)
122,272
(5,372)
(3,695)
(111,284)
(17,255)
0
(137,606)
$
(15,334) $
31,565
11,378
10,595
8,160
0
36,649
899
10,784
(18,734)
91,296
(6,733)
(7,442)
(129,879)
0
(676)
(144,730)
(53,434)
December 31,
2019
2018
$
$
5,704 $
(21,038)
(15,334) $
5,036
(58,470)
(53,434)
The United States Tax Cuts and Jobs Act (the “Tax Act”) was enacted on December 22, 2017 and introduced significant changes to the income tax
law in the United States. Effective in 2018, the Tax Act reduced the United States statutory tax rate from 35% to 21% and created new taxes on certain
foreign-sourced earnings and certain related-party payments, which are referred to as the global intangible low-taxed income tax and the base erosion tax,
respectively. In addition, in 2017 we were subject to a one-time transition tax on accumulated foreign subsidiary earnings not previously subject to income tax
in the United States.
Due to the timing of the enactment and the complexity involved in applying the provisions of the Tax Act, we made reasonable estimates of the
effects and recorded provisional expense of $15.3 million in our financial statements for the year ended December 31, 2017 in accordance with guidance in
Staff Accounting Bulletin No. 118 (“SAB 118”), which allows a measurement period of up to one year after the enactment date to finalize the recording of the
related tax impacts. This provisional expense included $10.1 million expense for the remeasurement of deferred tax balances to reflect the lower federal rate
and expense of $5.2 million for the one-time transition tax on accumulated foreign subsidiary earnings not previously subject to income tax in the United
States. Adjustments to these provisional amounts that we recorded in 2018 did not have a significant impact on our consolidated financial statements. Our
accounting for the effects of the enactment of U.S. Tax Reform is now complete. Due to our divestiture of our investment in Netsmart, the amounts noted
above do not include the provisional amounts recorded by Netsmart in 2017.
We had federal net operating loss (“NOL”) carryforwards of $174 million and $164 million as of December 31, 2019, and 2018, respectively. The
federal NOL carryforward includes US NOL carryovers of $8 million and Israeli NOL carryovers of $56 million that do not expire. As of December 31, 2019
and 2018, we had state NOL carryforwards of $1 million and $2 million, respectively. The NOL carryforwards expire in various amounts starting in 2020 for
both federal and state tax purposes. The utilization of the federal NOL carryforwards is subject to limitation under the rules regarding changes in stock
ownership as determined by the Internal Revenue Code.
92
For federal purposes, 2016 to 2019 tax years remain subject to income tax examination by federal authorities. For our state tax jurisdictions, 2008 to
2019 tax years remain open to income tax examination by state tax authorities. Tax years remain open in various foreign jurisdictions beginning in 2014. We
have a subsidiary in India that is entitled to a tax holiday that allows for tax-free operations during such tax holiday. This tax holiday for the subsidiary began
to partially expire in 2012 and fully expired in 2017. Tax savings realized from this holiday totaled $0.4 million for the year ended December 31, 2017, which
reduced our loss per share by less than $0.01 through 2017. There is a potential for a partial tax holiday for 5 years beginning on April 1, 2017, which is
contingent upon a certain level of capital expenditure spending, among other conditions. Tax savings impact of $0.1 million has been recorded for this
potential tax holiday for the year ended December 31, 2019, which impacted our diluted earnings per share by less than $0.01 in this year.
U.S. GAAP principles prescribe a threshold of more-likely-than-not to be sustained upon examination for the financial statement recognition and
measurement of a tax position taken or expected to be taken in a tax return. These principles also provide guidance on de-recognition, classification, interest
and penalties, accounting in interim periods, disclosure and transition.
Changes in the amounts of unrecognized tax benefits were as follows:
(In thousands)
Beginning balance as of January 1
Increases for tax positions related to the current year
Decreases for tax positions related to prior years
Increases for tax positions related to prior years
Decreases relating to settlements with taxing authorities
Increases acquired in business acquisitions
Foreign currency translation
Reductions due to lapsed statute of limitations
Ending balance as of December 31
2019
Year Ended December 31,
2018
2017
$
$
19,821 $
1,240
0
95
0
0
3
(555)
20,604 $
10,939 $
8,977
0
367
0
540
(5)
(997)
19,821 $
10,616
640
(146)
153
0
0
10
(334)
10,939
We had gross unrecognized tax benefits of $20.6 million and $19.8 million as of December 31, 2019 and 2018, respectively. If the current gross
unrecognized tax benefits were recognized, the result would be an increase in our income tax benefit of $20.7 million and $19.6 million, respectively. These
amounts are net of accrued interest and penalties relating to unrecognized tax benefits of $0.4 million and $0.2 million, respectively. We believe that it is
reasonably possible that $0.2 million of our currently remaining unrecognized tax benefits may be recognized by the end of 2020, as a result of a lapse of the
applicable statute of limitations.
We recognized interest and penalties related to uncertain tax positions in our consolidated statements of operations as follows:
(In thousands)
Interest and penalties included in the provision for income taxes
2019
Year Ended December 31,
2018
2017
$
229 $
543 $
446
The amount of interest and penalties included in our consolidated balance sheets is as follows:
(In thousands)
Interest and penalties included in the liability for uncertain tax positions
December 31,
2019
2018
$
427 $
198
During the year ended December 31, 2019, we recorded valuation allowance of $1.3 million related to the unvested stock compensation of covered
officers due to the potential deduction limitations under Section 162(m) provisions and $0.4 million against deferred tax assets of certain foreign deferred tax
assets. In addition, we released a valuation allowance of $1.2 million due to utilization of state net operating losses. During the year ended December 31,
2018, we released a valuation allowance of $42.7 million related to federal capital loss carryforwards utilized by capital gains incurred in 2018 and $22.1
million related to federal credit carryforwards. Of this total release of valuation allowances of $64.8 million, $55.3 million was allocated to the Netsmart gain
recorded in discontinued operations. In addition, we recorded a valuation allowance of $4.7 million related to the unvested stock compensation of covered
officers due to the potential deduction limitations under Section 162(m) provisions. In evaluating our ability to recover our deferred tax assets within the
jurisdiction from which they arise, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, tax-
planning strategies, and results of recent operations. In evaluating the objective evidence that historical results provide, we consider three years of cumulative
operating income (loss). Using all available evidence, we determined that it was uncertain that we will realize the deferred tax asset for certain of these
carryforwards within the carryforward period.
93
We file income tax returns in the United States federal jurisdiction, numerous states in the United States and multiple countries outside of the United
States. We are subject to the continuous examination of our income tax returns by the IRS and other tax authorities. A change in the assessment of the
outcomes of such matters could materially impact our consolidated financial statements.
We intend to indefinitely reinvest the undistributed earnings of our foreign subsidiaries as a general rule, as most of our foreign subsidiaries have third
party customers, as well as formal sales proposals that could require significant resources. Specifically, our subsidiary in India may repatriate all current 2019
earnings at the discretion of management. As of December 31, 2019, we have no other plans to repatriate any other funds at this time. A Netherlands holding
company currently holds all of our foreign subsidiaries. Our holding company makes it more efficient for us to share resources between the respective foreign
subsidiaries. As we have determined that the earnings of these subsidiaries are not required as a source of funding for our United States operations, such
earnings are not planned to be distributed to the United States in the foreseeable future. Determination of the amount of unrecognized income tax liability
related to these undistributed foreign subsidiary earnings, if repatriated, is currently not practicable.
11. Stock Award Plan
Total recognized stock-based compensation expense is included in our consolidated statements of operations as shown in the table below. Stock-based
compensation expense includes both non-cash expense related to grants of stock-based awards as well as cash expense related to the employee discount
applied to purchases of our common stock under our employee stock purchase plan.
(In thousands)
Cost of revenue:
Software delivery, support and maintenance
Client services
Total cost of revenue
Selling, general and administrative expenses
Research and development
Total stock-based compensation expense
2019
Year Ended December 31,
2018
2017
$
$
2,075 $
4,067
6,142
27,348
9,200
42,690 $
2,184 $
3,997
6,181
24,213
8,937
39,331 $
2,879
4,484
7,363
23,497
8,605
39,465
The estimated income tax benefit of stock-based compensation expense included in the provision for income taxes for the year ended December 31,
2019 is approximately $5.3 million. No stock-based compensation costs were capitalized during the years ended December 31, 2019, 2018 and 2017. The
calculation of stock-based compensation expenses includes an estimate for forfeitures at the time of grant. This estimate can be revised in subsequent periods
if actual forfeitures differ from those estimates, which are based on historical trends. Total unrecognized stock-based compensation expense related to non-
vested awards and options was $62.4 million as of December 31, 2019, and this expense is expected to be recognized over a weighted-average period of 2.3
years.
Allscripts Long-Term Incentive Plan
Allscripts adopted the 2019 Stock Incentive Plan (the “Plan”), which became effective May 23, 2019. The Plan provides for the granting of stock
options, service-based awards, performance-based share awards and market-based share awards, among other awards. The maximum number of shares
available for awards under the Plan is 5.5 million, plus the number of available shares of common stock under the Amended and Restated 2011 Stock
Incentive plan as of the effective date of the Plan. There were 1.9 million shares as of December 31, 2019 of common stock reserved for issuance under future
share-based awards to be granted to any of Allscripts employees, officers, directors or independent consultants at terms and prices to be determined by our
Board, and subject to the terms of the Plan.
We issue service-based, performance-based and market-based awards in the form of restricted stock units, stock options or restricted shares.
A description of each category of awards is presented below.
Service-based Share Awards
Service-based share awards include stock options, restricted stock units and restricted shares, and typically vest over a four-year period commencing
on the date of grant subject to continued service with the Company. Upon termination of an employee’s employment, any unvested service-based share
awards are forfeited unless otherwise provided in an employee’s employment agreement. Share units are awarded to directors and vest within one year. We
recognize the expense for service-based share awards over the requisite service period on a straight-line basis, net of estimated forfeitures.
There was $52.6 million of total estimated unrecognized stock-based compensation expense related to the service-based share awards as of December
31, 2019, which is expected to be recognized over a weighted-average period of 2.4 years.
94
Performance-based Share Awards
Performance-based share awards include restricted stock units and restricted shares. The purpose of such awards is to align management’s
compensation with our financial performance and other operational objectives and, in certain cases, to retain key employees over a specified performance
period. Awards granted under this category are based on the achievement of various targeted financial measures as defined by the Plan. The awards are earned
based on actual results achieved compared to targeted amounts. Stock-based compensation expense related to these awards is recognized over three-year and
four-year vesting periods under the accelerated attribution method if and when we conclude that it is probable that the performance conditions will be
achieved.
There was $0.2 million of total estimated unrecognized stock-based compensation expense as of December 31, 2019, assuming various target
attainments related to the performance-based share awards, which is expected to be recognized over a weighted-average period of 0.3 years.
Market-based Share Awards
Market-based share awards include restricted stock units. The purpose of such awards is to align management’s compensation with the performance
of our common stock relative to the market. Awards granted under this category are dependent on our total shareholder returns relative to a specified peer
group of companies over three-year performance periods with vesting based on three annual performance segments from the grant dates. Fair values of the
awards were estimated at the date of the grants using the Monte Carlo pricing model. The Compensation Committee of our Board determines the number of
awards that will vest considering overall performance over the three-year performance period following the completion of a performance period. Stock-based
compensation expense related to these awards is recognized over the three-year vesting periods under the accelerated attribution method.
There was $9.6 million of total estimated unrecognized stock-based compensation expense as of December 31, 2019, which is expected to be
recognized over a weighted-average period of 1.7 years.
Restricted Stock Units
The following table summarizes the activity for restricted stock units during the periods presented:
(In thousands, except per share amounts)
Unvested restricted stock units as of December 31, 2016
Awarded
Vested
Forfeited
Unvested restricted stock units as of December 31, 2017
Awarded
Vested
Forfeited
Unvested restricted stock units as of December 31, 2018
Awarded
Vested
Forfeited
Unvested restricted stock units as of December 31, 2019
Net Share-settlements
Shares
Weighted-Average
Grant Date Fair Value
6,247 $
3,690
(1,835)
(843)
7,259
4,024
(2,222)
(1,111)
7,950
4,777
(2,360)
(1,453)
8,914 $
13.54
12.52
13.74
16.97
12.57
13.25
13.03
12.43
12.81
10.15
12.62
12.20
11.53
Upon vesting, restricted stock units are generally net share-settled upon vesting to cover the required withholding tax and the remaining amount is
converted into an equivalent number of shares of common stock. The majority of restricted stock units that vested during the years ended December 31, 2019,
2018 and 2017 were net-share settled such that we withheld shares with value equivalent to the employees’ minimum statutory tax obligations for the
applicable income and other employment taxes and remitted the equivalent amount of cash to the appropriate taxing authorities. Total payments for the
employees’ minimum statutory tax obligations are reflected as a financing activity within the accompanying consolidated statements of cash flows. The total
shares withheld during the years ended December 31, 2019, 2018 and 2017 were 705 thousand, 695 thousand and 606 thousand, respectively, and were based
on the value of the restricted stock units on their vesting date as determined by our closing stock price. These net-share settlements had the effect of share
repurchases by us as they reduced the number of shares that would have otherwise been issued at the vesting date.
95
Stock Options
The following table summarizes the status of stock options outstanding and the changes during the periods presented:
(In thousands, except per share amounts)
Balance as of December 31, 2016
Options granted
Options exercised
Options forfeited
Balance as of December 31, 2017
Options granted
Options exercised
Options forfeited
Balance as of December 31, 2018
Options granted
Options exercised
Options forfeited
Balance as of December 31, 2019
Options
Outstanding
Weighted-Average
Exercise Price
Options
Exercisable
Weighted-Average
Exercise Price
1,903
0
(108)
(160)
1,635
0
(92)
(211)
1,332
0
0
(98)
1,234 $
13.95
0.00
14.01
15.00
13.85
0.00
14.01
14.74
13.69
0
0
14.01
13.67
1,431
13.98
1,635
13.85
1,332
13.69
1,234 $
13.67
We estimate the fair value of our service-based stock option awards on the date of grant using the Black-Scholes-Merton option-pricing model.
Option valuation models, including the Black-Scholes-Merton option-pricing model, require the input of certain assumptions that involve judgment. Changes
in the input assumptions can materially affect the fair value estimates and, ultimately, how much we recognize as stock-based compensation expense. Our
stock options have a contractual term of 7 years.
The aggregate intrinsic value of stock options outstanding or exercisable as of December 31, 2019 was zero, based on our closing stock price of $9.82
as of December 31, 2019. The intrinsic value of stock options outstanding represents the amount that would have been received by the option holders had all
option holders exercised their stock options as of that date.
The following activity occurred under the Plan:
(In thousands)
Total intrinsic value of stock options exercised
Total fair value of share awards vested
2019
Year Ended December 31,
2018
$
$
0 $
29,793 $
69 $
28,954 $
2017
45
25,220
The following table summarizes information about stock options outstanding under the Plan as of December 31, 2019:
Range of Exercise Prices
$12.72 to $14.01
$14.78 to $15.22
Allscripts Employee Stock Purchase Plan
Number of
Options
Outstanding
1,225,743 $
7,970 $
1,233,713
Weighted-Average
Exercise Price
13.66
14.80
Number of
Options
Exercisable
1,225,743 $
7,970 $
1,233,713
Weighted-Average
Exercise Price
13.66
14.80
Our Employee Stock Purchase Plan (the “ESPP”) allows eligible employees to authorize payroll deductions of up to 20% of their base salary to be
applied toward the purchase of full shares of common stock on the last business day of each offering period. Offering periods under the ESPP are three
months in duration and begin on each March 1st, June 1st, September 1st, and December 1st. Shares are purchased on the last day of each offering period at a
discount of 15% to the fair market value of our common stock as reported on Nasdaq based on the lower of the closing price either on the first or last business
day of each offering period. Employees are limited to purchasing shares under the ESPP having a collective fair market value no greater than $25,000 in any
one calendar year. The shares available for purchase under the ESPP may be drawn from either authorized but previously unissued shares of common stock or
from reacquired shares of common stock, including shares purchased by us in the open market and held as treasury shares.
We treat the ESPP as a compensatory plan in accordance with GAAP. There were 2.0 million and 1.6 million shares purchased under the ESPP during
the years ended December 31, 2019 and 2018, respectively.
96
12. Stockholders’ Equity
Stock Repurchases
On November 17, 2016, we announced that our Board approved a stock purchase program (the “2016 Program”) under which we may repurchase up
to $200 million of our common stock through December 31, 2019. On August 2, 2018, we announced that our Board approved a new stock purchase program
(the “2018 Program”) under which we may repurchase up to $250 million of our common stock through December 31, 2020, replacing the 2016 Program. We
repurchased 10.5 million of our common stock under the 2018 Program for a total of $111.5 million during 2019. We repurchased 3.6 million shares of our
common stock under the 2018 Program for a total $37.0 million during the fourth quarter of 2018. We repurchased 7.7 million shares of our common stock
under the 2016 Program for a total of $101.9 million during the nine months ended September 30, 2018. Any future stock repurchase transactions may be
made through open market transactions, block trades, privately negotiated transactions (including accelerated share repurchase transactions) or other means,
subject to our working capital needs, cash requirements for investments, debt repayment obligations, economic and market conditions at the time, including
the price of our common stock, and other factors that we consider relevant. Our stock repurchase program may be accelerated, suspended, delayed or
discontinued at any time.
Issuance of Common Stock and Warrants
On June 30, 2016, we issued to a commercial partner, as part of an overall commercial relationship, unregistered warrants to purchase (i) 900,000
shares of our common stock, par value $0.01 per share, at a price per share of $12.47, (ii) 1,000,000 shares of our common stock at a price per share of $14.34
and (iii) 1,100,000 shares of our common stock at a price per share of $15.59, in each case subject to customary anti-dilution adjustments. The warrants vest
in four equal annual installments of 750 thousand shares beginning in June 2017 and expire in June 2026. Our issuance of the warrants was a private
placement exempt from registration pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended. These warrants are not actively traded and were
valued based on an option pricing model that uses observable and unobservable market data for inputs. The warrants were valued at $11 million and are being
amortized into earnings over the four-year vesting period. The amortization expense is included as a reduction to revenue in the accompanying consolidated
statements of operations.
In June 2013, in connection with the issuance of the 1.25% Notes, we issued the 1.25% Warrants exercisable for 20.1 million shares of our common
stock (subject to anti-dilution adjustments under certain circumstances) with an initial exercise price of $23.135 per share, subject to customary adjustments.
The net proceeds from the sale of the 1.25% Warrants of $51.2 million are included as additional paid in capital in the accompanying consolidated balance
sheets as of December 31, 2019 and 2018. The 1.25% Warrants expire over a period of 70 trading days beginning on October 1, 2020 and are exercisable only
upon expiration. Additionally, if the market value per share of our common stock exceeds the strike price of the 1.25% Warrants on any trading day during the
70 trading day measurement period, we will, for each such trading day, be obligated to issue to the counterparties a number of shares equal in value to the
product of the amount by which such market value exceeds such strike price and 1/70th of the aggregate number of shares of our common stock underlying
the 1.25% Warrants transactions, subject to a share delivery cap. For each 1.25% Warrant that is exercised, we will deliver to the option counterparties a
number of shares of our common stock equal to the amount by which the settlement price exceeds the exercise price, divided by the settlement price, plus
cash in lieu of fractional shares. We will not receive any additional proceeds if the 1.25% Warrants are exercised. The number of warrants and the strike price
are subject to adjustment under certain circumstances. The 1.25% Warrants could separately have a dilutive effect to the extent that the market value per share
of our common stock (as measured under the terms of the warrant transactions) exceeds the applicable strike price of the 1.25% Warrants.
In June 2013, we agreed to issue a warrant to another commercial partner as part of an overall commercial relationship pursuant to which the warrant
holder has the right to purchase 1.5 million shares of our common stock at a strike price of $12.94 per share. The warrant vests in four equal annual
installments of 375 thousand shares (beginning in June 2014) and expires in June 2020. Our issuance of the warrant was a private placement exempt from
registration pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended. This warrant is not actively traded and was valued based on an option
pricing model that uses observable and unobservable market data for inputs. The warrant was valued at $10.2 million and was amortized into earnings over
the four-year vesting period. The amortization of the warrant value is included in stock-based compensation expense in the accompanying consolidated
statements of cash flows.
Issuance of 0.875% Convertible Senior Notes
In December 2019, we issued the 0.875% Convertible Senior Notes that at the option of the holders, may convert their respective notes into cash,
Allscripts’ common stock or a combination of cash and Allscripts’ common stock. The issuance of the 0.875% Convertible Senior Notes generated a $40.1
million equity component for the embedded conversion option, which was recorded as Additional paid-in capital within the consolidated balance sheets as a
discount that will be accreted into interest expense through January 1, 2027 using the interest method. The carrying value of the embedded conversion option
was $21.7 million as of December 31, 2019. Refer to Note 9 “Debt” for further information regarding the 0.875% Convertible Senior Notes and embedded
conversion option.
97
13. Earnings (Loss) Per Share
Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average shares of common stock outstanding. For purposes
of calculating diluted earnings per share, the denominator includes both the weighted average shares of common stock outstanding and dilutive common stock
equivalents. Dilutive common stock equivalents consist of stock options, restricted stock unit awards and warrants calculated under the treasury stock method.
The calculations of earnings (loss) per share are as follows:
(In thousands, except per share amounts)
Basic (loss) income per Common Share:
(Loss) income from continuing operations, net of tax
Net loss attributable to non-controlling interests
Net (loss) income from continuing operations attributable to
Allscripts Healthcare Solutions, Inc. stockholders
Income from discontinued operations, net of tax
Accretion of redemption preference on redeemable convertible
non-controlling interest - discontinued operations
Net income (loss) from discontinued operations attributable to Allscripts
Healthcare Solutions, Inc. stockholders
Net (loss) income attributable to Allscripts
Healthcare Solutions, Inc. stockholders
2019
Year Ended December 31,
2018
2017
$
(182,602) $
424
12,669
4,527
$
(184,523)
1,566
$
(182,178) $
17,196 $
(182,957)
0
0
0
395,138
30,348
(48,594)
(43,850)
346,544
(13,502)
$
(182,178) $
363,740 $
(196,459)
Weighted-average common shares outstanding
166,306
176,038
180,830
Basic (loss) income from continuing operations per Common Share
Basic income (loss) from discontinued operations per Common Share
Net (loss) income attributable to Allscripts Healthcare Solutions, Inc.
stockholders per Common Share
Diluted (loss) income per Common Share:
(Loss) income from continuing operations, net of tax
Net loss attributable to non-controlling interests
Net (loss) income from continuing operations attributable to
Allscripts Healthcare Solutions, Inc. stockholders
Income from discontinued operations, net of tax
Accretion of redemption preference on redeemable convertible
non-controlling interest - discontinued operations
Net income (loss) from discontinued operations attributable to Allscripts
Healthcare Solutions, Inc. stockholders
Net (loss) income attributable to Allscripts
Healthcare Solutions, Inc. stockholders
Weighted-average common shares outstanding
Dilutive effect of stock options, restricted stock unit awards
and warrants
Weighted-average common shares outstanding assuming dilution
$
$
$
$
$
$
(1.10) $
0.00 $
0.10 $
1.97 $
(1.10) $
2.07 $
(1.02)
(0.07)
(1.09)
(182,602) $
424
12,669 $
4,527
(184,523)
1,566
(182,178) $
17,196 $
(182,957)
0 $
395,138 $
30,348
0
0
(48,594)
(43,850)
346,544
(13,502)
$
(182,178) $
363,740 $
(196,459)
166,306
176,038
180,830
0
166,306
2,491
178,529
0
180,830
Diluted (loss) income from continuing operations per Common Share
Diluted income (loss) from discontinued operations per Common Share
Net (loss) income attributable to Allscripts Healthcare Solutions, Inc.
stockholders per Common Share
$
$
$
(1.10) $
0 $
0.10 $
1.94 $
(1.10) $
2.04 $
(1.02)
(0.07)
(1.09)
98
As a result of the net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders for the years ended December 31, 2019 and 2017, we used
basic weighted-average common shares outstanding in the calculation of diluted loss per share for each of these years, since the inclusion of any stock
equivalents would be anti-dilutive.
The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted earnings (loss) per share as the
effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive:
(In thousands)
Shares subject to anti-dilutive stock options, restricted stock unit awards and
warrants excluded from calculation
2019
Year Ended December 31,
2018
2017
27,945
26,175
26,515
14. Accumulated Other Comprehensive Loss
Accumulated Other Comprehensive Loss
Changes in the balances of each component included in accumulated other comprehensive loss (“AOCI”) are presented in the tables below. All
amounts are net of tax and exclude non-controlling interest.
(In thousands)
Balance as of December 31, 2016 (1)
Other comprehensive income (loss) before reclassifications
Net losses (gains) reclassified from accumulated
other comprehensive loss
Net other comprehensive income (loss)
Balance as of December 31, 2017 (2)
Other comprehensive (loss) income before reclassifications
Net (gains) losses reclassified from accumulated
other comprehensive loss
Net other comprehensive (loss) income
Balance as of December 31, 2018 (3)
Other comprehensive income (loss) before reclassifications
Net (gains) losses reclassified from accumulated
other comprehensive loss
Net other comprehensive income (loss)
Balance as of December 31, 2019 (3)
Foreign Currency
Translation
Adjustments
Unrealized Net
Gains (Losses) on
Available for Sale
Securities
Unrealized Net Gains
(Losses) on Foreign
Exchange Contracts
(6,028)
3,352
0
3,352
(2,676)
(2,908)
0
(2,908)
(5,584)
1,192
0
1,192
(4,392) $
$
(56,420)
(106,445)
162,865
56,420
0
0
0
0
0
0
0
0
0 $
619
1,697
(1,625)
72
691
(264)
(232)
(496)
195
61
(256)
(195)
0 $
Total
(61,829)
(101,396)
161,240
59,844
(1,985)
(3,172)
(232)
(3,404)
(5,389)
1,253
(256)
997
(4,392)
(1) Net of taxes of $463 thousand for unrealized net gains on marketable securities and foreign exchange contract derivatives.
(2) Net of taxes of $445 thousand for unrealized net gains on marketable securities and foreign exchange contract derivatives.
(3) Tax effects for the years ended December 31, 2019 and 2018 include $149 thousand arising from the revaluations of tax effects included in accumulated other
comprehensive income.
Income Tax Effects Related to Components of Other Comprehensive Loss
The following tables reflect the tax effects allocated to each component of other comprehensive loss (“OCI”)
(In thousands)
Foreign currency translation adjustments
Derivatives qualifying as cash flow hedges:
Foreign exchange contracts:
Net gains (losses) arising during the period
Net (gains) losses reclassified into income
Net change in unrealized (losses) gains on foreign exchange contracts
Other comprehensive income
Before-Tax Amount
Year Ended December 31, 2019
Tax Effect
Net Amount
$
$
1,192 $
0 $
1,192
82
(344)
(262)
930 $
(21)
88
67
67 $
61
(256)
(195)
997
99
(In thousands)
Foreign currency translation adjustments
Derivatives qualifying as cash flow hedges:
Foreign exchange contracts:
Net (losses) gains arising during the period
Net (gains) losses reclassified into income (1)
Net change in unrealized (losses) gains on foreign exchange contracts
Other comprehensive (loss) income
(1) Net of taxes of $68 thousand for unrealized net gains on foreign exchange contract derivatives.
(In thousands)
Foreign currency translation adjustments
Available for sale securities:
Net gain arising during the period
Net gain reclassified into income
Net change in unrealized gains on available for sale securities
Derivatives qualifying as cash flow hedges:
Foreign exchange contracts:
Net gains (losses) arising during the period
Net (gains) losses reclassified into income
Net change in unrealized gains (losses) on foreign exchange contracts
Other comprehensive income
Before-Tax Amount
Year Ended December 31, 2018
Tax Effect
Net Amount
$
$
(2,908) $
0 $
(2,908)
(357)
(516)
(873)
(3,781) $
93
284
377
377 $
(264)
(232)
(496)
(3,404)
Before-Tax Amount
Year Ended December 31, 2017
Tax Effect
Net Amount
$
3,352 $
0 $
3,352
(106,506)
162,865
56,359
61
0
61
(106,445)
162,865
56,420
2,776
(2,662)
114
59,825 $
(1,079)
1,037
(42)
19 $
1,697
(1,625)
72
59,844
$
15. Derivative Financial Instruments
The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates:
(In thousands)
Derivatives qualifying as cash flow hedges:
Foreign exchange contracts
Derivatives not subject to hedge accounting:
1.25% Call Option
1.25% Embedded cash conversion option
Total derivatives
Asset Derivatives
Liability Derivatives
Balance Sheet Location
Fair Value
Balance Sheet Location
Fair Value
December 31, 2019
Prepaid expenses and
other current assets
Other assets
N/A
100
$
0 Accrued expenses
$
0
84 N/A
Other liabilities
$
84
$
185
185
(In thousands)
Derivatives qualifying as cash flow hedges:
Foreign exchange contracts
Derivatives not subject to hedge accounting:
1.25% Call Option
1.25% Embedded cash conversion option
Total derivatives
N/A – We define “N/A” as disclosure not being applicable
Foreign Exchange Contracts
Asset Derivatives
Liability Derivatives
Balance Sheet Location
Fair Value
Balance Sheet Location
Fair Value
December 31, 2018
Prepaid expenses and
other current assets
Other assets
N/A
$
262 Accrued expenses
$
0
9,104 N/A
Other liabilities
$
9,366
9,974
9,974
$
We have entered into non-deliverable forward foreign currency exchange contracts with reputable banking counterparties in order to hedge a portion
of our forecasted future Indian Rupee-denominated (“INR”) expenses against foreign currency fluctuations between the United States dollar and the INR.
These forward contracts cover a decreasing percentage of forecasted monthly INR expenses over time. As of December 31, 2019, we had no forward
contracts outstanding. In the future, we may enter into additional forward contracts to increase the amount of hedged monthly INR expenses or initiate hedges
for monthly periods beyond December 2019.
The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the
consolidated statements of comprehensive income (loss):
(In thousands)
Amount of Gain (Loss)
Recognized in OCI
Year Ended December 31,
2018
2017
2019
Location of Gain (Loss) Reclassified
from
AOCI into Income
Amount of Gain (Loss) Reclassified
from AOCI into Income
Year Ended December 31,
2018
2017
2019
Foreign exchange contracts
$
82 $
(357) $
2,776 Cost of Revenue
$
124 $
165 $
905
Selling, general and
administrative
expenses
Research and
development
83
138
692
137
214
1,065
1.25% Call Option
In June 2013, concurrent with the issuance of the 1.25% Notes, we entered into the 1.25% Call Option with certain of the initial purchasers of the
1.25% Notes (the “Option Counterparties”). Assuming full performance by the option counterparties, the 1.25% Call Option is intended to offset cash
payments in excess of the principal amount due upon any conversion of the 1.25% Notes.
Aside from the initial payment of a premium to the Option Counterparties of $82.8 million for the 1.25% Call Option, we will not be required to make
any cash payments to the Option Counterparties under the 1.25% Call Option, and, subject to the terms and conditions thereof, will be entitled to receive from
the Option Counterparties an amount of cash, generally equal to the amount by which the market price per share of our common stock exceeds the strike price
of the 1.25% Call Option during the relevant valuation period. The strike price under the 1.25% Call Option is initially equal to the conversion price of the
1.25% Notes of $17.19 per share of our common stock.
The 1.25% Call Option, which is indexed to our common stock, is a derivative asset that requires mark-to-market accounting treatment due to the
cash settlement features until the 1.25% Call Option settles or expires. The 1.25% Call Option is measured and reported at fair value on a recurring basis
within Level 3 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the 1.25% Call Option, refer to Note 1,
“Basis of Presentation and Significant Accounting Policies.”
The 1.25% Call Option does not qualify for hedge accounting treatment. Therefore, the change in fair value of this instrument is recognized
immediately in our consolidated statements of operations in Other income (loss), net. Because the terms of the 1.25% Call Option are substantially similar to
those of the 1.25% Notes embedded cash conversion option, discussed next, we expect the net effect of those two derivative instruments on our results of
operations to continue to be minimal.
101
1.25% Notes Embedded Cash Conversion Option
The embedded cash conversion option within the 1.25% Notes is required to be separated from the 1.25% Notes and accounted for separately as a
derivative liability, with changes in fair value recognized immediately in our consolidated statements of operations in Other income (loss), net until the cash
conversion option settles or expires. The initial fair value liability of the embedded cash conversion option was $82.8 million, which simultaneously reduced
the carrying value of the 1.25% Notes (effectively an original issuance discount). The embedded cash conversion option is measured and reported at fair value
on a recurring basis within Level 3 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the embedded cash
conversion option, refer to Note 1, “Basis of Presentation and Significant Accounting Policies.”
The following table shows the net impact of the changes in fair values of the 1.25% Call Option and 1.25% Notes embedded cash conversion option
in the consolidated statements of operations:
(In thousands)
1.25% Call Option
1.25% Embedded cash conversion option
Net (loss) income included in other income, net
16. Commitments
Commitment with Strategic Partner
2019
Year Ended December 31,
2018
2017
$
$
(9,020) $
9,789
769 $
(37,474) $
37,803
329 $
29,498
(30,118)
(620)
We completed renegotiations with Atos to improve the operating cost structure of our private cloud hosting operations during 2019. The new
agreement also provides for the payment of initial annual base fees of $35 million per year (an increase from $30 million) plus charges for volume-based
services currently projected using volumes estimated based on historical actuals and forecasted projections. Expenses under our agreements with Atos, which
are included in cost of revenue in our consolidated statements of operations, are as follows:
(In thousands)
Expenses incurred under Atos agreements
17. Discontinued Operations
Netsmart Discontinued Operation
2019
Year Ended December 31,
2018
2017
$
100,089 $
55,903 $
58,787
On December 31, 2018, we sold all of the Class A Common Units of Netsmart held by the Company in exchange for $566.6 million in cash plus a
final settlement as determined following the closing. Prior to the sale, Netsmart comprised a separate reportable segment, which due to its significance to our
historical consolidated financial statements and results of operations, is reported as a discontinued operation as a result of the sale. Refer to Note 4, “Business
Combinations and Other Investments” for additional information about this transaction.
102
The following table summarizes Netsmart’s major income and expense line items as reported in the consolidated statements of operations for the
years ended December 31, 2018 and 2017:
(In thousands)
Major income and expense line items related to Netsmart:
Revenue:
Software delivery, support and maintenance
Client services
Total revenue
Cost of revenue:
Software delivery, support and maintenance
Client services
Amortization of software development and acquisition related assets
Total cost of revenue
Gross profit
Selling, general and administrative expenses
Research and development
Amortization of intangible and acquisition-related assets
Income from discontinued operations of Netsmart
Interest expense
Other income
Loss from discontinued operations of Netsmart before
income taxes
Income tax benefit
Year ended December 31,
2018
2017
$
$
214,065
131,166
345,231
198,204
110,430
308,634
51,079
78,317
29,876
159,272
149,362
85,583
17,937
16,409
29,433
(49,939)
925
(19,581)
45,253
25,672
60,100
94,061
34,357
188,518
156,713
125,807
25,315
24,029
(18,438)
(59,541)
101
(77,878)
22,933
(54,945)
$
(Loss) income from discontinued operations, net of tax for Netsmart
$
(1) Activity includes both Netsmart and intercompany transactions that would not have been eliminated if Netsmart’s results were not consolidated.
Horizon Clinicals and Series2000 Revenue Cycle Discontinued Operation
Two of the product offerings acquired with the EIS Business in 2017, Horizon Clinicals and Series2000 Revenue Cycle, were sunset after March 31,
2018. The decision to discontinue maintaining and supporting these solutions was made prior to our acquisition of the EIS Business and, therefore, they are
presented below as discontinued operations. Until the end of the first quarter of 2018, we were involved in ongoing maintenance and support for these
solutions until customers transitioned to other platforms. No disposal gains or losses were recognized during the year ended December 31, 2018 related to
these discontinued solutions. We had $0.9 million of accrued expenses associated with the Horizon Clinicals and Series2000 Revenue Cycle businesses on the
consolidated balance sheets as of December 31, 2018
103
The following table summarizes the major income and expense line items of these discontinued solutions, as reported in the consolidated statements
of operations for the years ended December 31, 2018 and 2017:
(In thousands)
Major classes of line items constituting pretax profit (loss) of
discontinued operations for Horizon Clinicals and
Series2000 Revenue Cycle:
Revenue:
Software delivery, support and maintenance
Client services
Total revenue
Cost of revenue:
Software delivery, support and maintenance
Client services
Total cost of revenue
Gross profit
Research and development
Income from discontinued operations for Horizon Clinicals
and Series2000 Revenue Cycle before income taxes
Income tax provision
Income from discontinued operations, net of tax for Horizon
Clinicals and Series2000 Revenue Cycle
18. Business Segments
Year ended December 31,
2018
2017
$
$
9,441
404
9,845
2,322
830
3,152
6,693
1,651
5,042
(1,311)
$
3,731
$
10,949
1,044
11,993
2,918
261
3,179
8,814
1,148
7,666
(2,990)
4,676
We primarily derive our revenues from sales of our proprietary software (either as a direct license sale or under a subscription delivery model), which
also serves as the basis for our recurring service contracts for software support and maintenance and certain transaction-related services. In addition, we
provide various other client services, including installation, and managed services such as outsourcing, private cloud hosting and revenue cycle management.
During the first quarter of 2019, we realigned our reporting structure as a result of the divestiture of our investment in Netsmart on December 31,
2018, the evolution of the healthcare IT industry and our increased focus on the payer and life sciences market. As a result, we changed the presentation of
our reportable segments to Provider and Veradigm. The new Provider segment is comprised of our core integrated clinical software applications, financial
management and patient engagement solutions targeted at clients across the entire continuum of care. The new Veradigm segment primarily focuses on the
payer and life sciences market. These changes to our reportable segments had no impact on operating segments. The segment disclosures below for the years
ended December 31, 2018 and 2017 have been revised to our current presentation.
We sold all of our investment in Netsmart on December 31, 2018. Prior to the sale, Netsmart comprised a separate reportable segment, which due to
its significance to our historical consolidated financial statements and results of operations, is reported as a discontinued operation as a result of the sale. In
addition, the results of operations related to two of the product offerings acquired with the EIS Business (Horizon Clinicals and Series2000) are also presented
throughout these financial statements as discontinued operations and are included within the Provider reportable segment, except for acquisition-related
deferred revenue adjustments, which are included in “Unallocated Amounts”. Refer to Note 17, “Discontinued Operations.”
As a result of the above changes, as of December 31, 2019, we had eight operating segments, which are aggregated into two reportable segments. The
Provider reportable segment includes the Hospitals and Health Systems, Ambulatory, CarePort, FollowMyHealth®, EPSiTM, EIS-Classics and 2bPrecise
strategic business units, each of which represents a separate operating segment. This reportable segment derives its revenue from the sale of integrated clinical
software applications, financial management and patient engagement solutions, which primarily include EHR-related software, connectivity and coordinated
care solutions, financial and practice management software, related installation, support and maintenance, outsourcing, private cloud hosting, revenue cycle
management, training and electronic claims administration services. The Veradigm reportable segment is comprised of the Veradigm business unit, which
represents a separate operating segment. This reportable segment provides data-driven clinical insights with actionable tools for clinical workflow, research,
analytics and media. Its solutions, targeted at key healthcare stakeholders, help improve the quality, efficiency and value of healthcare delivery.
104
Our Chief Operating Decision Maker (“CODM”) uses segment revenues, gross profit and income from operations as measures of performance and to
make decisions about the allocation of resources. In determining these performance measures, we do not include in revenue the amortization of acquisition-
related deferred revenue adjustments, which reflect the fair value adjustments to deferred revenue acquired in a business combination. We also exclude the
amortization of intangible assets, stock-based compensation expense, non-recurring expenses and transaction-related costs, and non-cash asset impairment
charges from the operating segment data provided to our CODM. Non-recurring expenses relate to certain severance, product consolidation, legal, consulting
and other charges incurred in connection with activities that are considered one-time. Accordingly, these amounts are not included in our reportable segment
results and are included in an “Unallocated Amounts” category within our segment disclosure. The “Unallocated Amounts” category also includes (i)
corporate general and administrative expenses (including marketing expenses) and certain research and development expenses related to common solutions
and resources that benefit all of our business units (refer to discussion above), all of which are centrally managed and (ii) revenue and the associated cost from
the resale of certain ancillary products, primarily hardware. We do not track our assets by segment.
(In thousands)
Revenue:
Provider
Veradigm
Unallocated Amounts
Total revenue
Gross profit:
Provider
Veradigm
Unallocated Amounts
Total gross profit
Income (loss) from operations:
Provider
Veradigm
Unallocated Amounts
Total income (loss) from operations
19. Supplemental Disclosures
2019
Year Ended December 31,
2018
2017
$
$
$
$
$
$
1,597,115
161,216
13,346
1,771,677
672,206
104,896
(63,522)
713,580
396,724
43,996
(465,176)
(24,456)
$
$
$
$
$
$
1,616,022
140,326
(6,386)
1,749,962
710,063
100,708
(86,228)
724,543
402,544
43,641
(539,237)
(93,052)
$
$
$
$
$
$
1,441,212
69,879
(13,383)
1,497,708
674,112
43,817
(85,130)
632,799
426,099
23,816
(437,431)
12,484
The majority of the restricted cash balance as of December 31, 2019 represents the remaining balance of the escrow account established as part of the
acquisition of Netsmart in 2016 to be used by Netsmart to facilitate the integration of our HomecareTM business within Netsmart and an escrow fund related
to a previous acquisition associated with the acquired EIS Business.
(In thousands)
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents
Restricted cash
Total cash, cash equivalents and restricted cash
105
December 31
2019
2018
$
$
129,668 $
7,871
137,539 $
174,243
10,552
184,795
(In thousands)
Cash paid during the period for:
Interest
Income taxes paid, net of tax refunds
Non-cash transactions:
Accretion of redemption preference on redeemable convertible
non-controlling interest - discontinued operations
Exchange of NantHealth, Inc. common stock for net assets acquired
of NantHealth provider/patient engagement solutions business including value
assigned to commercial agreement
Obligations incurred to purchase capitalized software or enter into finance leases
Contributions of assets in exchange for equity interest
Issuance of treasury stock to commercial partner
Accrued expenses consist of the following:
(In thousands)
Royalties, certain third-party product costs and licenses
Practice Fusion settlement
Other
Total Accrued expenses
2019
Year Ended December 31,
2018
2017
19,604
42,972
$
$
28,888
10,108
$
$
21,183
6,675
0
$
48,594
$
43,850
0
$
0
$
42,750
0
0
701
$
$
$
1,501
4,000
1,121
$
$
$
1,897
0
334
$
$
$
$
$
$
$
December 31,
2019
2018
$
$
35,431
145,000
90,231
270,662
$
$
26,371
0
80,697
107,068
Other consists of various accrued expenses and no individual item accounted for more than 5% of the current liabilities balance at the respective
balance sheet dates.
Prepaids and other current assets consists of the following:
(In thousands)
Prepaid assets
Other current assets
Total Prepaid and other current assets
Other assets consist of the following:
(In thousands)
Fair value of 1.25% Call Option
Long-term deferred hosting fees
Long-term prepaid commissions
Investments in non-marketable securities
Long-term deposits and other assets
Total Other assets
20. Geographic Information
December 31,
2019
2018
146,036
1,954
147,990
$
$
December 31,
2019
2018
84
36,002
32,860
43,806
12,015
124,767
$
$
140,352
2,103
142,455
9,104
20,805
32,660
37,040
9,597
109,206
$
$
$
$
Revenues are attributed to geographic regions based on the location where the sale originated. Our revenues by geographic area are summarized
below:
(In thousands)
United States
Canada
Other international
Total
2019
1,701,173 $
16,495
54,009
1,771,677 $
Year Ended December 31,
2018
1,697,178 $
15,377
37,407
1,749,962 $
$
$
2017
1,440,842
15,818
41,048
1,497,708
106
A summary of our long-lived assets, comprised of fixed assets by geographic area, is presented below:
(In thousands)
United States
India
Israel
Canada
Other international
Total
21. Contingencies
December 31,
2019
2018
78,122
5,321
3,240
51
1,605
88,339
$
$
111,836
4,231
3,830
60
1,956
121,913
$
$
In addition to commitments and obligations in the ordinary course of business, we are currently subject to various legal proceedings and claims that
have not been fully adjudicated. We intend to vigorously defend ourselves, as appropriate, in these matters.
No less than quarterly, we review the status of each significant matter and assess our potential financial exposure. We accrue a liability for an
estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant
judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and
accruals are based only on the information available to our management at the time the judgment is made.
The outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. In
the opinion of our management, except as set forth below with respected to the expected resolution of the Practice Fusion investigations, the ultimate
disposition of pending legal proceedings or claims will not have a material adverse effect on our consolidated financial position, liquidity or results of
operations. However, if one or more of these additional legal proceedings were resolved against or settled by us in a reporting period for amounts in excess of
our management’s expectations, our consolidated financial statements for that and subsequent reporting periods could be materially adversely affected.
Additionally, the resolution of a legal proceeding against us could prevent us from offering our products and services to current or prospective clients or cause
us to incur increased compliance costs, either of which could further adversely affect our operating results.
On May 1, 2012, Physicians Healthsource, Inc. filed a class action complaint in the U.S. District Court for the Northern District of Illinois against us.
The complaint alleges that, on multiple occasions between July 2008 and December 2011, we or our agent sent advertisements by fax to the plaintiff and a
class of similarly situated persons, without first receiving the recipients’ express permission or invitation in violation of the Telephone Consumer Protection
Act, 47 U.S.C. § 227 (the “TCPA”). The plaintiff sought $500 for each alleged violation of the TCPA, treble damages if the Court finds the violations to be
willful, knowing or intentional, and injunctive and other relief. Allscripts answered the complaint denying all material allegations and asserting a number of
affirmative defenses, as well as counterclaims for breach of a license agreement. On March 31, 2016, plaintiff filed its motion for class certification. On May
31, 2016, we filed our opposition to plaintiff’s motion for class certification, and simultaneously moved for summary judgment on all of plaintiff’s claims. On
June 2, 2017, an order was entered denying class certification and, accordingly, the case will not proceed on a class-wide basis. In January 2020, the parties
stipulated to a voluntary dismissal of the case with prejudice, with each side bearing its own costs and fees. The matter is now resolved.
The Enterprise Information Solutions business (the “EIS Business”) acquired from McKesson Corporation (“McKesson”) on October 2, 2017 is
subject to a May 2017 civil investigative demand (“CID”) from the U.S. Attorney’s Office for the Eastern District of New York. The CID requests documents
and information related to the certification McKesson obtained for Horizon Clinicals in connection with the U.S. Department of Health and Human Services’
Electronic Health Record Incentive Program. In August 2018, McKesson received an additional CID seeking similar information for Paragon. McKesson has
agreed, with respect to the CIDs, to indemnify Allscripts for amounts paid or payable to the government (or any private relator) involving any products or
services marketed, sold or licensed by the EIS Business as of or prior to the closing of the acquisition.
107
Practice Fusion, acquired by Allscripts on February 13, 2018, received in March 2017 a request for documents and information from the U.S.
Attorney’s Office for the District of Vermont pursuant to a CID. Between April 2018 and June 2019, Practice Fusion received from the U.S. Department of
Justice (the “DOJ”) seven additional requests for documents and information through four additional CIDs and three Health Insurance Portability and
Accountability Act (“HIPAA”) subpoenas. The document and information requests received by Practice Fusion related to both the certification Practice
Fusion obtained in connection with the U.S. Department of Health and Human Services’ Electronic Health Record Incentive Program and Practice Fusion’s
compliance with the Anti-Kickback Statute (“AKS”) and HIPAA as it relates to certain business practices engaged in by Practice Fusion. In March 2019,
Practice Fusion received a grand jury subpoena in connection with a criminal investigation related to Practice Fusion’s compliance with the AKS. On August
6, 2019, Practice Fusion reached an agreement in principle with the DOJ to resolve all of the DOJ’s outstanding civil and criminal investigations, including
the investigation by the U.S. Attorney’s Office for the District of Vermont, and we announced that on January 27, 2020, Practice Fusion entered into the
Settlement Agreements resolving the investigations conducted by the DOJ and the U.S. Attorney’s Office. See risk factor entitled “The failure by Practice
Fusion to comply with the terms of its settlement agreements with the DOJ could have a material and adverse impact on our business, results of operations
and financial condition, and, even if Practice Fusion complies with those settlement agreements, the costs and burdens of compliance could be significant, and
we may face additional investigations and proceedings from other governmental entities or third parties related to the same or similar conduct underlying the
agreements with the DOJ.” The Settlement Agreements require Practice Fusion to pay a criminal fine of $25.3 million and a forfeiture payment of $959,700
and a civil settlement of $118.6 million, which includes $5.2 million designated for the state Medicaid program expenditures. The terms of Settlement
Agreements resolved, among other things, allegations that Practice Fusion, long before its acquisition by Allscripts and concerning conduct about which
Allscripts was unaware at the time of the acquisition, violated the AKS through the manner by which a sponsored Clinical Decision Support arrangement was
sold to an opioid manufacturer and other AKS allegations made by the DOJ against Practice Fusion as well as False Claims Act allegations pertaining to
Meaningful Use payments the federal government made to users of Practice Fusion’s EHR system. The settlement amount is included in Other income (loss),
net within the consolidated statements of operations and Accrued expenses within the consolidated balance sheets for the year ended December 31, 2019.
108
22. Quarterly Financial Information (Unaudited)
The following tables contain a summary of our unaudited quarterly consolidated results of operations for our last eight fiscal quarters, which have been
restated to illustrate Netsmart as a discontinued operation.
(In thousands, except per share amounts)
Revenue
Cost of revenue
Gross profit
Selling, general and administrative expenses
Research and development
Asset impairment charges
Goodwill impairment charge
Amortization of intangible and acquisition-related
assets
(Loss) income from operations
Interest expense
Other income (loss), net
(Impairment) recovery on long-term investments
Equity in net income (loss) of unconsolidated
investments
Loss from continuing operations
before income taxes
Income tax benefit (provision)
Net loss
Net loss attributable to non-controlling interest
Net loss attributable to Allscripts Healthcare
Solutions, Inc. stockholders
Net loss attributable to Allscripts Healthcare Solutions, Inc.
stockholders per share: (5)
Basic
Continuing operations
Discontinued operations
Net loss attributable to Allscripts Healthcare Solutions, Inc.
stockholders per share
Diluted
Continuing operations
Discontinued operations
Net loss attributable to Allscripts Healthcare Solutions, Inc.
stockholders per share
$
December 31,
September 30,
2019
2019 (2)
June 30,
2019 (1)
March 31,
2019
Quarter Ended
$
450,984
270,923
180,061
112,835
62,912
6,800
25,700
6,840
(35,026)
(11,725)
4,798
(1,696)
$
444,184
268,882
175,302
101,152
63,873
248
0
6,847
3,182
(10,839)
781
0
$
444,460
260,338
184,122
105,542
63,414
3,691
0
6,732
4,743
(10,424)
(144,994)
0
125
386
218
(43,524)
24,554
(18,970)
0
(6,490)
765
(5,725)
0
(150,457)
527
(149,930)
0
432,049
257,954
174,095
100,245
64,310
98
0
6,797
2,645
(10,184)
513
1,045
(64)
(6,045)
(1,932)
(7,977)
424
$
(18,970)
$
(5,725)
$
(149,930)
$
(7,553)
(0.12)
0.00
(0.12)
(0.12)
0.00
(0.12)
$
$
$
$
$
$
$
$
$
$
$
$
109
(0.03)
0.00
(0.03)
(0.03)
0.00
(0.03)
$
$
$
$
$
$
(0.90)
0.00
(0.90)
(0.90)
0.00
(0.90)
$
$
$
$
$
$
(0.04)
0.00
(0.04)
(0.04)
0.00
(0.04)
(In thousands, except per share amounts)
Revenue
Cost of revenue
Gross profit
Selling, general and administrative expenses
Research and development
Asset impairment charges
Goodwill impairment charge
Amortization of intangible and acquisition-related assets
(Loss) income from operations
Interest expense
Other income (loss), net
Gain on sale of businesses, net
Impairment of long-term investments
Equity in net (loss) income of unconsolidated
investments
(Loss) income from continuing operations
before income taxes
Income tax benefit (provision)
(Loss) income from continuing operations, net of tax
Loss from discontinued operations
Gain on sale of Netsmart
Income tax effect on discontinued operations
Income (loss) from discontinued operations, net of tax
Net income (loss)
Net loss attributable to non-controlling interest
Accretion redemption preference on redeemable
non-controlling interest - discontinued operations
Net income (loss) attributable to Allscripts Healthcare
Solutions, Inc. stockholders
$
December 31,
2018
September 30,
2018
June 30,
2018 (4)
March 31,
2018 (3)
Quarter Ended
$
442,346
254,187
188,159
99,992
66,096
28,091
13,466
6,957
(26,443)
(13,989)
658
0
0
$
432,430
254,478
177,952
108,125
63,032
0
0
6,609
186
(13,251)
(536)
0
0
$
441,464
267,697
173,767
122,913
74,491
30,075
0
6,382
(60,094)
(11,979)
(14)
173,129
(9,987)
433,722
249,057
184,665
119,937
64,790
0
0
6,639
(6,701)
(11,695)
(34)
(871)
(5,500)
(270)
(177)
767
(61)
(40,044)
5,449
(34,595)
(39,854)
500,471
(40,126)
420,491
385,896
1,033
(13,778)
1,637
(12,141)
(13,857)
0
2,152
(11,705)
(23,846)
4
91,822
(7,256)
84,566
(14,109)
0
3,815
(10,294)
74,272
2,700
(24,862)
(299)
(25,161)
(5,016)
0
1,662
(3,354)
(28,515)
790
(12,148)
(12,149)
(12,148)
(12,149)
$
374,781
$
(35,991)
$
64,824
$
(39,874)
Net income (loss) attributable to Allscripts Healthcare Solutions, Inc.
stockholders per share: (5)
Basic
Continuing operations
Discontinued operations
Net income (loss) attributable to Allscripts Healthcare Solutions,
Inc. stockholders per share
Diluted
Continuing operations
Discontinued operations
Net income (loss) attributable to Allscripts Healthcare Solutions,
Inc. stockholders per share
$
$
$
$
$
$
(0.19)
2.36
2.17
(0.19)
2.33
2.14
$
$
$
$
$
$
(0.07)
(0.13)
(0.20)
(0.07)
(0.13)
(0.20)
$
$
$
$
$
$
0.49
(0.13)
0.36
0.49
(0.13)
0.36
$
$
$
$
$
$
(0.14)
(0.08)
(0.22)
(0.14)
(0.08)
(0.22)
(1) Results of operations for the quarter include the results of operations of a third party engaged in a specialty prescription drug platform since June 10, 2019.
(2) Results of operations for the quarter include the results of operations of Pinnacle and Diabetes and Collaborative Registries since July 2, 2019.
(3) Results of operations for the quarter include the results of operations of Practice Fusion since February 13, 2018.
(4) Results of operations for the quarter include the results of operations of Health Grid since May 18, 2018.
(5) The sum of the quarterly per share amounts may not equal per share amounts reported for year to date periods. This is due to changes in the number of weighted-average
shares outstanding and the effects of rounding for each period.
110
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
None.
Item 9A. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, we conducted
an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e)
promulgated under the Exchange Act, as of the end of the period covered by this Form 10-K.
Based on management’s evaluation, our chief executive officer and our chief financial officer concluded that our disclosure controls and procedures are
designed to, and were effective as of December 31, 2019 to, provide assurance at a reasonable level that the information we are required to disclose in reports that
we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that
such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow
for timely decisions regarding required disclosure.
Management’s Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) and
15d-15(f) under the Exchange Act. Under the supervision and with the participation of our management, including our chief executive officer and chief
financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2019 based on the
guidelines established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013
framework). Our internal control over financial reporting includes policies and procedures that provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external reporting purposes in accordance with GAAP.
Based on the results of our evaluation, our management concluded that our internal control over financial reporting was effective as of December 31,
2019. We reviewed the results of management’s assessment with the Audit Committee of our Board. The effectiveness of our internal control over financial
reporting as of December 31, 2019 has been audited by Grant Thornton LLP, an independent registered public accounting firm, as stated in its report which is
included in Part II, Item 8, “Financial Statements and Supplementary Data” of this Form 10-K.
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting during the quarter ended December 31, 2019, which were identified in
connection with management’s evaluation required by paragraph (d) of Rules 13a-15 and 15d-15 under the Exchange Act, that have materially affected, or are
reasonably likely to materially affect, our internal control over financial reporting.
Inherent Limitations on Effectiveness of Controls
Our management, including our chief executive officer and chief financial officer, do not expect that our disclosure controls or our internal control
over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not
absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource
constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of
controls can provide absolute assurance that we have detected all control issues and instances of fraud, if any, within our company. These inherent limitations
include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally,
controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The
design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any
design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in
conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system,
misstatements due to error or fraud may occur and not be detected.
111
Item 10. Directors, Executive Officers and Corporate Governance
PART III
The information concerning our executive officers required by this Item is incorporated by reference from Part I, Item 1 of this Form 10-K, under the
heading “Executive Officers.”
Other information required by this Item is incorporated by reference from the information contained under the proposal “Election of Directors,” the
heading “Directors,” and the subheadings “Delinquent Section 16(a) Reports,” “Code of Conduct” and “Audit Committee Financial Experts” under the
heading “Corporate Governance” in our 2020 Proxy Statement (the “2020 Proxy Statement”) to be filed with the U.S. Securities and Exchange Commission
(the “SEC”) within 120 days after December 31, 2019.
Item 11. Executive Compensation
The information required by this Item is incorporated by reference from information contained under the headings “Compensation Discussion and
Analysis” and “Executive Compensation” and the subheadings “Board Oversight of Risk Management,” “Compensation Committee Interlocks and Insider
Participation,” and “Compensation of Directors” under the heading “Corporate Governance” in the 2020 Proxy Statement to be filed with the SEC within 120
days after December 31, 2019.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The information required by this Item is incorporated by reference from information contained under the headings “Security Ownership of Certain
Beneficial Owners and Management” and “Equity Compensation Plan Information” in the 2020 Proxy Statement to be filed with the SEC within 120 days
after December 31, 2019.
Item 13. Certain Relationships and Related Transactions and Director Independence
The information required by this Item is incorporated by reference from information contained under the subheadings “Certain Relationships and
Related Transactions” and “Board Meetings and Committees” under the heading “Corporate Governance” in the 2020 Proxy Statement to be filed with the
SEC within 120 days after December 31, 2019.
Item 14. Principal Accountant Fees and Services
The information required by this Item is incorporated by reference from information contained under the subheadings “Fees and Related Expenses
Paid to Auditors” and “Pre-Approval of Audit and Permissible Non-Audit Services of the Independent Registered Public Accounting Firm” under the
proposal “Ratification of Appointment of Independent Registered Public Accounting Firm” in the 2020 Proxy Statement to be filed with the SEC within 120
days after December 31, 2019.
112
Item 15. Exhibits and Financial Statement Schedules
(a)(1) Financial Statements
Our consolidated financial statements are included in Part II of this Form 10-K:
PART IV
Report of Independent Registered Public Accounting Firm
Report of Independent Registered Public Accounting Firm
Consolidated Balance Sheets as of December 31, 2019 and 2018
Consolidated Statements of Operations for the years ended December 31, 2019, 2018 and 2017
Consolidated Statements of Comprehensive Income for the years ended December 31, 2019, 2018 and 2017
Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2019, 2018 and 2017
Consolidated Statements of Cash Flows for the years ended December 31, 2019, 2018 and 2017
Notes to Consolidated Financial Statements
Page
56
59
60
62
63
64
65
66
(a)(2) Financial Statement Schedules
(In thousands)
Allowance for doubtful accounts and sales credits
Year ended December 31, 2019
Year ended December 31, 2018
Year ended December 31, 2017
Schedule II—Valuation and Qualifying Accounts
Balance at
Beginning of
Year
Charged to
Expenses/
Against
Revenue
Deferred
Revenue
Reclassification
Write-Offs,
Net of
Recoveries
Balance at
End of
Year
$
$
$
50,406
31,386
28,655
8,788
21,156
7,384
(6,029)
5,512
1,482
(8,221) $
(7,648) $
(6,135) $
44,944
50,406
31,386
All other schedules are omitted, since the required information is not applicable or is not present in amounts sufficient to require submission of the
schedule, or because the information required is included in the consolidated financial statements and notes thereto.
113
2.1
2.2
2.3
2.4
2.5
2.6
2.7
(a)(3) Exhibits
Exhibit
Number
Exhibit Description
* Contribution and Investment Agreement, dated as of March 20, 2016, by
and among Allscripts Healthcare Solutions, Inc., GI Netsmart Holdings
LLC, Nathan Holding LLC and Andrews Henderson LLC
* Agreement and Plan of Merger, dated as of March 20, 2016, by and among
Nathan Intermediate LLC, Nathan Merger Co., Netsmart, Inc. and Genstar
Capital Partners V, L.P.
* Purchase Agreement, dated as of August 1, 2017, by and between
McKesson Corporation and Allscripts Healthcare, LLC.
Amendment No. 1 to Purchase Agreement, dated as of October 2, 2017, by
and between McKesson Corporation and Allscripts Healthcare, LLC.
Filed
Herewith
Furnished
Herewith
Incorporated by Reference
Form Exhibit
Filing Date
8-K 2.1
March 23, 2016
8-K 2.2
March 23, 2016
8-K 2.1
August 4, 2017
10-Q 2.3
November 9, 2017
* Asset Purchase Agreement, dated as of August 3, 2017, between Allscripts
8-K 2.1
August 31, 2017
Healthcare Solutions, Inc. and NantHealth, Inc.
* Asset Purchase Agreement, dated as of February 15, 2018, by and among
Hyland Software, Inc., Allscripts Healthcare, LLC, PF2 EIS LLC, Allscripts
Software, LLC and Allscripts Healthcare Solutions, Inc.
* Agreement and Plan of Merger, dated as of January 5, 2018, by and among
Allscripts Healthcare, LLC, Presidio Sub, Inc., Practice Fusion, Inc. and
Fortis Advisors LLC, as representative of the Holders
8-K 2.1
February 16, 2018
10-Q 2.2
May 8, 2018
2.8
* Agreement and Plan of Merger, dated as of April 27, 2018, by and among
10-Q 2.2
August 6, 2018
Allscripts Healthcare, LLC, FollowMyHealth Merger Sub, Inc., Health Grid
Holding Company, the persons listed on the schedules thereto and Raj Toleti
in his capacity as the representative of the Stockholders
* Unit Purchase Agreement, dated as of December 7, 2018, by and among
Allscripts Healthcare, LLC, Allscripts Next, LLC, Allscripts Healthcare
Solutions, Inc. and the Purchasers named in the schedules thereto.
Fifth Amended and Restated Certificate of Incorporation of Allscripts
Healthcare Solutions, Inc.
By-Laws of Allscripts Healthcare Solutions, Inc.
Indenture dated as of June 18, 2013, between Allscripts Healthcare
Solutions, Inc. and Wells Fargo Bank, National Association, as Trustee
Form of 1.25% Cash Convertible Senior Note due 2020 (included in Exhibit
4.1)
Indenture, dated as of December 9, 2019, by and between Allscripts
Healthcare Solutions, Inc. and U.S. Bank National Association
8-K 2.1
December 11, 2018
10-K 3.1
February 29, 2016
8-K 3.1
8-K 4.1
August 20, 2015
June 18, 2013
8-K 4.2
June 18, 2013
8-K 4.1
December 4, 2019
Form of 0.875% Convertible Senior Note due 2027 (included in Exhibit 4.3)
8-K 4.2
December 4, 2019
Description of the Registrant’s Securities Registered Pursuant to Section 12
of the Securities Exchange Act of 1934
X
2.9
3.1
3.2
4.1
4.2
4.3
4.4
4.5
114
Exhibit
Number
10.1
10.2
10.3
Exhibit Description
Deferred Prosecution Agreement, dated January 27, 2020
Civil Settlement Agreement, dated January 26, 2020
Filed
Herewith
Furnished
Herewith
Form Exhibit
Filing Date
Incorporated by Reference
8-K 10.1
January 27, 2020
8-K 10.2
January 27, 2020
Second Amended and Restated Credit Agreement, dated as of February 15,
8-K 10.1
February 15, 2018
2018, by and among Allscripts Healthcare Solutions, Inc., Allscripts
Healthcare, LLC, the lenders from time to time parties thereto, JPMorgan
Chase Bank, N.A., as Administrative Agent, and Fifth Third Bank,
KeyBank National Association, SunTrust Bank, and Wells Fargo Bank,
National Association, as Syndication Agents
10.4
First Amendment, dated as of August 7, 2019, to the Second Amended and
8-K 10.2
August 9, 2019
Restated Credit Agreement, dated as of February 15, 2018, among
Allscripts Healthcare Solutions, Inc., Allscripts Healthcare, LLC, the
lenders from time to time party thereto, and JPMorgan Chase Bank, N.A.,
as Administrative Agent
10.5
Guarantee and Collateral Agreement, dated as of June 28, 2013, by and
among Allscripts Healthcare Solutions, Inc., Allscripts Healthcare, LLC
and certain other subsidiaries party thereto, and JPMorgan Chase Bank,
N.A., as administrative agent
8-K 10.2
July 2, 2013
10.6
Convertible note hedge transaction confirmation, dated as of June 12, 2013,
8-K 10.1
June 18, 2013
10.7
10.8
10.9
by and between JPMorgan Chase Bank, National Association, London
Branch and Allscripts Healthcare Solutions, Inc.
Amendment to convertible note hedge transaction, dated as of June 14,
2013, by and between JPMorgan Chase Bank, National Association,
London Branch and Allscripts Healthcare Solutions, Inc.
Convertible note hedge transaction confirmation, dated as of June 12, 2013,
by and between Citibank, N.A. and Allscripts Healthcare Solutions, Inc.
Amendment to convertible note hedge transaction, dated as of June 14,
2013, by and between Citibank, N.A., and Allscripts Healthcare Solutions,
Inc.
8-K 10.2
June 18, 2013
8-K 10.3
June 18, 2013
8-K 10.4
June 18, 2013
10.10
Convertible note hedge transaction confirmation, dated as of June 12, 2013,
8-K 10.5
June 18, 2013
by and between Deutsche Bank AG, London Branch and Allscripts
Healthcare Solutions, Inc.
10.11
Amendment to convertible note hedge transaction, dated as of June 14,
8-K 10.6
June 18, 2013
2013, by and between Deutsche Bank AG, London Branch and Allscripts
Healthcare Solutions, Inc.
10.12
Warrant transaction confirmation, dated as of June 12, 2013, by and
8-K 10.7
June 18, 2013
between JPMorgan Chase Bank, National Association, London Branch and
Allscripts Healthcare Solutions, Inc.
115
Exhibit
Number
10.13
10.14
10.15
10.16
10.17
10.18
10.19
10.20
10.21
10.22
10.23
10.24
10.25
Exhibit Description
Warrant transaction confirmation, dated as of June 14, 2013, by and
between JPMorgan Chase Bank, National Association, London Branch
and Allscripts Healthcare Solutions, Inc.
Warrant transaction confirmation, dated as of June 12, 2013, by and
between Citibank, N.A., and Allscripts Healthcare Solutions, Inc.
Warrant transaction confirmation, dated as of June 14, 2013, by and
between Citibank, N.A., and Allscripts Healthcare Solutions, Inc.
Capped call transaction confirmation, dated as of December 4, 2019, by
and between JPMorgan Chase Bank, National Association, New York
Branch and Allscripts Healthcare Solutions, Inc.
Capped call transaction confirmation, dated as of December 4, 2019, by
and between Wells Fargo Bank, National Association and Allscripts
Healthcare Solutions, Inc.
Capped call transaction confirmation, dated as of December 4, 2019, by
and between Bank of America, N.A. and Allscripts Healthcare Solutions,
Inc.
Capped call transaction confirmation, dated as of December 4, 2019, by
and between Deutsche Bank AG, London Branch and Allscripts
Healthcare Solutions, Inc.
Additional capped call transaction confirmation, dated as of December
18, 2019, by and between JPMorgan Chase Bank, National Association,
New York Branch and Allscripts Healthcare Solutions, Inc.
Additional capped call transaction confirmation, dated as of December
18, 2019, by and between Wells Fargo Bank, National Association and
Allscripts Healthcare Solutions, Inc.
Additional capped call transaction confirmation, dated as of December
18, 2019, by and between Bank of America, N.A. and Allscripts
Healthcare Solutions, Inc.
Additional capped call transaction confirmation, dated as of December
18, 2019, by and between Deutsche Bank AG, London Branch and
Allscripts Healthcare Solutions, Inc.
Warrant transaction confirmation, dated as of June 12, 2013, by and
between Deutsche Bank AG, London Branch, and Allscripts Healthcare
Solutions, Inc.
Warrant transaction confirmation, dated as of June 14, 2013, by and
between Deutsche Bank AG, London Branch, and Allscripts Healthcare
Solutions, Inc.
116
Filed
Herewith
Furnished
Herewith
Form
Exhibit
Filing Date
Incorporated by Reference
8-K
10.8
June 18, 2013
8-K
8-K
8-K
10.9
June 18, 2013
10.10
June 18, 2013
10.1
December 4, 2019
8-K
10.2
December 4, 2019
8-K
10.3
December 4, 2019
8-K
10.4
December 4, 2019
8-K
10.1
December 18, 2019
8-K
10.2
December 18, 2019
8-K
10.3
December 18, 2019
8-K
10.4
December 18, 2019
8-K
10.11
June 18, 2013
8-K
10.12
June 18, 2013
Exhibit
Number
Exhibit Description
Filed
Herewith
Furnished
Herewith
Form
Exhibit
Filing Date
Incorporated by Reference
10.26
† Allscripts Healthcare Solutions, Inc., Amended and Restated 1993 Stock
10-Q
10.3
October 13, 2009
Incentive Plan (as amended and restated effective October 8, 2009)
10.27
† Allscripts Healthcare Solutions, Inc. 2001 Non-Statutory Stock Option
10-K
10.19
March 31, 2003
Plan
10.28
† Amendments to the Allscripts Healthcare Solutions, Inc. 2001
10-Q
10.12
November 10, 2008
Nonstatutory Stock Option Plan
10.29
† Amended and Restated Allscripts Healthcare Solutions Inc. Incentive
Plan
10.30
† Allscripts Healthcare Solutions, Inc. Second Amended and Restated 2011
Stock Incentive Plan
8-K
8-K
10.1
10.1
May 23, 2014
May 24, 2017
10.31
† Amended and Restated Allscripts Healthcare Solutions, Inc. Director
10-Q
10.16
August 9, 2013
Deferred Compensation Plan
10.32
† Form of Restricted Stock Unit Award Agreement (Directors)
10-KT
10.37
March 1, 2011
10.33
† Form of Restricted Stock Unit Award Agreement (February 2011)
10-KT
10.38
March 1, 2011
10.34
† Form of Performance-Based Restricted Stock Unit Award Agreement
10-KT
10.39
March 1, 2011
10.35
† Form of Performance-Based Restricted Stock Unit Award Agreement
10-KT
10.40
March 1, 2011
(TSR)
10.36
† Form of Restricted Stock Unit Award Agreement for Non-Employee
10-Q
10.4
August 9, 2011
Directors (2011 Stock Incentive Plan)
10.37
† Form of Time-Based Vesting Restricted Stock Unit Award Agreement for
10-Q
10.5
August 9, 2011
Employees (2011 Stock Incentive Plan)
10.38
† Form of Stock Option Agreement
10.39
† Form of Performance-Based Restricted Stock Unit Award Agreement
(TSR)
10-K
10-K
10.38
March 1, 2013
10.39
March 1, 2013
10.40
† Form of Performance-Based Restricted Stock Unit Award Agreement
10-K
10.29
March 3, 2014
(TSR) (February 2014)
10.41
† Form of Performance-Based Restricted Stock Unit Award Agreement
10-K
10.40
March 1, 2013
(TSR) for Paul M. Black
10.42
†
Amendment to Performance-Based Restricted Stock Unit Award
Agreement, dated February 25, 2014, between Allscripts Healthcare
Solutions, Inc. and Paul M. Black
10.43
† Amendment No. 1 to Performance-Based Restricted Stock Unit Award
Agreement, dated December 24, 2012, between Allscripts Healthcare
Solutions, Inc. and Paul M. Black
117
10-K
10.31
March 2, 2015
10-K
10.31
March 3, 2014
Exhibit
Number
10.44
†
Exhibit Description
Amendment No. 2 to Performance-Based Restricted Stock Unit Award
Agreement, dated December 24, 2012, between Allscripts Healthcare
Solutions, Inc. and Paul M. Black
10.45
10.46
† Form of Restricted Stock Unit Award Agreement for Paul M. Black
† Employment Agreement, dated as of December 19, 2012, between
Allscripts Healthcare Solutions, Inc. and Paul M. Black
Filed
Herewith
Furnished
Herewith
Form
Exhibit
Filing Date
Incorporated by Reference
8-K
99.1
December 31, 2014
10-K
8-K
10.41
March 1, 2013
10.1
December 19, 2012
10.47
† Amendment No. 1 to Employment Agreement, effective October 1, 2015,
8-K
10.1
October 7, 2015
10-K
10.67
March 1, 2013
10-K
10.39
March 3, 2014
10-K
10.40
March 3, 2014
10-K
10.49
February 27, 2017
10.48
10.49
10.50
10.51
21.1
23.1
24.1
31.1
31.2
32.1
†
†
†
†
between Allscripts Healthcare Solutions, Inc. and Paul M. Black
Employment Agreement, dated as of October 10, 2012 but effective as of
October 29, 2012, between Allscripts Healthcare Solutions, Inc. and
Richard Poulton
Employment Agreement, dated as of October 10, 2012 but effective as of
November 12, 2012, between Allscripts Healthcare Solutions, Inc. and
Dennis Olis
Employment Agreement, dated as of May 28, 2013, between Allscripts
Healthcare Solutions, Inc. and Brian Farley
Employment Agreement, dated as of October 30, 2016, effective
November 1, 2016, between Allscripts Healthcare Solutions, Inc. and
Lisa Khorey
Subsidiaries
Consent of Grant Thornton LLP
Powers of Attorney (included on the signature page hereto)
Rule 13a - 14(a) Certification of Chief Executive Officer
Rule 13a - 14(a) Certification of Chief Financial Officer
Section 1350 Certifications of Chief Executive Officer and Chief
Financial Officer
101.INS
Inline XBRL Instance Document – the instance document does not appear
in the Interactive Data File because its XBRL tags are embedded within
the Inline document
101.SCH
Inline XBRL Taxonomy Extension Schema
101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase
101.LAB
Inline XBRL Taxonomy Extension Label Linkbase
101.PRE
Inline XBRL Taxonomy Extension Presentation Linkbase
101.DEF
Inline XBRL Taxonomy Definition Linkbase
104
The cover page from the Company’s Annual Report on Form 10-K for the
year ended December 31, 2019, formatted in Inline XBRL and included
in Exhibit 101
Indicates management contract or compensatory plan.
†
* Omitted schedules will be furnished supplementally to the SEC upon request
Item 16. Form 10-K Summary
None.
118
X
X
X
X
X
X
X
X
X
X
X
X
X
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
SIGNATURES
Date: March 2, 2020
Allscripts Healthcare Solutions, Inc.
BY:
/S/ PAUL M. BLACK
Paul M. Black
Chief Executive Officer
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Paul M. Black, Richard J.
Poulton and Dennis M. Olis, jointly and severally, his or her attorney-in-fact, each with the power of substitution, for him or her in any and all capacities, to
sign any amendments to this Annual Report on From 10-K and to file the same, with exhibits thereto and other documents in connections therewith, with the
Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his or her substitute or substitutes, may do or
cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following
persons on behalf of the registrant and in the capacities and on the dates indicated.
Signature
/S/ PAUL M. BLACK
Paul M. Black
/S/ DENNIS M. OLIS
Dennis M. Olis
/S/ MARA G. ASPINALL
Mara G. Aspinall
/S/ P. GREGORY GARRISON
P. Gregory Garrison
/S/ JONATHAN J. JUDGE
Jonathan J. Judge
/S/ MICHAEL A. KLAYKO
Michael A. Klayko
/S/ YANCEY L. SPRUILL
Yancey L. Spruill
/S/ DAVE B. STEVENS
Dave B. Stevens
/S/ DAVID D. STEVENS
David D. Stevens
Title
Chief Executive Officer and Director
(Principal Executive Officer)
Chief Financial Officer
(Principal Financial and Accounting Officer)
Director
Director
Director
Chairman of the Board and Director
Director
Director
Director
119
Date
March 2, 2020
March 2, 2020
March 2, 2020
March 2, 2020
March 2, 2020
March 2, 2020
March 2, 2020
March 2, 2020
March 2, 2020
Exhibit 4.5
DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES
EXCHANGE ACT OF 1934
Allscripts Healthcare Solutions, Inc. (“Allscripts,” “we,” “us” or “our”) has one class of securities registered under Section 12 of
the Securities Exchange Act of 1934: our common stock. The following summary of the material terms of our capital stock is not
meant to be complete and is qualified by reference to Allscripts’ Fifth Amended and Restated Certificate of Incorporation (the
“Certificate of Incorporation”) and Allscripts’ By-Laws, as amended and restated (the “By-Laws”), each of which is attached as
an exhibit to our Annual Report on Form 10-K, and to all applicable provisions of the General Corporation Law of the State of
Delaware (the “DGCL”).
Authorized Capital Stock
Allscripts’ current authorized capital stock consists of 349,000,000 shares of common stock, $0.01 par value per share, and
1,000,000 shares of preferred stock, $0.01 par value per share.
Allscripts Common Stock
Voting and Other Rights. Holders of Allscripts common stock are entitled to one vote for each share held of record on all matters
submitted to a vote of stockholders, including the election of directors, and do not have cumulative voting rights. Generally, matters
other than the election of directors to be decided by the stockholders will be decided by the vote of holders of a majority of the
shares of Allscripts common stock entitled to vote on the subject matter and represented in person or by proxy at a meeting at
which a quorum is present except where a different standard is required by the DGCL. Each director is elected by the vote of the
majority of the votes cast with respect to that director’s election. The rights, preferences and privileges of holders of common stock
are subject to, and may be adversely affected by, the rights of holders of shares of any series of preferred stock that Allscripts may
designate and issue at any time in the future.
Dividend Rights; Rights Upon Liquidation. Holders of Allscripts common stock are entitled to receive dividends ratably, if any, as
may be declared by the board of directors out of legally available funds. Upon Allscripts’ liquidation, dissolution or winding-up,
holders of Allscripts common stock are entitled to share ratably in all assets remaining after payment of Allscripts’ debts and other
liabilities, subject to the rights of holders of shares of any series of preferred stock that Allscripts may designate and issue at any
time in the future.
Other Rights. Holders of Allscripts common stock currently have no pre-emptive, subscription or conversion rights. There are no
sinking fund provisions or redemption provisions applicable to Allscripts common stock.
Allscripts Preferred Stock
The Allscripts board of directors is authorized, without further stockholder approval but subject to any limitations prescribed by
law, to establish from time to time one or more classes or series of preferred stock covering up to an aggregate of 1,000,000 shares
of preferred stock, and to issue these shares of preferred stock in one or more series. Each class or series of Allscripts preferred
stock will cover the number of shares and will have the preferences, voting powers, qualifications and special or relative rights or
privileges as are determined by the board of directors, which may include, among others, dividend rights, liquidation preferences,
voting rights, conversion rights and redemption rights.
The Allscripts board of directors may authorize the issuance of preferred stock with voting or conversion rights that could dilute the
voting power or other rights of the holders of Allscripts common stock. The issuance of preferred stock could also delay, defer or
prevent a change of control of Allscripts or otherwise negatively affect the market price of Allscripts common stock.
Anti-Takeover Provisions
Some provisions of Delaware law and our Certificate of Incorporation and By-Laws could make the following more difficult:
•
•
•
acquisition of us by means of a tender offer;
acquisition of us by means of a proxy contest or otherwise; or
removal of our incumbent officers and directors.
These provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These
provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We
believe that these provisions give our board of directors the flexibility to exercise its fiduciary duties in a manner consistent with
the interests of our stockholders.
Advance Notice Requirements. Our By-Laws establish advance notice procedures with respect to stockholder proposals and the
nomination of candidates for election as directors.
Delaware Law. Our Certificate of Incorporation contains an election to be governed by Section 203 of the DGCL. Section 203 of
the DGCL generally prohibits certain “business combinations,” including certain mergers, sales and leases of assets and tender or
exchange offers, by a corporation or certain subsidiaries with an interested stockholder who beneficially owns 15% or more of a
corporation’s voting stock, within three years after the person or entity becomes an interested stockholder, unless:
•
the board of directors of the corporation has approved, before the acquisition time, either the
business combination or the transaction that resulted in the person becoming an interested
stockholder,
2
•
•
upon consummation of the transaction that resulted in the person becoming an interested
stockholder, the person owns at least 85% of the corporation’s voting stock (excluding shares
owned by directors who are officers and shares owned by employee stock plans in which
participants do not have the right to determine confidentially whether shares will be tendered in a
tender or exchange offer), or
after the person or entity becomes an interested stockholder, the business combination is
approved by the board of directors and authorized by the vote of at least two-thirds of the
outstanding voting stock not owned by the interested stockholder.
No Stockholder Action by Written Consent; Special Meeting of Stockholders. Our Certificate of Incorporation prohibits our
stockholders from acting by written consent without a meeting, and provides that special meetings of the stockholders may be
called only by the Chairman of our board of directors or the board of directors in the manner provided in the By-Laws.
Undesignated Preferred Stock. The ability of our board of directors to issue shares of preferred stock without any action on the part
of our stockholders may impede a takeover of us and prevent a transaction favorable to the holders of our common stock.
3
ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
SUBSIDIARIES
Subsidiary
Allscripts Holdings, LLC
Allscripts Holdings 2, LLC
Coniston Exchange, LLC
Allscripts Healthcare US, LP
Allscripts Healthcare, LLC
Allscripts Managed Services, LLC
Allscripts Software, LLC
California Healthcare Medical Billing, LLC
Allscripts Analytics, LLC
Allscripts Next, LLC
2bPrecise, LLC
2bPrecise Ltd.
PF2 EIS LLC
Nathan Holding LLC
Practice Fusion, Inc.
Ringadoc, Inc.
Evalytica, LLC
Health Grid Holding Company LLC
HealthGrid Coordinated Care Solutions LLC.
Health Grid, LLC
Mahathi Software LLC.
PF2 Enterprise Information Solutions Canada
Allscripts Canada Corporation
Allscripts Healthcare IT (Canada) Corporation (f/k/a NantHealth Canada, Inc.)
Allscripts Healthcare International Holdings, LLC
Allscripts (Mauritius) Limited
Allscripts (India) LLP
Nant Health Technologies Private Limited
Allscripts Healthcare IT (Malaysia) SDN. BHD.
Allscripts Healthcare IT (Singapore) PTE. LTD.
Allscripts Healthcare IT (Australia) PTY. LTD.
Allscripts Healthcare (IT) UK LTD.
Allscripts (United Kingdom) Limited
dbMotion, Ltd.
dbMotion, Inc.
Careport Health, LLC.
Allscripts CV
Allscripts BV
Allscripts Healthcare IT (Mauritius) Limited
Core Medical Solutions Holdings PTY LTD.
Core Medical Solutions PTY. LTD.
Pulse8, LLC
EXHIBIT 21.1
Jurisdiction or
State of
Organization
Delaware
Delaware
Delaware
Delaware
North Carolina
Delaware
Delaware
California
Delaware
Delaware
Delaware
Israel
Delaware
Delaware
Delaware
Delaware
California
Delaware
Delaware
Florida
Florida
Canada
Canada
Canada
Delaware
Mauritius
India
India
Malaysia
Singapore
Australia
United Kingdom
United Kingdom
Israel
Delaware
North Carolina
Netherlands
Netherlands
Mauritius
Australia
Australia
Maryland
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We have issued our reports dated March 2, 2020, with respect to the consolidated financial statements and internal control over
financial reporting included in the Annual Report of Allscripts Healthcare Solutions, Inc. on Form 10-K for the year ended December 31,
2019. We consent to the incorporation by reference of said reports in the Registration Statements of Allscripts Healthcare Solutions, Inc. on
Forms S-8 (File No. 333-37238, File No. 333-90129, File No. 333-104416, File No. 333-107793, File No. 333-59212, File No. 333-135282,
File No. 333-141600, File No. 333-154775, File No. 333-164294, File No. 333-167846, File No. 333-175053, File No. 333-175819, File No.
333-188902, File No. 333-196415, File No. 333-218174 and File No. 333-225329).
Exhibit 23.1
/s/ GRANT THORNTON LLP
Raleigh, North Carolina
March 2, 2020
Exhibit 31.1
I, Paul M. Black, certify that:
1.
I have reviewed this Annual Report on Form 10-K of Allscripts Healthcare Solutions, Inc.;
CERTIFICATION
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange
Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:
a.
b.
c.
d.
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent
fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially
affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant's auditors and the audit committee of the registrant's Board of Directors (or persons performing the equivalent functions):
a.
b.
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably
likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control
over financial reporting.
Date: March 2, 2020
/s/ Paul M. Black
Chief Executive Officer
Exhibit 31.2
I, Dennis M. Olis, certify that:
1.
I have reviewed this Annual Report on Form 10-K of Allscripts Healthcare Solutions, Inc.;
CERTIFICATION
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange
Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:
a.
b.
c.
d.
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent
fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially
affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant's auditors and the audit committee of the registrant's Board of Directors (or persons performing the equivalent functions):
a.
b.
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably
likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control
over financial reporting.
Date: March 2, 2020
/s/ Dennis M. Olis
Chief Financial Officer
The following statement is being made to the Securities and Exchange Commission solely for purposes of Section 906 of the Sarbanes-Oxley Act of
2002 (18 U.S.C. 1350), which carries with it certain criminal penalties in the event of a knowing or willful misrepresentation.
Exhibit 32.1
Securities and Exchange Commission
450 Fifth Street, NW
Washington, D.C. 20549
Re: Allscripts Healthcare Solutions, Inc.
Ladies and Gentlemen:
In accordance with the requirements of Section 906 of the Sarbanes-Oxley Act of 2002 (18 USC 1350), each of the undersigned hereby certifies that:
(i) this Annual Report on Form 10-K for the year ended December 31, 2019, which this statement accompanies, fully complies with the requirements of
section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
(ii) the information contained in this Annual Report on Form 10-K for the year ended December 31, 2019, fairly presents, in all material respects, the
financial condition and results of operations of Allscripts Healthcare Solutions, Inc.
Date: March 2, 2020
/S/ PAUL M. BLACK
Paul M. Black
Chief Executive Officer
/S/ DENNIS M. OLIS
Dennis M. Olis
Chief Financial Officer
A signed original of this written statement required by Section 906 has been provided to Allscripts Healthcare Solutions, Inc. and will be retained by
Allscripts Healthcare Solutions, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.